
SHAHROKH F. SHARIAT, M.D.



CITIZENSHIP: Austrian

LANGUAGES: Fluent in English, German, French, Spanish, and Farsi

CURRENT POSITIONS

Professor and Chairman

Department of Urology
Medical University of Vienna
Vienna General Hospital
Währinger Gürtel 18-20
A-1090 Vienna, Austria
Tel: +43 1 40400 26150
Cell: +43 664 8001651010
Fax: +43 1 40400 2332
Email: sfshariat@gmail.com or shahrokh.shariat@meduniwien.ac.at

4/2013-present

Adjunct Professor of Urology and Medical Oncology

Weill Cornell Medical College
New York, NY, USA

4/2013-present

Adjunct Professor of Urology

University of Texas Southwestern Medical Center
Dallas, TX, USA

5/2013-present

ACADEMIC RESUME (status 9/1/2014)

691 peer-reviewed and 80 non-peer-reviewed research papers

(**h-index: 61**; total number of citations: 15685; www.scopus.com 9/1/2014)

(**h-index: 80**; i10-index: 420; total number of citations: 39127; www.google scholar.com 9/1/2014)

12 book chapters; >700 abstracts at national and international meetings

Four patents; 74 national and international rewards

Member of 24 academic societies

Editorial board of 25 scientific journals

EDUCATION & MEDICAL TRAINING

UNIVERSITY OF VIENNA MEDICAL SCHOOL, Vienna, Austria <i>Doctor of Medicine</i> <i>Thesis: "Impact of dialysis on serum total PSA, free PSA and free to total PSA ratio: is prostate cancer detection compromised in patients on chronic hemodialysis?"</i>	1993 – 1998
UNIVERSITY OF LA LAGUNA MEDICAL SCHOOL, La Laguna, Spain	1995 – 1996
SWISS FEDERAL INSTITUTE OF TECHNOLOGY, Lausanne, Switzerland <i>Pre-diploma in mathematics, physics, chemistry with distinction</i>	1992 – 1993
LYCEE FRANÇAIS DE VIENNE, Vienna, Austria <i>French Baccalaureate and Austrian Matura</i>	1979 – 1992

ACADEMIC TRACK

MEDICAL UNIVERSITY OF VIENNA, Vienna, Austria <i>Professor and Chairman of Urology</i>	4/2013 - present
WEILL CORNELL MEDICAL COLLEGE / NEW YORK-PRESBYTERIAN HOSPITAL, New York, NY <i>Adjunct Professor of Urology and Medical Oncology</i> <i>Assistant Professor of Urology and Associate Professor of Medical Oncology</i> <i>Associate Professor of Urology and Associate Professor of Medical Oncology</i> <i>Director, Bladder Cancer Outcomes and Translational Research</i> <i>Director, Urologic Oncology Fellowship Program</i>	4/2013 – present 2010 – 2012 2012 – 2013 2011 – 2013 2012 – 2013
MEMORIAL SLOAN-KETTERING CANCER CENTER, New York, NY <i>Fellow/Faculty Instructor, Urologic Oncology</i>	6/2008 – 7/2010
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, TX <i>Adjunct Professor of Urology</i> <i>Chief Resident in Urology</i> <i>Resident in Urology</i> <i>Intern in Surgery</i> <i>Faculty Instructor, Urologic Oncology</i>	2013 – present 2007– 2008 2004– 2007 2003– 2004 2002– 2003
BAYLOR COLLEGE OF MEDICINE, Houston, TX <i>Faculty Instructor, Urologic Oncology</i> <i>Postdoctoral Fellowship, Urologic Oncology</i> <i>Postdoctoral Frost Fellowship in Gene Therapy for Urologic Diseases</i>	2001– 2002 1999– 2000 1998– 1999

PROFESSIONAL MEMBERSHIPS

• European Association of Urology (Europe)	1999
• Endourological Society (USA)	1999
• American Association for Cancer Research (USA)	1999
• American Society of Clinical Oncology (USA)	1999
• Society of Basic Urologic Research (USA)	2000

- Association of U.S. Trained European Physicians (USA); Founder 2000
- American Association of Clinical Urologists, Inc. (USA) 2001
- Bladder Cancer Research Consortium (International); Founder and Director 2002
- Texas Medical Association (USA) 2003
- American Urological Association (USA) 2004
- Society of Urologic Oncology (USA) 2004
- Bladder Cancer Early Detection Network (International); Founder and Director 2006
- American College of Surgeons (USA) 2008
- Upper Tract Urothelial Carcinoma Collaboration (International); Founder and Director 2008
- International Bladder Cancer Network (IBCN) 2008
- Bladder Cancer Advocacy Network (North America) 2010
- Österreichische Gesellschaft für Urologie und Andrologie (Austria)
Arbeitskreis: Geschlechtsspezifische Medizin in der Urologie 2011
- Academic Men's Health Network (International) 2011
- Foundation for Men's Health (FMH); oncology-related advisory committee 2011
- American Society of Men's Health (ASMH); Executive committee and board of directors 2011
- Minimally Invasive Robotic Association (International) 2011
- Society of University Urologists (USA) 2011
- Iranian American Urological Society (North American); Co-founder and member 2012
- New York Academy of Sciences (USA) 2012
- New York Section of the American Urological Association (USA) 2012
- European Academy of Sciences and Arts (Europe) 2014
- Association of Academic European Urologists 2014

HONORS & AWARDS (selected from 62)

- **Award for the First Term of Studies** 1995
Dean of the University of Vienna - Medical School (Austria)
- **“Matricula de Honor” Honorary Award for best student in 1995/1996** 1996
University of La Laguna - Medical School (Spain)
- **Award for the Second Term of Studies** 1997
Dean of the University of Vienna - Medical School (Austria)
- **Performance Grant for Outstanding Study Success in 1996/1997** 1997
Dean of the University of Vienna – Medical School (Austria)
- **Performance Grant for Outstanding Study Success in 1997/1998** 1998
Dean of the University of Vienna - Medical School (Austria)
- **Andlinger Educational Fellowship Grant, American-Austrian Foundation (USA)** 1998
- **Young Investigator Award, Hans und Rosa Blanca Foundation (Austria)** 1999
- **Performance Grant for Outstanding Achievements in Research** 1999
Dean of the University of Vienna - Medical School (Austria)
- **Grant, Methods in Clinical Cancer Research. Vail, Colorado** 1999
The American Association for Cancer Research and the American Society of Clinical Oncology
- **Travel Grant, Molecular Biology in Clinical Oncology. Aspen, Colorado** 2000
The American Association for Cancer Research

- **Glaxo SmithKline Scholar Award**, *for promising clinical/translational cancer research* 2001
American Association of Cancer Research
- **Pfizer Scholar in Urology Award**
- **Winner of the Science Day 2001 Project** – Baylor College of Medicine, Houston, TX 2001
- **First Place Poster** 2001
2nd Alexander Research Symposium, Baylor College of Medicine, Houston, TX
Expression of TGF- β 1 and its receptors in transitional cell carcinoma of the bladder.
- **AUA / Praecis Gerald P. Murphy Scholar** 2002
- **American Cancer Society Institutional Research Grant (IRG#93-034-06)** 2002
Development of a nomogram for prediction of the development of distant prostate cancer metastases and mortality.
- **Best Poster** 2002
Society of Urologic Oncology Annual Meeting, National Cancer Institute,
December 13 - 14, 2002, National Institutes of Health, Bethesda, Maryland.
Preoperative serum levels of pro-PSA isoforms are associated with biologically aggressive prostate cancer.
- **2000 Outstanding Intellectuals of the 21st Century** 2003
International Biographical Center, Cambridge, England (Registration number 965274)
- **Best Poster** 2004
Society for Urodynamics and Female Urology 2004 Meeting. Scottsdale, Arizona.
February 26-29, 2004.
- **“Best Poster” in urothelial cancer** 2004
European Association of Urology Annual Meeting, Vienna, March 26, 2004.
Urine detection of survivin is a sensitive marker for the non-invasive diagnosis of bladder cancer.
- **“Best Poster” in urogenital trauma** 2005
21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006.
Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale.
- **“Best Poster” in bladder cancer: diagnosis and staging III** 2006
21st European Association of Urology Annual Meeting, Paris, April 5-8, 2006. Survivin expression is associated with bladder cancer presence, stage, progression, metastasis, and mortality.
- **AUA / Threshold Pharmaceuticals Gerald P. Murphy Scholar** 2006
- **AUA / Novacea Gerald P. Murphy Scholar** 2007
- **Listed in the “Guide to America’s Top Urologists 2007”** – *Consumers’ Research Council of America is an independent research company based in Washington, DC that evaluated professional services throughout America (www.consumerresearchcncl.org).* 2007
- **“Best Poster” in prostate cancer: staging I** 2007
22nd European Association of Urology Annual Meeting, Berlin, March 21-4, 2007.
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence.
- **Best Poster** 2007
Society of Urologic Oncology Eight Annual Meeting, National Cancer Institute, November

29th-December 1st, 2007, National Institutes of Health, Bethesda, Maryland.

Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.

- **“Best Poster” in prostate cancer: prognostic factors and predictors of outcome** 2008
23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008. Early post-operative plasma transforming growth factor- β 1 is a powerful predictor of biochemical progression after radical prostatectomy.
- **“Best Poster” in diagnosis and staging of urothelial tumours II** 2008
23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-9, 2008. Multiple bio-markers for the prediction of bladder cancer recurrence and mortality.
- **“Best Poster” in Prostate Cancer: Staging (I)** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. Improved prediction of disease relapse after radical prostatectomy using a panel of preoperative blood-based biomarkers.
- **“Best Poster” in Prostate Cancer: Advanced (I)** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. J.Urol 179(4): 186, 2008. The effect of androgen deprivation therapy on the rate of subsequent non-cancer morbidities.
- **“Best Poster” in Urothelial Cancer: Surgical Therapy** 2008
American Urological Association Annual Meeting, Orlando, FL, May 17-22, 2008. More extensive lymphadenectomy improves the prognosis of patients with upper tract urothelial carcinoma without nodal metastases.
- **Reviewer of the month January – European Urology** 2008
- **ASCO Cancer Foundation Merit Award** 2008
American Society of Clinical Oncology Cancer Foundation and the ASCO/National Cancer Institute/EORTC Scientific Committee, Annual Meeting on Molecular Markers in Cancer, Hollywood, FL.
- **Listed in the “Guide to America’s Top Urologists 2008”** 2008
- **Best Poster** 2008
Society of Urologic Oncology Annual Meeting, National Cancer Institute, December 4-6th, 2008, National Institutes of Health, Bethesda, MD. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with bladder cancer.
- **Merit Award** 2009
ASCO Cancer Foundation Board of Directors and the 2009 Genitourinary Cancers Symposium Program Committee, Genitourinary Cancers Symposium in Orlando, FL. Use of pre-treatment biomarker levels to improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence
- **“Best Poster” in Transitional Cell Carcinoma Pathology** 2009
24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. Predictive value of the combination of immunohistochemical markers in patients with pT1 disease at radical cystectomy.
- **“Best Poster” in Management of Advanced Urothelial Pathology** 2009
24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. Improved prediction of clinical outcomes in patients with advanced bladder cancer using a panel of four cell cycle regulators.

- **“Best Poster” in Upper and Lower Urinary Tract Carcinoma** 2009
*24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009.
 Proposal for subclassification of pT3 urothelial cancer of the renal pelvis.*
- **First Prize for the Best Abstract** 2009
*25th European Association of Urology Annual Meeting, Barcelona, Spain. April 16-20,
 2010. Her2 expression status provides independent prognostic information in patients with
 urothelial carcinoma of the bladder: a rationale for targeted therapy.*
- **“Best Poster” in Urothelial Cancer: Natural history and pathophysiology/markers** 2010
*American Urological Association Annual Meeting, San Francisco, CA,
 May 29-June 3, 2010. J.Urol 183(4): 662-663, 2010.*
- **BJU Int Reviewer of Year 2010** 2011
- **Senior author of Merit award to Eugene Cha at 2011 Genitourinary Cancers
 Symposium from ASCO/ASTRO/SUO.** February 2011. San Orlando, FL. 2011
*Immunocytology is a strong predictor of bladder cancer presence in patients with painless
 hematuria: a multicentre study*
- **“Best Poster” in Hematuria and bladder cancer diagnosis session** 2011
*26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria.
 Risk assessment of patients who present with asymptomatic hematuria: Development
 and validation of a nomogram for prediction of bladder cancer presence. 3/19/2011
 Abstract 149, page 128.*
- **“Best Poster”** 2011
*26th Annual EAU Congress. 18-22 March 2011, Vienna, Austria.
 pT3 substaging is a prognostic indicator in lymph node negative urothelial carcinoma
 of the bladder 3/19/2011*
- **Senior author of “Best Abstract”** 2011
*8th Men’s Health World Congress and 4th European Men’s Health Conference.
 2-5 October 2011, Vienna, Austria
 Obesity adversely impacts disease-specific outcomes in urothelial carcinoma of the
 urinary bladder 10/3/2011*
- **2011 Men’s Health World Congress outstanding contribution award** 2011
*8th Men’s Health World Congress and 4th European Men’s Health Conference.
 2-5 October 2011, Vienna, Austria*
- **BJU International Reviewer of Year 2011** 2012
- **Senior author of Merit award to Eugene Cha at 2012 Genitourinary Cancers
 Symposium from ASCO/ASTRO/SUO.** February 2-4, 2012. San Francisco, CA. 2012
Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma
- **Senior author of Merit award to Michael Rink at 2012 Genitourinary Cancers
 Symposium from ASCO/ASTRO/SUO.** February 2-4, 2012. San Francisco, CA. 2012
*Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to
 radical cystectomy: a prospective study*
- **Co-author of “Best Poster” in Session 75: Prognostic biomarkers in urothelial carcinoma** 2012
*7th Annual EAU Congress. 24-28th February 2012
 Circulating tumour cells can not predict clinical or nodal stage, but survival after radical cystectomy
 for urothelial carcinoma of the bladder.*

- **Second author of Best Clinical Research Paper Published in European Urology** 2011
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration
- **Co-author of “Best Poster”** in Radical prostatectomy: Pathological issues and surgical margins, 27th Annual EAU Congress. 24-28th February 2012 2012
Comparative analyses of surgical modalities for the management of prostate cancer: A multi-institutional study of positive surgical margin rates on 22,403 patients operated on in the new millennium
- Mentor of **Ferdinand C. Valentine Student Research Grant in Urology** to medical student Joseph J. Crivelli, New York, NY, USA 2012
Intravesical application of nanoparticle-mediated microwave thermotherapy for treatment of bladder cancer
- **Senior author of “Best Poster”** in Bladder Cancer: Metastatic Disease/Staging American Urological Association Association Annual Meeting, Atlanta, GA, USA 2012
Tuesday, May 22, 2012 3:30 PM-5:30 PM
Abstract 1904: Extranodal extension is a powerful prognostic factor in bladder cancer patients with lymph node metastasis
- **Senior author** of Dr. Johannes Ritschl Forschungspreis of the Österreichischen Krebshilfe Niederösterreich, Austria (recipient: Harun Fajkovic, MD) 2012
Prognostic value of extranodal extension and other lymph node parameters in bladder cancer patients
- **Leading Physician of the World & Top Urologic Oncologist in New York, NY, USA** 2012
bestowed by Doctors of Excellence, The Leading Physicians of the World, The International Association of Oncologists.
- Senior author of **Best Clinical Research Paper Published in European Urology in 2012** 2012
Michael Rink: *Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery*
- **Compassionate Doctor Recognition** 2012-2013
by Vitals.com in conjunction with PatientsChoice.org
http://www.vitals.com/doctors/Dr_Shahrokh_Shariat/credentials#ixzz33bEiXwTM
- **Resident’s Corner Award for the Best Scientific Paper published in European Urology by a resident in 2012** 2013
Eugene Cha: *Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study*
European Urology, Volume 61, Issue 1, January 2012, Pages 185-192
- **European Association of Urology Best Paper published on Clinical Research in the Urological Literature Award.** EAU Scientific Congress Office. 2013
28th Annual EAU Congress, Milan, Italy. March 15-19th 2013
Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy
- **Senior author of “Best Poster”** in Poster Session 13: Bladder cancer: gene expression and molecular classification; 28th Annual EAU Congress. March 2013, Milan, Italy. 2013

Prediction and reversibility of cisplatin-resistance in bladder cancer: HOXA9 a novel epigenetic biomarker. Abstract number: 156

- **Senior author of “Best Poster”** in Poster Session 47: Urothelial cancer: Transurethral surgery and intravesical recurrence Hematuria and bladder cancer diagnosis session 2013
28th Annual EAU Congress. March 2013, Milan, Italy.
Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: Development of an optimized post-operative nomogram using decision curve analysis
Abstract number: 576
- **Senior author of “Best Poster”** in Poster Session 62: Urothelial cancer treatment: 2013
Predicting outcomes; 28th Annual EAU Congress. March 2013, Milan, Italy.
Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non muscle-invasive urothelial carcinoma of the bladder. Abstract number: 754
- **Senior author of “Best Poster”** in Poster Session 62: Urothelial cancer treatment: 2013
Predicting outcomes; 28th Annual EAU Congress. March 2013, Milan, Italy.
Female gender is associated with higher risk of disease recurrence in patients with primary T1 high grade urothelial carcinoma of the bladder. Abstract number: 752
- **Senior author of “Best Poster”** in Poster Session 58: Urothelial cancer treatment: 2013
intravesical approaches; 28th Annual EAU Congress. March 2013, Milan, Italy.
Statin use is not associated with prognosis or BCG-response in patients with non-muscle invasive bladder cancer. Abstract number: 701
- **Senior author of Best Abstract in prostate cancer**, American Urological Association 2013
Annual Meeting ,San Diego, CA. May 4-8th 2013
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical prostatectomy?
- **Senior author of Best Abstract in bladder cancer**, American Urological Association 2013
Annual Meeting ,San Diego, CA. May 4-8th 2013
Concordance in molecular marker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study
- **Senior author of Best Abstract in bladder cancer**, American Urological Association 2013
Annual Meeting ,San Diego, CA. May 4-8th 2013
Concordance in molecular marker status between bladder tumors at time of transurethral resection and subsequent radical cystectomy: results of a 5-year prospective study
- **Patients' Choice Award** 2013
by Vitals.com in conjunction with PatientsChoice.org
http://www.vitals.com/doctors/Dr_Shahrokh_Shariat/credentials#ixzz33bEiXwTM
- Senior author of **Third Prize for the Best Abstract by a Resident** 2014
29th European Association of Urology Annual Meeting, Stockholm, Sweden
Malte Rieken: *Comparison of the EORTC tables and the newly introduced EAU categories for risk stratification of patients with no-muscle invasive bladder cancer*
- Senior author of **Best Poster Prize** in Upper Tract Urothelial Carcinoma poster session 2014
29th European Association of Urology Annual Meeting, Stockholm, Sweden
Malte Rieken: *Frequency and prognostic value of PTEN loss in patients with upper tract urothelial carcinoma*

- **Matula Award**, 29th European Association of Urology Annual Meeting, Stockholm, Sweden 2014

OPEN PROTOCOLS

- **Phase I trial of adenoviral mediated suicide gene therapy with hsv-tk followed by intravenous administration of ganciclovir in patients with locally advanced and refractory superficial bladder cancer** 2000
GCRC, IRB, IND and FDA Protocol
Baylor College of Medicine, Principal Investigators: Shariat S. and Lerner S.
- **Phase I/II trial of caspase-induced apoptotic prostate cancer cell kill using a gene therapeutic method** 2001
GCRC, IRB, IND and FDA Protocol
Baylor College of Medicine, Principal Investigators: Shariat S., Slawin K., Spencer D.
- **Microarray analysis of zone-specific gene expression in response to medical therapy for BPH** 2000
Baylor College of Medicine, Principal Investigators: Shariat S., Slawin K., Spencer D.
- **Pre-clinical and human applications of suicide gene therapy for bladder cancer** 2000
Bladder cancer National Cancer Institute Specialized Program of Research Excellence.
Baylor College of Medicine, Principal Investigators: Shariat S. and Lerner S.
- **Prospective randomization of patients treated with radical cystectomy to adjuvant chemotherapy based on biomarker panel status** 2008
GCRC and IRB Protocol
University of Texas Southwestern Dallas, Principal Investigators: Shariat S. and Lotan Y.
- **Prospective evaluation of biomarker panel in patients with high-risk non-muscle invasive bladder cancer** 2010
GCRC and IRB Protocol
University of Texas Southwestern Dallas, Principal Investigator: Lotan Y.
Weill Cornell Medical Center, Principal Investigator: Shariat S.
- **Discovery of biomarkers for bladder and kidney cancer** 2010
IRB No. 1007011131
Weill Cornell Medical Center, Principal Investigators: Scherr D. and Shariat S.
- **Use of multiphoton microscopy in the diagnosis of cancer** 2010
IRB No. 0506007919
Weill Cornell Medical Center, Principal Investigator: Scherr D., Co-Investigator: Shariat S.
- **Rapid multiplexed detection of pathogens with DNA nanobarcodes** 2010
IRB No. 1006011064
Weill Cornell Medical Center, Principal Investigator: Scherr D., Co-Investigator: Shariat S.
- **Development of the Cornell prostate cancer biobank for the National Cancer Institute – Early Detection Research Network (NCI-EDRN) for prostate cancer biomarker research** 2010
IRB No. 0711009545
Weill Cornell Medical Center, Principal Investigator: Scherr D., Co-Investigator: Shariat S.
- **Molecular profiling of bladder cancer** 2011
IRB No. 1011011386
Weill Cornell Medical Center, Principal Investigator: Shariat S.

- **Optical coherence tomography as an adjunct to white light cystoscopy for intravesical real time imaging and staging of bladder cancer** 2010
IRB No. 0807009899
Weill Cornell Medical Center, Principal Investigator: Scherr D., Co-Investigator: Shariat S.
- **Database of urological malignancies** 2010
Weill Cornell Medical Center, Principal Investigators: Scherr D. and Shariat S.
- **A genotype-phenotype urothelial cancer study** 2010
Memorial Sloan-Kettering Cancer Center, Principal Investigator: Bajorin D.
Weill Cornell Medical Center, Principal Investigator: Shariat S.
- **An investigation of the NMP22® BladderChek® test for early detection of bladder cancer** 2011
University of Texas Southwestern Dallas, Principal Investigators: Lotan Y.
Weill Cornell Medical Center, Principal Investigator: Shariat S.
- **Mitomycin C versus Bacillus Calmette-Guerin in the intravesical treatment of non-muscle-invasive bladder cancer patients: a randomized phase III non-inferiority trial** 2011
Memorial Sloan-Kettering Cancer Center, Principal Investigator: Dalbagni G.
Weill Cornell Medical Center, Principal Investigator: Shariat S.
- **A Phase II, open-label, controlled, randomized study of the CDX-1307 vaccine regimen as neoadjuvant and adjuvant therapy in patients with newly diagnosed muscle-invasive bladder cancer expressing hCG-β** 2011
IRB No. 1005011061
Weill Cornell Medical Center, Principal Investigator: Tagawa S., Co-investigator: Shariat S.
- **Randomization of NMP22® BladderChek® versus Cytology in the surveillance of low-risk bladder cancer** 2011
University of Texas Southwestern Dallas, Principal Investigators: Lotan Y.
Weill Cornell Medical Center, Principal Investigator: Shariat S.
- **Evaluation of the UroVysion™ Test in Predicting Recurrence and/or Progression of Disease in Patients Receiving initial BCG or BCG plus Interferon therapy for Primary High Grade Papillary and CIS Urothelial Carcinoma of the Bladder** 2011
University of Texas Southwestern Dallas, Principal Investigators: Lotan Y.
Weill Cornell Medical Center, Principal Investigator: Shariat S.
STATUS: pending
- **A randomized phase III study of neo-adjuvant docetaxel and androgen deprivation prior to radical prostatectomy versus immediate radical prostatectomy in patients with high-risk, clinically localized prostate cancer (CALGB 90203)** 2012
Weill Cornell Medical Center, Principal Investigator: Tagawa S., Co-investigator: Shariat S.

GRANT FUNDING

- **Frost gene therapy for urologic diseases fellowship program** 1999
Frost Foundation, Inc. (USD 90,000)
Baylor College of Medicine, Principal Investigators: Lerner S., Slawin K., Shariat S.
- **Gene therapy for urologic diseases** 1999
Max Kade Foundation, Inc. (USD 53,350)

Baylor College of Medicine, Principal Investigator: Shariat S.

- **Gene therapy for urologic diseases fellowship** 2001
Prostate Cancer Research Initiative - PCRI (USD 90,000)
Baylor College of Medicine, Principal Investigators: Lerner S., Slawin K., Shariat S.
- **Identification of blood, urine, and tissue biomarkers associated with presence, pathologic features, and/or clinical outcomes in patients with urologic cancers.** 2001
Erwin Schrödinger Scholarship from the Austrian Academy of Science. (USD 50,000)
Principal Investigator: Shariat S.
- **Canadian Institutes of Health Research** 11/2010
 Genomic signatures in bladder cancer
 Principal Investigator: Black P.; Co-investigator: **Shariat S.**
- **CTSC Pilot award** 6/2012
 Metabolomic prognostication and prediction of response to therapy in non-muscle invasive bladder cancer (USD 45,000)
 Principal Investigator: **Shariat S.**

PATENTS

- **Method to determine prognosis after therapy for prostate cancer** 2002
 Inventors: Shahrokh Shariat, Kevin Slawin
 A method for prognosis of patients with prostate cancer, e.g., clinically localized prostate cancer, is provided.
 EP1373899 Patent record available from the European Patent Office
 US20030054419 Patent record available from the US Patent Office
 WO02068960 Patent record available from the World Intellectual Property Organization, Granted 2002-09-06
- **Methods to determine prognosis after therapy for bladder cancer** 2003
 Inventors: Shahrokh Shariat, Kevin Slawin, Seth Lerner
 A method to diagnose, stage and predict prognosis of bladder cancer patients is provided, e.g., using TGF- β 1, IL-6, IL-6sR, uPA, uPAR and IGFBP-3.
 US20030032074 Patent record available from the US Patent Office
 WO02099114 Patent record available from the World Intellectual Property Organization, Granted 2003-06-19
- **Prognostic methods for patients with prostatic disease** 2004
 Inventors: Shahrokh Shariat, Kevin Slawin, Michael Kattan, Peter Scardino
 A method to diagnose, stage and predict prognosis of prostate cancer patients is provided.
 EP1540350 Patent record available from the European Patent Office
 US20030235816 Patent record available from the US Patent Office
 WO2004027432 Patent record available from the World Intellectual Property Organization, Granted 2004-08-05
- **Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma** 2010

Inventor: Shahrokh Shariat

The present invention is an apparatus, system and method for detecting bladder cancer are provided that includes a substrate including one or more sFas binding agents and one or more reagents that indicate the amount of sFas present in the sample.

US07759077 Patent record available from the US Patent Office, Granted 2010-07-20

PROFESSIONAL RESPONSIBILITIES

EDITORIAL WORK

- Editorial Board Member, European Urology 1/2008 – 12/2010
Associate Editor 1/2011 – present
- Editorial Board Member, Immunotherapy 3/2008 – present
- Contributor to Urology, Faculty of 1000 Medicine 5/2008 – 9/2010
- Editorial Board Member, Debates on Bladder Cancer 9/2009 – present
- Contributor, UpToDate 11/2009 – present
- Editorial Board Member, Oncology Reports 12/2009 – present
- Editorial Board Member, BJU Int 2/2010 – present
- Editorial Board, Journal of Men's Health 3/2010 – present
- Editorial Board Member, World Journal of Clinical Oncology 4/2010 – present
- Editorial Board Member, Journal of Molecular Biomarkers and Diagnosis 6/2010 – present
- Editorial Board Member, Journal of Molecular Imaging and Dynamics 8/2010 – present
- Editorial Board Member, World Journal of Clinical Urology 12/2010 – present
- International Scientific Board, Archivos Españoles De Urologia 1/2011 – present
- Consulting Editor, International Brazilian Journal of Urology 1/2011 – present
- Editorial Board Member, ISRN Oncology 2/2011 – present
- Editorial Board Member, Urology: Current Research (OMICS Publishing Group) 3/2011 – present
- Editorial Board Member, World Journal of Urology 7/2011 – present
Associate Editor 9/2011 – present
- Editorial Board Member, Frontiers in Genitourinary Oncology 2/2012 – present
- Co-editor of book on Prostate cancer –original scientific reports and case studies. Edited by Spiess P.E. 6/2012
- Scientific board of Spectrum Urologie –offizielle Organ des Berufsverbands der Österreichischen Urologen (BVU). 2/2013 - present
- Bladder Cancer Advocacy Network's scientific advisory board 3/2013 - present
- Editorial Board Member, Advances in Therapy (ISSN: 0741-238X) www.advancesintherapy.com 3/2013 - present
- Editorial Board Member, Journal of Tumor (ISSN 1819-6187) 4/2013 - present
- Editorial Board Member, American Journal of Urology (ISSN 2162-9722) 5/2013 - present
- Editorial Board Member, Bladder Cancer 8/2014 - present
- *Editor in chief*, Urologie Scan 9/2014 - present
- Editorial Board Member, International Journal of Urology & Urological Practice 9/2014 - present (<http://www.journalnetwork.org/journals/international-journal-of-urology-and-urological-practice>)
- Editorial board, Nature Reviews Urology 10/2014 - present
- *Editor in chief*, Current Opinion in Urology (ISSN 0963-0643) 11/2014 - present
- Editorial board, Minerva Urologica e Nefrologica (ISSN 0393-2249) 11/2014 - present

MODERATED SESSIONS AT MEETINGS

- **Chair of Moderated Poster session:** Urothelial tumours: Basic research I (Poster session 33) at the 23rd European Association of Urology Annual Meeting, Milano, Italy. March 26-29, 2008. 2008
- **Chair of Moderated Poster session:** Genetics and basic research in urothelial tumours (Poster session 26) at the 24th European Association of Urology Annual Meeting, Stockholm, Sweden. March 17-21, 2009. 2009
- **Chair of Moderated Poster session II:** Basic research at the Northeastern Section AUA 61st Annual Meeting, Montreal, Quebec, Canada. October 7-11, 2009. 2009
- **Chair of Moderated Poster session 64:** Prostate cancer: markers II at the American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. 2010
- **Chair of Moderated Debate** on *Current Approaches to Bladder Cancer* at Seventh Annual Current Trends in Genitourinary Malignancies, New York, NY (10/16/2010). 2010
- **Chair of Session** – *Does it really matter to consider gender when managing male patients in primary care?* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France. 2010
- **Chair of Session** – *Comprehensive long term outcomes of male urogenital cancers.* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/29/2010) 2010
- **Chair of Panel Discussion** – *Why and how to care for patients with advanced PCA in a multidisciplinary approach.* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Chair of Panel Discussion** – *Developing a men's health curriculum: teaching men's health to medical students & health professionals.* 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Chair of Moderated Poster Session** at the 7th Men's Health World Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France (10/30/2010) 2010
- **Moderator of Prostate Cancer Clinical Case Discussion** at the 4th Journee d' onco-urologie of the Association Marocaine d'Urologie, Fes, Morocco (12/18/2010) 2010
- **Chair of Moderated Poster session 64:** Prostate cancer: markers II at the American Urological Association Annual Meeting, San Francisco, CA, May 29-June 3, 2010. 2010
- **Chair of Moderated Poster session 26:** Prostate cancer diagnosis at the 26th Annual European Association of Urology Congress. 18-22 March 2011, Vienna, Austria. 2011
- **Chair of Session:** Onkologie at the 44. Alpenländische Urologensymposium, Wolkenstein, Bozen, IT, March 30-April 2, 2011. 2011
- **Introduction session** at Young Urological Associates of the European Association of Urology. 9-10 April 2011, Lago Maggiore, Italy (4/9/11) 2011

- **Chair of Sessions** - The Inaugural International Prostate Cancer Symposium. 2011
May 10-12, 2011, New York, USA.
Prostate cancer complications and their management.
Surgical training mini-session.
- **Chair of Sessions** - 8th Men's Health World Congress & 4th European Men's Health Conference. 2-5 October 2011, Vienna, Austria 2011
Urologic care for the elderly patient
Debate on PSA screening for prostate cancer
- **Chair of Session** – Menopause, Andropause, Anti-aging. 8-10 December, Vienna, Austria 2011
Urology and Andrology
- **Chair of moderated poster session 91: Prostate cancer: Active surveillance** 2012
at the 26th Annual European Association of Urology Congress.
24-28 February 2012, Paris, France.
- **Chair of Session** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 9-10 November 2012, Linz, Austria 2012
Was sollte ich wissen? Leitlinien und Nomogramme
- **Chair of Session** - *Diagnostics, prognostic factors and risk stratification of upper tract urothelial carcinoma* at the Summit on Upper Tract Urothelial Carcinoma, Society of Urologic Oncology Annual Meeting, November 28-30, 2012, Bethesda, MD, USA 2012
- **Chair of session 2**, 19th St Lawrence Urological Group, 1/26/2013
McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013
- **Chair of moderated poster session 62: Urothelial cancer treatment: predicting outcomes** 3/19/2013
28th Annual EAU Congress. March 2013, Milan, Italy.
- **Chair of wissenschaftlichen Sitzung Katheterismus** 7/3/2013
Wilhelimenspital, Vienna, Austria
- **Chair of session, 33rd Congress of the Societe Internationale d'Urologie, Vancouver, Canada**
Surgical Tips 1: Endoscopic Management of Urothelial Cancer 9/9/2013
ICUD Consultation 2013: Upper Tract Urothelial Carcinoma 9/10/2013
- **Chair of local Lilly meeting on prostate cancer** 10/11/2013
Hilton Hotel, Vienna, Austria
- **Organizator/Chair** First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
- **Chair** of Session VI at 23rd International Symposium of the Endourology and ESWL 3/8/2014
Section of the Polish Urological Association, Wroclaw, Poland
- **Chair of moderated poster session: in Upper Tract Urothelial Carcinoma** 4/2014
29th Annual EAU Congress. April 2013, Stockholm, Sweden
- **Chair of session, 34th Congress of the Societe Internationale d'Urologie, Glasgow, UK**
Debate: why do women have a worse prognosis from bladder cancer? 10/14/2014
- **Chair of session, 24. Jahrestagung der MKÖ, Linz, AUT** 10/18/2014
Kontinenz und Schmerz – Zukunftsperspektiven

- **Chair of local Lilly meeting on BPH/LUTS/ED** 10/24/2014
Albertina, Vienna, Austria
- **Chair of local Atellas meeting on castration-resistant prostate cancer** 10/25/2014
Aula der Wissenschaften, Vienna, Austria
- **Chair of Session** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 7-8 November 2012, Linz, Austria 11/7/2014
Smoking kills- die Rolle der Urologie

GUIDELINE PANEL

- Member, Prognostic factors panel of **The International Consultation on Urological Diseases** and the **EAU** consensus meeting on Kidney Cancer. 2010
- Member of Biomarkers panel of **The WHO International Consultation on Prostate Cancer** 2010
- Chair of Early detection factors and Prognostic factors panel of **The International Consultation on Urological Diseases** & the AUA / EAU consensus meeting on Bladder Cancer. 2011
- Member of **EAU Guidelines panel on New Technologies** 2011-3
- Member of **EAU guidelines on Non-Muscle-invasive Carcinoma of the Bladder** 2011-present
- Guideline chair of **The International Consultation on Urological Diseases** on Upper tract urothelial carcinoma. Presentation at SIU 2013 in Vancouver, Canada 9/2013 2012
Panel chair of the Predictive and prognostic factors and pathology panel
- Member of **EAU guidelines on Upper Tract Urothelial Carcinoma** 2012-present
- Co-chair of **Summit on Upper Tract Urothelial Carcinoma** held under the auspices of the Society of Urologic Oncology at the annual meeting in Bethesda, MD 12/2012 2012
- Chair of **The International Consultation on Urological Diseases** & the SIU consensus meeting on Upper Tract Urothelial Carcinoma. 2013

MEETING REVIEWER

- Abstract reviewer for **24th Annual European Association of Urology Congress** 2008
17-21 March 2009, Stockholm, Sweden; Subject: Prostate cancer: PSA and markers
- Abstract reviewer for **25th Annual European Association of Urology Congress** 2009
16-20 April 2010, Barcelona, Spain; Subject: Prostate cancer: PSA and markers
- Abstract reviewer for **7th Men`s Health World Congress** “How To Overcome The Challenges?” 28-30 October 2010, Nice, France; Subject: Oncology 2010
- Abstract reviewer for **26th Annual European Association of Urology Congress** 2010
18-22 March 2011, Vienna, Austria; Subject: Prostate cancer: PSA and markers
- Abstract reviewer for the **8th Men`s Health World Congress** and **4th European Men`s Health Conference**. 2-5 October 2011, Vienna, Austria 2011
- Abstract reviewer for the **13th Annual Meeting of the Society of Urologic Oncology** 2012
November 28-30, 2012, Bethesda, MD, USA

- Reviewer for the **National Agency for the Evaluation of Universities and Research Institutes (ANVUR)**. Mission: assessment of research performed in the time frame 2004-2010 by researchers of all Italian universities and research institutes (eValuation of Quality of Research, VQR 2004-2010). 2012
- Member of **Bladder Cancer Advocacy Network – BCAN’s Scientific Review Group** to review applications for the Young Investigator Awards program 2013
- Abstract reviewer for the **14th Annual Meeting of the Society of Urologic Oncology** December 4 - 6, 2013, Bethesda, MD, USA 2013
- Abstract reviewer for **29th Annual European Association of Urology Congress** 11-15 April 2014, Stockholm, Sweden; Subject: urothelial tumours: management of infiltrative/advanced tumors: surgical management 2013
- Abstract reviewer for **Deutsche Gesellschaft der Urologie** 2014

SCIENTIFIC COMMITTEE MEMBER

- **Member of Scientific Committee** of the 7th Men’s Health World Congress and 3rd European Men’s Health Conference. A multidisciplinary approach to men’s health: How to overcome the challenges? 28-30 October 2010, Nice, France 2010
- **Chair of Scientific Committee and Best Poster Award Committee** of the 8th Men’s Health World Congress and 4th European Men’s Health Conference. 2-5 October 2011, Vienna, Austria 2011
- **Guest Editor** of special issue on bladder cancer of the World Journal of Urology (ISSN: 0724-4983 and 1433-8726) 2011
- **Co-chair of the Best Presentation Award Committee** of 19th Association Marocaine d’Urologie Annual Meeting 2011
- **Chair of the Best Presentation Award Committee** of 20th Association Marocaine d’Urologie Annual Meeting 2012
- **Member of Bladder Cancer Scientific Program Committee** for the 13th Annual Meeting of the Society of Urologic Oncology, November 28-30, Bethesda, MD, USA 2012
- **Co-chair of Summit on Upper Tract Urothelial Carcinoma Program** at the 13th Annual Meeting of the Society of Urologic Oncology, November 28, Bethesda, MD, USA 2012
- **Guest Editor** of special issue on “Prostatakazinom” in Spectrum Urologie 2012
- **Member of Best Presentation Award Committee** 19th St Lawrence Urological Group, McGill University Health Centre, Montreal, Quebec, Canada 1/25-27, 2013 2013
- **Member of Bladder Cancer Scientific Program Committee** for the 14th Annual Meeting of the Society of Urologic Oncology, December 4-6, Bethesda, MD, USA 2013
- **Guest Editor** of special issue on *Biomarkers in Uro-oncology* in Urologic Oncology 2013
- **Guest Editor** of special issue on “Das Harnblasenkarzinom” in Spectrum Urologie 2013
- **Scientific programme committee chair**, First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013

- **Scientific programme committee member** of the Societe Internationale d’Urologie 11/2013-10/2015
- **Guest Editor** of special issue on “High risk non muscle invasive bladder cancer” 9/2014
-

JOURNAL REVIEWER

- Urology 1/2001 – present
- Journal of Clinical Oncology 3/2002 – present
- American Journal of Cancer 4/2002 – present
- European Urology 5/2003 – present
- Journal of Urology 1/2004 – present
- Cancer Chemotherapy and Pharmacology 2/2004 – present
- Expert Review of Molecular Diagnostics 4/2004 – present
- Biochimica et Biophysica Acta – Proteins and Proteomics 6/2004 – present
- BioMed Central Urology 7/2004 – present
- International Journal of Cancer 10/2004 – present
- BJU International 7/2005 – present
- European Journal of Cancer 9/2005 – present
- Artificial Intelligence in Medicine 2/2005 – present
- Urologic Oncology: Seminars and Original Investigations 1/2006 – present
- Medical Principles and Practice 2/2006 – present
- EAU – EBU Update Series 8/2006 – present
- International Brazilian Journal of Urology 8/2006 – present
- Cancer Letters 8/2006 – present
- Biomarker Insights 9/2006 – present
- The Scandinavian Journal of Clinical & Laboratory Investigation 10/2006 – present
- Human Pathology 11/2006 – present
- Clinical Cancer Research 12/2006 – present
- Experimental and Molecular Pathology 1/2007 – present
- Clinical Genetics: An International Journal of Genetics and Molecular Medicine 2/2007 – present
- Yonsei Medical Journal 2/2007 – present
- Apoptosis: An International Journal on Programmed Cell Death 3/2007 – present
- Biomarkers in Medicine 4/2007 – present
- European Journal of Surgical Oncology 7/2007 – present
- World Journal of Surgical Oncology 8/2007 – present
- Cleveland Clinic Journal of Medicine 9/2007 – present
- Pathology: The Official Journal of the Royal College of Pathologists of Australasia 9/2007 – present
- Cancer: Interdisciplinary International Journal of the American Cancer Society 9/2007 – present
- Expert Review of Anticancer Therapy 10/2007 – present
- Neoplasia: An International Journal for Oncology Research 10/2007 – present
- Nature Clinical Practice Oncology 11/2007 – present
- Expert Opinion on Therapeutic Targets 11/2007 – present
- Asian Journal of Andrology 11/2007 – present
- Current Opinion in Molecular Therapeutics 12/2007 – present
- Expert Review of Proteomics 1/2008 – present
- Expert Opinion on Medical Diagnostics 2/2008 – present
- World Journal of Urology 3/2008 – present
- Laboratory Investigation 4/2008 – present
- Radiotherapy and Oncology 6/2008 – present
- Cancer Treatment Review 8/2008 – present

- BioMed Central Cancer 1/2009 – present
- Annals of Oncology 3/2009 – present
- International Journal of Urology 3/2009 – present
- Lancet Oncology 7/2009 – present
- The Journal of Sexual Medicine 8/2009 – present
- The Prostate 9/2009 – present
- Molecular Cancer Therapeutics 10/2009 – present
- Nature Reviews Clinical Oncology 11/2009 – present
- Cancer Epidemiology, Biomarkers and Prevention 3/2010 – present
- International Journal of Surgery 3/2010 – present
- Expert Opinion on Investigational Drugs 4/2010 – present
- Tumor Biology - The International Society of Oncology and BioMarkers 5/2010 – present
- Critical Reviews in Oncology/Hematology 6/2010 – present
- The Journal of Proteome Research 6/2010 – present
- Cancer Treatment Reviews 9/2010 – present
- Molecular Medicine 11/2010 – present
- Journal of Endourology 11/2010 – present

VISITING PROFESSORSHIPS

- **Visiting Professor**, University of Montreal, Montreal, Quebec, Canada 9/2008
The benefits of early androgen blockade;
Urologic trauma: experience at Parkland Memorial Hospital;
Potential effect of testosterone supplements of prostate cancer biology
- **Visiting Professor**, XXV Jornadas Urológicas De La Filial Sur de la Sociedad Chilena de Urología. 13-15 Agosto 2010, Temuco, Chile. 8/2010
Cancer Vesical Sin Invasión Muscular
Role of surgery in invasive and advanced bladder cancer
Perioperative chemotherapy for muscle invasive bladder cancer
Urine biomarkers for bladder cancer detection and surveillance
- **Visiting Professor**, Sociedad Chilena de Urología, Santiago de Chile, Chile 8/2010
Update on non-muscle invasive bladder cancer
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider pre-surgical therapy?
- **Visiting Professor**, Department of Urology, University of Hamburg, Hamburg, Germany 11/2010
Evidence-based management of non-muscle invasive bladder cancer (11/3/2010)
Martini Prostate Klinik, University of Hamburg, Hamburg, Germany
Disease state-specific integration of biomarkers for prostate cancer (11/4/2010)
- **Visiting Professor**, Div. of Urology, Maimonides Medical Center, Brooklyn, NY, USA 4/16/2012
Optimal stage-specific management of prostate cancer
- **Visiting Professor**, Division of Urology, Instituto Do Cancer Do Estado De Sao Paulo (ICESP) and Department of Urology, University of Sao Paulo (USP), Sao Paulo, SP, Brazil 4/26-27/2012
How to integrate research in daily clinical setting
- **Visiting Professor**, Dept. of Urology, Universitaetsklinikum Aachen, Aachen, DL 11-12/12/2013
How to optimize outcomes in muscle-invasive bladder cancer: role of surgery and chemotherapy

- **Visiting Professor**, Div. of Urology, Dept. of Surgery, University of Oxford, Oxford, UK 7/2014
Personalized management of f bladder cancer: where is the future

INVITED PRESENTATIONS AND COURSES

- **Invited Lecturer**, Austrian-Iranian Medical Society, Vienna, Austria. 8/14/2007
Genitourinary Oncology: the US perspective
- **Invited Lecturer**, Association des Urologues du Quebec, Montebello, Canada. 9/6/2008
Marqueurs urinaires; Déclenchement du hormono-therapy dans le cancer de la prostate non-avancé
- **Invited Lecturer**, Medizinische Universität Wien, Vienna, Austria. 9/12/2008
Prostate cancer biomarkers: an update and future perspectives
- **Invited Lecturer**, The International Bladder Cancer Network Meeting, Barcelona, Spain. 10/16/2008
Statistical needs in marker research
- **Invited Lecturer**, Society of Urologic Oncology, Bethesda, MD. 12/3/2008
Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer.
- **Invited Lecturer**, Grand rounds of the Department of Urology at New York University, New York, NY. 6/17/2009
Molecular markers for bladder cancer
- **Invited Lecturer**, Austrian-Iranian Medical Society, Vienna, Austria. 8/23/2009
Trends in Prostate Cancer Management
- **Invited Lecturer**, Department of Urology at University of Texas Southwestern Medical Center, Dallas, TX. 9/15-16/2009
*Integration of biomarkers in a programmatic approach to bladder cancer
Timing and duration of early androgen deprivation therapy*
- **Invited Panelist**, Northeastern Section AUA 61st Annual Meeting, Montreal, Canada. 10/8/2009
Testosterone supplementation in prostate cancer and its risks.
- **Invited Lecturer**, Northeastern Section AUA 61st Annual Meeting, Montreal, Canada. 10/8/2009
Residents' Breakfast: How to Select a Urology Fellowship Program
- **Invited Lecturer**, Glickman Urological Institute, Cleveland Clinic, Cleveland, OH. 10/29/2009
Molecular markers can improve the clinical decision-making in patients with bladder cancer
- **Invited Lecturer**, Society of Urologic Oncology, Bethesda, MD. 12/4/2009
Her2 expression status provides independent prognostic information in patients with urothelial carcinoma of the bladder
- **Invited Lecturer**, European School of Urology course at the time of the 26th Annual EAU Congress, Barcelona, Spain. 4/18/2010
How to write a manuscript and get it published in European Urology.
- **Invited Lecturer**, Resident Forum of the 2010 American Urological Association, San Francisco, CA. 5/29/2010
Choosing a fellowship - Getting Started: A Blueprint for Post-Residency Life
- **Invited Lecturer**, 36 Gemeinsame Tagung der Bayerischen Urologenvereinigung und 6/10/2010

der Österreichischen Gesellschaft für Urologie, Munich, Germany

Blasenkarzinom: Grundlagen

- **Invited Lecturer**, Sociedad Chilena de Urologia, Santiago de Chile, Chile. 8/19/2010
Update on non-muscle invasive bladder cancer
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider pre-surgical therapy?
- **Invited Lecturer**, Innovations in Urology First Annual Meeting, Milan, Italy 9/18/2010
Pelvic Lymph Node Dissection for Prostate Cancer: extended, limited, or not at all?
- **Invited Lecturer**, Seventh Annual Current Trends in Genitourinary Malignancies, 10/16/2010
 New York, NY.
Surgery for early-stage bladder cancer. Debate: radiation therapy is suboptimal for bladder cancer.
- **Invited Lecturer** at the session Prostate Cancer II of the 7th Men's Health World 10/29/2010
 Congress and 3rd European Men's Health Conference. 28-30 October 2010, Nice, France.
Prostate cancer overview and recent advances - how can a common disease be so controversial
- **Invited Lecturer** at the 7th Men's Health World Congress and 3rd European Men's 10/29/2010
 Health Conference. *Update on the management of bladder cancer in 2010*
- **Invited Lecturer**, 4th Journee d' onco-urologie of the Association Marocaine 12/18/2010
 d'Urologie, Fes, Morocco.
Recent advances in prostate cancer –a controversial common disease
Management of non-invasive bladder cancer
- **Lecturer**, ICUD-EAU International Consultation on Bladder cancer 2011 3/18/2011
Chapter 3: Markers
- **Lecturer**, European Society of Residents in Urology and Young Urologists Office 3/19/2011
 Vienna, Austria
How to make it in Urology
Panel discussion on career challenges in 2011
- **Lecturer**, ESU Course 20 How to write a manuscript and get it published in 3/21/2011
 European Urology, Vienna, Austria
Clinical research original article: how to write the best introduction section
Clinical research original article: how to write the results and discussion sections
Review article: the critical interpretation of the summarized evidence: why is the author's touch of class essential to write the perfect manuscript?
- **Lecturer**, Sub-pleenary session 8: ICUD-EAU International Consultation on Bladder cancer 3/21/2011
 Vienna, Austria
Markers of early detection in bladder cancer
Prognostic/predictive markers in bladder cancer
- **Invited Lecturer**, 44. Alpenländische Urologensymposium, Wolkenstein, Bozen, IT 4/1/2011
Integration neuer Biomarker in der Diagnostik und Therapie von Blasenkarzinom
Optimales Management des invasiven Blasenkarzinoms- Wertigkeit der Chirurgie unter Integration der Chemotherapie
- **Panel** – *Management of the small renal mass.* EAU 4th leading light meeting. 4/9/2011
 7-9 April 2011, Lago Maggiore, Italy (4/9/11)
- **Invited Lecturer**, Tumor board at Columbia University College of Physicians 4/19/2011
 and Surgeons

Upper tract urothelial carcinoma: new data and old news

- **Invited Lecturer**, Association Marocaine d'Urologie Annual Meeting 2011 4/28-29/2011
Skhirat, Morocco.
Biomarkers for early detection
Management of T1 high grade urothelial carcinoma of the bladder
Panel discussion on bladder cancer
Ablative therapy for small renal cortical tumors
- **Invited Lecturer**, Interactive Genitourinary Cancer Conference (IGUCC) 4/30/2011
Budapest, Hungary.
Interpreting trends in prostate cancer
Panel discussion on prostate cancer biomarkers
- **Course lecturer**, American Urological Association Annual Meeting, Washington, DC 5/17/2011
Multidisciplinary management of urothelial carcinoma: stage- and site-specific discussions upper tract urothelial carcinoma
- **Invited Lecturer**, Societa Italiana di Urologia Oncologica (SIUrO), Naples, Italy 6/23-24/11
Clinical utility of nuclear matrix protein 22 for the management of bladder cancer
Lymphadenectomy for prostate cancer: extended, standard, limited or not at all?
- **Course lecturer**, ESU-Weill Cornell Masterclass in General urology, Salzburg, AUT 7/11-15/2011
Management of localized prostate cancer
Management of metastatic prostate cancer
Management of penile cancer
Management of upper tract urothelial carcinoma
- **Invited lecturer**, AUA Foundation/Society of Basic Urologic Research Conference 7/16-17/2011
AUA Headquarters, Linthicum, MD, USA
Aging and urothelial carcinoma: an oncogeriatric matter
- **Invited lecturer**, New York Section of the American Urological Association 9/11/2011
109th Annual Meeting, Paris, France
Bladder-sparing approaches to invasive bladder cancer
The role of early cystectomy in muscle invasive bladder cancer
- **Invited lecturer**, 8th Men's health world congress and 4th European men's health conference, Vienna, AUT 10/3-4/2011
Early androgen deprivation- what is the evidence?
Integration of multidisciplinary care in the management of high-risk prostate cancer
- **Invited lecturer**, Andrologisch-Onkologisches Herbstseminar 10/8/2011
Arbeitskreise für Andrologie und Onkologie, Berufsverband der Österreichischen Urologen
Das Prostatakarzinom: warum bestehen bei einer so häufigen Erkrankung so viele Kontroversen?
- **Invited lecturer**, 5th Global Uro-Oncology Meeting under the auspices of the 10/15-16/2011
World Urological Oncology Federation, Berlin, Germany
Management of invasive bladder cancer in the elderly
- **Course lecturer**, 31st Congress of the Societe International d'Urologie, Berlin, DE 10/19/2011
Updates on upper tract urothelial carcinoma: diagnosis, staging, and management
- **Invited lecturer**, Menopause, Andropause, Anti-aging. 8-10 December, Vienna, AUT 12/ 2011
Das Prostatkarzinom: eine paradoxe Krankheit
- **Invited lecturer**, 5th EAU Leading Lights in Urology Meeting. March 29-30, Madrid, SPA 3/2012

The risks of 5 α -reductase inhibitors for prostate cancer prevention
The role of neoadjuvant and adjuvant treatment in advanced bladder cancer
The future of urologic oncology research

- **Invited Lecturer**, 20th Association Marocaine d'Urologie (AMU) Annual Meeting and 20th Congres Francophone D' Urologie (FASULF) 2012, Marrakech, Morocco. 4/4-7/2012
Traitement intravésical du cancer de vessie: thérapie de première ligne et algorithme de prise en charge
Cancer du rein de petite taille: place de la radiofréquence, de la cryothérapie
- **Invited Lecturer**, Department of Surgery, Maimonides Medical Center, Brooklyn, NY, USA 4/16/2012
Lymphadenectomy for prostate cancer: extended, standard, limited, or not at all
- **Invited Lecturer**, III Simposio Internacional de Cancer Urologico, Sao Paulo, SP, Brazil 4/20- 21/2012
Intravesical therapy for T1high grade (T1G3)
Role of urinary and tissue markers in bladder cancer detection and prognosis
Bladder cancer in elderly: what is different?
Prognostic markers in upper tract urothelial carcinoma: what have we learned in the last 5 years
Upper tract urothelial carcinoma: when is conservative therapy indicated and safe?
Case Discussion: Bladder Cancer
Role of ablative therapy
Case Discussion: Kidney Cancer
The biologic and clinical importance of teratoma
Active surveillance: reasonable or risky?
Case Discussion: Prostate Cancer
- **Invited Lecturer**, Department of Urology, Albert Einstein College of Medicine, Montefiore Medical Center Center, Bronx, NY, USA 5/7/2012
Upper tract urothelial carcinoma: what have we learned in the last 5 years?
- **Invited Lecturer**, Clinical Medicine, Weill Cornell Medical Associates-East Side New York, NY, USA 5/17/2012
Prostate cancer: a thinking man's approach
- **Course Director and Lecturer**, American Urological Association Association Annual Meeting, Atlanta, GA, USA 5/22/2012
0511C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
- **Invited Lecturer**, Sol and Margaret Berger Department of Urology, Beth Israel Medical Center, New York, NY, USA 6/14/2012
Management of upper tract urothelial carcinoma
- **Course Director and Lecturer**, EAU/Weill Cornell Seminar in "ESU Master Class in Urology", Salzburg, AUT 7/9-14/2012
Non-muscle invasive bladder cancer: diagnosis & overview
Chemotherapy for bladder cancer
Workshop: why & how to publish in European Urology
Workshops: fellows' case presentations
- **Invited Lecturer**, Australian and New Zealand Urogenital and Prostate Clinical Trials Group (ANZUP) Annual Scientific Meeting, Sydney, Australia. 7/16-17/2012

State of the art in the diagnosis and treatment of upper tract urothelial carcinoma
Optimal management of bladder cancer- integrating surgery and systemic therapy
Role of surgery in the treatment of high-risk non-metastatic prostate cancer
Genitourinary carcinoma clinical trial concept development

- **Invited Lecturer**, Weill Cornell Medical College & Eli Lilly & Co 11/7/2012
 2nd Men's Health Symposium: From Academic Research to New Drug Developments,
 Weill Cornell Medical College, New York, NY, USA
Bladder cancer: opportunities for innovation
- **Invited Lecturer**, Fortbildungstagung der Österreichischen Gesellschaft 11/10/2012
 für Urologie und Andrologie. 9-10 November 2012. Linz, Austria
Radikale Prostatektomie- state of the art surgery
13 Tipps für eine erfolgreiche Karriere in der urologischen Forschung
- **Invited Lecturer**, Society of Basic Urologic Research Annual Symposium, 11/17/2012
 November 15-8, 2012. Miami, FL, USA
Biomolecular predictors of urothelial cancer behavior and treatment outcomes
- **Panelist**, Summit on Upper Tract Urothelial Carcinoma, Society of Urologic 11/ 28/2012
 Oncology Annual Meeting, Bethesda, MD, USA
Achieving consensus on clinical risk stratification
Management of localized disease
- **Invited Lecturer**, 19th St Lawrence Urological Group, McGill University 1/25-27, 2013
 Health Centre, Montreal, Quebec, Canada
My 15 tips for a successful career in academic urology
How to choose a fellowship – a primer for residents
Concepts and controversies in the management of upper tract urothelial carcinoma
Integration surgery and systemic therapy for invasive bladder cancer
- **Invited Lecturer**, Joint session of the European association of urology (EAU) and 3/15/2013
 the Maghreb Union countries. 28th Annual EAU Congress. March 2013, Milan, Italy.
Management of non invasive bladder tumors
- **Invited Lecturer**, Plenary session 2 – Debate: How much surgery for upper tract 3/17/2013
 urothelial cancer? 28th Annual EAU Congress. March 2013, Milan, Italy.
Nephroureterectomy or partial ureterectomy?
- **Course Director and Lecturer**, 28th Annual EAU Congress. March 2013, Milan, Italy. 3/18/2013
 ESU course 31 Current concepts and controversy in the diagnosis and management
 of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Course Lecturer**, 28th Annual EAU Congress. March 2013, Milan, Italy. 3/19/2013
 ESU course 20 How to write a manuscript and get it published in European Urology
How to write a clinical research article
- **Invited Lecturer**, National Urology Residents Preceptorship Program (NURPP), 5/5/ 2013
 AUA 2013 Annual Meeting, May 4-8, San Diego, CA
Fellowships- a primer for residents

- Invited Lecturer**, American Society for Men's Health, AUA 2013 Annual Meeting, May 4-8, San Diego, CA, USA 5/6/2013
Localized Prostate Cancer: Active Surveillance versus Active Treatment?
- Chair and lecturer**, Association of American-Iranian Urologists (AAIU), AUA 2013 Annual Meeting, May 4-8, San Diego, CA, USA 5/6/2013
T1 bladder cancer: conservative therapy is the initial way to go
- **Course director and lecturer**, American Urological Association Association Annual Meeting 2013, San Diego, CA, USA 5/7/2013
0511C: Contemporary Concepts and Controversies in the Diagnosis and Management of Upper Tract Urothelial Carcinoma (UTUC)
 - **Invited lecturer**, 6th EAU Leading Lights in Urology Meeting. June 6-8th, Lisbon, Portugal 6/2013
Prostate cancer screening: pro
 - **Invited lecturer**, 1st International uroanatomy congress. June 14th, Izmir, Turkey 6/14-15/2013
Anatomic steps of radical cystectomy and extended lymphadenectomy: rationale and video
Surgical approach to anatomic open prostatectomy- tips and tricks
Robotic urologic surgery and anatomy: against
Radiologic and sectional uroanatomy – challenger
 - **Invited lecturer**, Open Medical Institute Satellite Symposium, Urothelial Cancer, Under the auspices of Weill Cornell Medical College and the American Austrian Foundation in collaboration with Postgraduate medical Education Center, European Health Center, Otwock, Poland 7/5/2013
Non-muscle invasive bladder cancer: diagnosis, risk stratification, and management
Integrating surgery and systemic therapy for invasive bladder cancer
Modern management of upper tract urothelial carcinoma
Bladder cancer cases presentations and discussion
 - **Course lecturer**, ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/8-12/2013
Update on management of advanced and metastatic renal cancer
Testicular cancer: treatment stage by stage
 - **Invited lecturer, World Urologic Oncology Federation, Vancouver, Canada 9/8/2013**
Variant histology in urothelial carcinoma: clinical impact
 - **Invited lecturer, International Young Urologists' Association, Vancouver, Canada 9/8/2013**
Optimal integration of chemotherapy with surgery
 - **Invited lecturer, 33rd Congress of the Societe Internationale d'Urologie, Vancouver, Canada**
Why Optimal Endoscopic Management Matters 9/9/2013
IC06: Management of urothelial carcinoma: stage- and site-specific discussions 9/11/2013
Diagnosis and management of upper tract urothelial carcinoma
IC10: Non-Muscle-Invasive Bladder Cancer Diagnosis and Treatment 9/12/2013
Risk-Based Clinical Decision Making in NMIBC
Intravesical Immunotherapy Today
 - **Invited lecturer**, 30 Jahrestagung ACO ASSO 2013, St Wolfgang, AUT 10/3-5/2013
Primumresektion beim metastasierten Nierenzellkarzinom: der Standard?
 - **Course lecturer**, ESU- Cornell Masterclass in Genitourinary Oncology, Salzburg, AUT 10/7/2013
Penis cancer: diagnosis, staging and treatment

Diagnosis, risk-stratification and management of bladder cancer

- **Invited lecturer**, Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften fuer Haematologie und Onkologie, Wien, AUT 10/21/2013
Therapiestrategien beim Nicht-Urothelkarzinom
- **Invited lecturer**, 8. Urologisch/Onkologisches Symposium, Interdisziplinäre Behandlung von urogenitalen Karzinomen, Barmherzige Brüder Krankenhaus, Wien, AUT 11/9/2013
State of the Art der Diagnose und Therapie des nicht-muskelinvasiven Urothelkarzinoms
- **Invited lecturer**, Prag Urologic Society, Prag, CZ 11/14/2013
/Optimal integration of surgery and chemotherapy for the management of muscle-invasive bladder cancer
- **Invited lecturer**, Fortbildungstagung der Oesterreichischen Gesellschaft fuer Urologie und Andrologie, Redoutensaele, Linz, AUT 11/16/2013
Konstante PDE-5-Hemmung—Welche Patienten profitieren?
- **Invited lecturer**, Update Blasenkarzinom, Landeskrankenhaus Hall i. Tirol, AUT 11/22/2013
Operative Therapiestrategien des muskelfiltrierenden Blasentumors
- **Invited lecturer**, First Interdisciplinary Prostate Cancer Symposium, Vienna, AUT 11/29/2013
Prostate cancer: a common disease with many faces
- **Invited lecturer**, Pediatric Surgery Postgraduate Seminars, Vienna, AUT 12/4/2013
Neuropathic Bladder, Bladder Reconstruction, Research in Regenerative Urology, and Pediatric Voiding Disorders
Primer for a successful career as a physician-scientist
- **Invited guest**, 12th Meeting of the Association of Academic European Urologists, Paris, FR 12/7/2013
Prediction of cisplatin-resistance in bladder cancer: HOXA- as a novel epigenetic biomarker
- **Invited lecturer**, Dept. of Urology, Universitätsklinikum Aachen, Aachen, DL 11/12/2013
Upper tract urothelial carcinoma: from diagnosis to therapy
How to obtain the best results in the management of muscle-invasive bladder cancer 12/12/2013
- **Invited lecturer**, Fun meeting, Semmelweis Klinik, Budapest, Hungary 2/21/2014
T1 High Grade Bladder Cancer: How to Separate The Pussycat from the Tiger
- **Invited lecturer**, State of the art and horizons in oncology, Medical Univ Vienna, Comprehensive Cancer Center, Vienna, Austria 3/4/2014
Surgical management of bladder cancer
- **Invited lecturer**, 23rd International Symposium of the Endourology and ESWL Section of the Polish Urological Association, Wroclaw, Poland 3/8/2014
Optimal endoscopic management of T1 bladder cancer
Upper tract urothelial carcinoma: role of endoscopy
- **Invited lecturer**, USANZ 67th Annual Scientific Meeting, Brisbane, AUS 3/17-9/2014
Clinical impact of histologic variants urothelial and non-urothelial cancer
Prostate cancer plenary: high-risk
Upper tract tumors: controversies revisited in 2014
Prostate cancer prevention: it is neither possible nor achievable
Prostate cancer and hormone therapy: treating biochemically relapsed prostate cancer
Meet the expert: bladder cancer

- **Invited lecturer**, 2.Fachtagung Prostatakarzinom, Vienna, AUT 3/21/2014
“Darf’s ein bisschen mehr sein”- Chirurgie beim fortgeschrittenen Prostatakarzinom
Interaktive Falldiskussion: Veteranen versus Jungstars
“Wer zuerst kommt...”- Enzalutamide versus Abiraterone
- **Course Director and Lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/13/2013
 ESU course 31 Current concepts and controversy in the diagnosis and management of upper tract urothelial carcinoma (UTUC)
Prognostic and predictive factors, pathology
Treatment of localized high risk (invasive) and metastatic cancer
- **Course Lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/14/2013
 ESU course 20 How to write a manuscript and get it published in European Urology
How to write a clinical research article
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
 Joint session of the EAU and the Iranian Urological Association (IUA)
Identifying high risk localized prostate cancer
- **Invited and moderator lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
 Joint session of the EAU and the Maghreb Union Countries
Biomarkers of prostate cancer aggressiveness
Bladder cancer session
Surgical quality indicators of radical cystectomy
- **Invited lecturer**, plenary session, 29th Annual EAU Congress, Stockholm, Sweden. 4/13/2014
 Diagnosis and treatment of non-muscl invasive bladder cancer
How to improve the outcome of transurethral resection of bladder tumors
- **Invited lecturer**, 29th Annual EAU Congress, Stockholm, Sweden. 4/11/2014
 Innovation Approaches in Urological Cancers. Satellite Symposium Ipsen
“Think out of the box” : Target tumor microenvironment to improve prostate cancer management
- **Invited lecturer**, Frühjahrstagung des Berufsverbandes der Österreichischen Urologen 2014, Panhans Grand Hotel, NÖ, AUT. 2/5/2014
 Festvortrag: *Das Blasenkarzinom: aktuelle Therapieoptionen*
- **Invited lecturer**, Wrap-Up EAU 2014, Museumsquartier, Vienna, AUT. 9/5/2014
Das Blasenkarzinom
- **Co-chair** of Betmiga™ launch symposium, Sophiensäle, Vienna, AUT. 10/5/2014
- **Invited lecture** at 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft Für Urologie and Andrologie, Erlangen, DE. 15/5/2014
Diagnostik und Therapie des oberen Harntraktumors
- **Chair** at 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft Für Urologie and Andrologie, Erlangen, DE. 15/5/2014
Kontroversen in der Urologie
- **2nd Challenges in Endourology, Paris, France**
Chair of Workshop entitled Clinical Innovations in Endourology 2/6/2014
Chair of Live Surgery Session II: Upper and Lower Tract 3/6/2014
- **The British Association of Urological Surgeons Annual Meeting, Liverpool, UK**

- Invited lecture:** Personalised Therapeutic Strategies in Urothelial Cancer 6/23/2014
- Course lecture:** How successful authors approach writing a clinical or surgical paper at BJU International Course - How to Get Published in a Modern Surgical Journal 6/24/2014
- Invited lecture:** Contemporary concepts in upper tract urothelial carcinoma 6/26/2014
- **Invited lectures,** Friends of Israel Urology, Tel Aviv, Israel 7/3/2014
Saturation biopsy of the prostate: con
Prostatic invasion of the urothelial carcinoma
- **Invited lecture,** Uroforum 2014, Barcelona, Spain 7/8/2014
Future of non-muscle invasive bladder cancer management
- **Course lectures,** ESU-Weill Cornell Masterclass in General Urology, Salzburg, AUT 7/10/2014
High risk prostate cancer: surgery or radiotherapy?
Treatment of biochemical progression after local therapy
Castrate resistant prostate cancer
- **Invited lecture,** FinnBladder 30 year Anniversary Meeting, Turku, Finland 9/1/2014
Unmet needs and objectives in bladder cancer care
- **Invited lecture,** 66.Kongressder Deutschen Gesellschaft für Urologie, Düsseldorf, GE 10/4/2014
Blasenkarzinom- was muss ich 2014 wissen?
- **Invited lectures,** 34th Congress of the Societe Internationale d'Urologie, Glasgow, UK
Major observations in upper tract urothelial carcinoma: aristolochia acid 10/12/2014
Oncologic outcomes of organ-sparing surgery for invasive penile cancer 10/13/2014
Disparate twins: biological and clinical differences between bladder and upper tract urothelial carcinoma 10/14/2014
- **Invited lecture,** 18. Österreich Tag-Wieviel Körper braucht der Mensch, Wien 10/16/2014
Wieviel Potenz macht den Mann zum Mann?
- **Invited lecture,** Urocyclicum 2014, St Wolfgang, Salzkammergut, Österreich 10/17/2014
Trends in der Urologie
- **Invited lecture,** Czech Urological Society Annual Meeting 2014, Brno, Czech Republic 10/23/2014
Trends and novelties in upper tract urothelial carcinoma
- **Invited lecture** – Fortbildungstagung der Österreichischen Gesellschaft für Urologie und Andrologie. 7-8 November 2012, Linz, Austria 11/7/2014
Rauchen- der Einfluss in der Uro-Onkologie
- **Invited lecture** – 6.Symposium Urologische Forschung der Deutschen Gesellschaft für Urologie, Homburg/Saar, Germany 11/14/2014
15 Tips für eine erfolgreiche Karriere as Physician-scientist

PEER-REVIEWED PUBLICATIONS

(**h-index:** 6; total number of citations: 15685; www.scopus.com accessed 9/1/2014)

(**h-index:** 80; i10-index: 420; total number of citations: 39127; www.google.com accessed 9/1/2014)

1. Trudeau V, Gandaglia G, Shiffmann J, Popa I, **Shariat SF**, Montorsi F, Perrotte P, Trinh QD, Karakiewicz PI, Sun M Robot-assisted versus laparoscopic nephroureterectomy for upper-tract

- urothelial cancer: A population-based assessment of costs and perioperative outcomes. *Can Urol Assoc J.* 2014 Sep;8(9-10):E695-E701. PMID: 25408809
2. Aziz A, **Shariat SF**, Roghmann F, Brookman-May S, Stief CG, Rink M, Chun FK, Fisch M, Novotny V, Froehner M, Wirth MP, Schnabel MJ, Fritsche HM, Burger M, Pycha A, Brisuda A, Babjuk M, Vallo S, Haferkamp A, Roigas J, Noldus J, Stredle R, Volkmer B, Bastian PJ, Xylinas E, May M. Prediction of Cancer-Specific Survival After Radical Cystectomy in pT4a Urothelial Carcinoma of the Bladder - Development of a Tool for Clinical Decision-making. *BJU Int.* 2014 Nov 10. PMID: 25381844
 3. Mathieu R, **Shariat SF**, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Tewari A, Montorsi F, Briganti A, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth LA, Rieken M, Bachman A, Xylinas E, Robinson BD, Bensalah K, Margreiter M. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World J Urol.* 2014 Oct 26. PMID: 25344896
 4. Colin P, Irani J, Drouin SJ, **Shariat SF**, Rouprêt M. Prognostic factors of upper tract urothelial carcinomas and impact on survival: A systematic review for the yearly scientific report of the French National Association of Urology.] *Prog Urol.* 2014 Sep 5. pii: S1166-7087(14)00204-8. PMID: 25199726
 5. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer.* 2014 Sep 3. PMID: 25186283
 6. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, **Shariat SF**, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. *Eur Urol.* 2014 Sep 22. PMID: 25257030
 7. Hofbauer SL, Pantuck AJ, de Martino M, Lucca I, Haitel A, **Shariat SF**, Belldegrun AS, Klatter T. The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. *Urol Oncol.* 2014 Sep 15. PMID: 25240758
 8. van Rhijn BW, Catto JW, Goebell PJ, Knüchel R, **Shariat SF**, van der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Dräger BJ, Kiemeny LA. Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. *Urol Oncol.* 2014 Sep 9. PMID: 25217465
 9. Sevcenco S, Haitel A, Ponhold L, Susani M, Fajkovic H, **Shariat SF**, Hiess M, Spick C, Szarvas T, Baltzer PA. Quantitative apparent diffusion coefficient measurements obtained by 3-tesla MRI are correlated with biomarkers of bladder cancer proliferative activity. *PLoS One.* 2014 Sep 9;9(9):e106866. PMID: 25202965
 10. Colin P, Irani J, Drouin SJ, **Shariat SF**, Rouprêt M. Prognostic factors of upper tract urothelial carcinomas and impact on survival: A systematic review for the yearly scientific report of the French National Association of Urology.] *Prog Urol.* 2014 Sep 5. pii: S1166-7087(14)00204-8. PMID: 25199726
 11. Haddad AQ, Kapur P, Singla N, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Sagalowsky A, Lotan Y, Margulis V. Validation of

- mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. *Cancer*. 2014 Sep 3. PMID: 25186283
12. Gupta A, Atoria CL, Ehdaie B, **Shariat SF**, Rabbani F, Herr HW, Bochner BH, Elkin EB. Risk of Fracture After Radical Cystectomy and Urinary Diversion for Bladder Cancer. *J Clin Oncol*. 2014 Sep 2. PMID: 25185104
 13. Al Hussein Al Awamlh B, Wang LC, Nguyen DP, Rieken M, Lee RK, Lee DJ, Flynn T, Chrystal J, **Shariat SF**, Scherr DS. Is continent cutaneous urinary diversion a suitable alternative to orthotopic bladder substitute and ileal conduit after cystectomy? *BJU Int*. 2014 Aug 28. PMID: 25168771
 14. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer-specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. *J Urol*. 2014 Jul 22. PMID: 25063493
 15. Neuzillet Y, Colin P, Phé V, **Shariat SF**, Rouprêt M. Surgical treatment of upper tract urothelial carcinomas by nephroureterectomy: State of the art for the yearly scientific report of the French National Association of Urology. *Prog Urol*. 2014 Aug 26. PMID: 25158323
 16. Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Fairey AS, Rendon R, Izawa J, Black PC, Lacombe L, **Shariat SF**, Kassouf W. Conditional Survival After Radical Nephroureterectomy for Upper Tract Carcinoma. *Eur Urol*. 2014 Aug 18. PMID: 25145551
 17. Hofbauer SL, de Martino M, Seemann C, Zamani N, Lucca I, Haitel A, **Shariat SF**, Klatter T. Associations between presenting symptoms, clinicopathological parameters, and prognosis in a contemporary series of patients with renal cell carcinoma. *Korean J Urol*. 2014 Aug;55(8):505-10. Epub 2014 Aug 8. PMID:25132943
 18. Hofbauer SL, Stangl KI, de Martino M, Lucca I, Haitel A, **Shariat SF**, Klatter T. Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma. *Br J Cancer*. 2014 Aug 12. PMID: 25117808
 19. Yakoubi R, Colin P, Seisen T, Léon P, Nison L, Bozzini G, **Shariat SF**, Rouprêt M. Radical nephroureterectomy versus endoscopic procedures for the treatment of localised upper tract urothelial carcinoma: A meta-analysis and a systematic review of current evidence from comparative studies. *Eur J Surg Oncol*. 2014 Jul 25. Review. PMID: 25108813
 20. Nuhn P, Novara G, Seitz C, Gupta A, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Tritschler S, Martínez-Salamanca JI, Ficarra V, Karakiewicz PI, Mazzoleni G, **Shariat SF**, Bastian PJ. Prognostic value of prior history of urothelial carcinoma of the bladder in patients with upper urinary tract urothelial carcinoma: results from a retrospective multicenter study. *World J Urol*. 2014 Jul 22. PMID: 25048439
 21. Krabbe LM, Svatek RS, **Shariat SF**, Messing E, Lotan Y. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort. *Urol Oncol*. 2014 Jul 16. PMID: 25044253
 22. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeny LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Freja B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, **Shariat**

- SF**, Palou J. Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. *Eur Urol*. 2014 Jul 16. PMID: 25043942
23. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, Briganti A, **Shariat SF**. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. *Br J Cancer*. 2014 Jul 15;111(2):213-9. PMID: 25003663
 24. de Martino M, Zhuang D, Klätte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, **Shariat SF**. Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib. *Cancer Biol Ther*. 2014 Jun 27;15(9). PMID: 24971884
 25. Compoj E, West J, Mian M, Kluth LA, Karl A, Dechet C, **Shariat SF**, Stief CG, Trenti E, Palermo S, Lodde M, Horninger W, Madersbacher S, Pycha A. Comparison of Complications from Radical Cystectomy between Old-Old versus Oldest-Old Patients. *Urol Int*. 2014 Jun 24. PMID: 24969739
 26. Sevcenco S, Ponhold L, Heinz-Peer G, Fajkovic H, Haitel A, Susani M, **Shariat SF**, Szarvas T, Baltzer PA. Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. *Urol Oncol*. 2014 Jun 21. PMID: 24962659
 27. Becker A, Ravi P, Roghmann F, Trinh QD, Tian Z, Larouche A, Kim S, **Shariat SF**, Kluth L, Dahlem R, Fisch M, Graefen M, Eichelberg C, Karakiewicz PI, Sun M. Laparoscopic radical nephrectomy vs laparoscopic or open partial nephrectomy for T1 renal cell carcinoma: comparison of complication rates in elderly patients during the initial phase of adoption. *Urology*. 2014 Jun;83(6):1285-93. PubMed PMID: 24862392.
 28. Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, Moschini M, Sun M, Karakiewicz PI, **Shariat SF**, Montorsi F, Briganti A. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. *Eur Urol*. 2014 May 29. PMID: 24882672.
 29. Lucca I, **Shariat SF**, Hofbauer SL, Klätte T. Outcomes of minimally invasive simple prostatectomy for benign prostatic hyperplasia: a systematic review and meta-analysis. *World J Urol*. 2014 May 31. PubMed PMID: 24879405.
 30. Rieken M, Djajadiningrat RS, Kluth LA, Favaretto RL, Xylinas E, Guimaraes GC, Soares FA, Kent M, Sjoberg DD, Horenblas S, **Shariat SF**. Predictors of Cancer-specific Mortality After Disease Recurrence in Patients with Squamous Cell Carcinoma of the Penis. *Eur Urol*. 2014 Jun 9. PMID: 24924553.
 31. Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer SL, de Martino M, Karakiewicz PI, Briganti A, Trinh QD, Seitz C, Fritsche HM, Burger M, Lotan Y, Kramer G, **Shariat SF**, Klätte T. Adjuvant cisplatin-based combination chemotherapy for lymph node-positive urothelial carcinoma of the bladder following radical cystectomy: a retrospective international study of more than 1500 patients. *BJU Int*. 2014 Jun 6. PubMed PMID: 24905084.
 32. Simonis K, **Shariat SF**, Rink M. Smoking and smoking cessation effects on oncological outcomes in nonmuscle invasive bladder cancer. *Curr Opin Urol*. 2014 May 30. PubMed PMID: 24887046.
 33. Lotan Y, Svatek RS, Krabbe LM, Xylinas E, Klätte T, **Shariat SF**. Prospective External Validation of Model for Bladder Cancer Detection. *J Urol*. 2014 May 21. PubMed PMID: 24859442.
 34. Aziz A, Fritsche HM, Gakis G, Kluth LA, Al-Sayed Hassan F, Engel O, Dahlem R, Otto W, Gierth M, Denzinger S, Schwentner C, Stenzl A, **Shariat SF**, Fisch M, Burger M, Rink M. Comparative

- analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. *Urol Oncol.* 2014 May 22. PubMed PMID: 24856977.
35. Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, Nyirády P, Rouprêt M, Margulis V, Lotan Y, de Martino M, Hofbauer SL, Karakiewicz PI, Briganti A, Novara G, **Shariat SF**, Klatter T. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU Int.* 2014 May 13. PubMed PMID: 24825476.
 36. Tschirdewahn S, Reis H, Niedworok C, Nyirady P, Szendrői A, Schmid KW, **Shariat SF**, Kramer G, Vom Dorp F, Rübber H, Szarvas T. Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. *Urol Oncol.* 2014 May 7. PubMed PMID: 24814404.
 37. Ehdaie B, **Shariat SF**, Savage C, Coleman J, Dalbagni G. Postoperative nomogram for disease recurrence and cancer-specific death for upper tract urothelial carcinoma: comparison to American joint committee on cancer staging classification. *Urol J.* 2014 May 6;11(2):1435-41. PubMed PMID: 24807756.
 38. Margreiter M, Heinisch BB, Schwarzer R, Klatter T, **Shariat SF**, Ferlitsch A. Lower urinary tract symptoms in patients with liver cirrhosis. *World J Urol.* 2014 May 6. PubMed PMID: 24798455.
 39. Rieken M, Schubert T, Xylinas E, Kluth L, Rouprêt M, Trinh QD, Lee RK, Al Hussein Al Awamlh B, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Bachmann A, **Shariat SF**; for the UTUC Collaboration. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol.* 2014 Apr 13. pii: S0748-7983(14)00380-1. PubMed PMID: 24780094.
 40. Schmid M, **Shariat SF**, Soave A, Engel O, Fisch M, Rink M. Contemporary gender-specific outcomes in Germany after radical cystectomy for bladder cancer. *Curr Urol Rep.* 2014 Jun;15(6):409. PubMed PMID: 24756451.
 41. Weibl P, Hora M, Kollarik B, **Shariat SF**, Klatter T. Management, pathology and outcomes of Bosniak category IIF and III cystic renal lesions. *World J Urol.* 2014 Apr 18. PubMed PMID: 24744224.
 42. Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, Remzi M, Weibl P, **Shariat SF**, Baltzer PA. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *Eur J Radiol.* 2014 Jun;83(6):909-13. doi: 10.1016/j.ejrad.2014.02.026. Epub 2014 Mar 24. PubMed PMID: 24709332.
 43. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, **Shariat SF**, Maggi M, Zattoni F, Carini M, Novara G. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. *J Sex Med.* 2014 Apr 7. PubMed PMID: 24708055.
 44. de Martino M, Leitner CV, Seemann C, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatter T. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma. *BJU Int.* 2014 Apr 4. PubMed PMID: 24698164.
 45. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the

- International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep*. 2014 May;15(5):404. PubMed PMID: 24682884.
46. **Shariat SF**. Incorporating biomarker research in a real-world setting: challenges of a prophecy. *Urol Oncol*. 2014 Apr;32(3):219-21. PubMed PMID: 24679461.
 47. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, **Shariat SF**, Fisch M, Rink M. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol*. 2014 Mar 13. pii: S0748-7983(14)00348-5. PubMed PMID: 24674298.
 48. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, **Shariat SF**, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg*. 2014 Apr;57(2):82-8. PubMed PMID: 24666444; PubMed Central PMCID: PMC3968195.
 49. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, **Shariat S**, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A. How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. *J Endourol*. 2014 Mar 24. PubMed PMID: 24660774.
 50. Szarvas T, Reis H, Kramer G, **Shariat SF**, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübber H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. *Hum Pathol*. 2014 Apr;45(4):674-82. PubMed PMID: 24656090.
 51. **Shariat SF**, Klatter T. Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. *BJU Int*. 2014 Apr;113(4):516-7 PubMed PMID: 24629083.
 52. Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, **Shariat SF**, Rübber H, Dorp FV. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. *Int J Cancer*. 2014 Feb 24. doi: 10.1002/ijc.28808. PubMed PMID: 24615121.
 53. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, **Shariat SF**, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. *Eur Urol*. 2014 Feb 26. pii: S0302-2838(14)00167-5. PubMed PMID: 24613684.
 54. Sevcenco S, Krssak M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, **Shariat SF**, Baltzer PA. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. *World J Urol*. 2014 Mar 9. PubMed PMID: 24609220.
 55. de Martino M, **Shariat SF**, Hofbauer SL, Lucca I, Taus C, Wiener HG, Haitel A, Susani M, Klatter T. Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer. *World J Urol*. 2014 Feb 23. PubMed PMID: 24562316.
 56. Schoenthaler M, Avcil T, Sevcenco S, Nagele U, Hermann TE, Kuehhas FE, **Shariat SF**, Frankenschmidt A, Wetterauer U, Miernik A. Single-Incision Transumbilical Surgery (SITUS) versus Single-Port Laparoscopic Surgery and conventional laparoscopic surgery: a prospective randomized comparative study of performance with novices in a dry laboratory. *World J Urol*. 2014 Feb 23. [Epubahead of print] PubMed PMID: 24562315.
 57. Hansen J, Gandaglia G, Bianchi M, Sun M, Rink M, Tian Z, Meskawi M, Trinh QD, **Shariat SF**, Perrotte P, Chun FK, Graefen M, Karakiewicz PI. Re-assessment of 30-, 60- and 90-day mortality rates in non-metastatic prostate cancer patients treated either with radical prostatectomy or radiation therapy. *Can Urol Assoc J*. 2014 Jan-Feb;8(1-2):E75-80. doi: 10.5489/cuaj.749. PubMed PMID: 24554978; PubMed Central PMCID: PMC3926930.

58. Becker A, Bianchi M, Hansen J, Tian Z, **Shariat SF**, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol.* 2014 Feb 11. PubMed PMID: 24515596.
59. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, **Shariat SF**, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol.* 2014 Jan 28. pii: S0302-2838(14)00095-5. doi: 10.1016/j.eururo.2014.01.026. PubMed PMID: 24495466.
60. Klatter T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, **Shariat SF**. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol.* 2014 Feb 1. PubMed PMID: 24495451.
61. Gandaglia G, Popa I, Abdollah F, Schiffmann J, **Shariat SF**, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol.* 2014 Jan 24. PubMed PMID: 24486024.
62. Messer JC, **Shariat SF**, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. *Urology.* 2014 Apr;83(4):863-7. PubMed PMID: 24485993.
63. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, **Shariat SF**, Rouprêt M. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int.* 2014 Jan 21. PubMed PMID: 24447471.
64. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, **Shariat SF**. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol.* 2014 May;32(4):433-40. PubMed PMID: 24433754.
65. Lee DJ, Xylinas E, Rieken M, Khani F, Klatter T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, **Shariat SF**, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol.* 2013 Dec 25. PMID: 24388440.
66. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, **Shariat SF**, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. *Eur Urol.* 2013 Dec 27. PubMed PMID: 24388438.
67. Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, **Shariat SF**, Stenzl A, Fisch M, Gakis G. Impact of preoperative anemia on oncologic outcomes of upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol.* 2014 Feb;191(2):316-22. vPMID:24036235

68. Sevcenco S, Heinz-Peer G, Ponhold L, Javor D, Kuehhas FE, Klingler HC, Remzi M, Weibl P, **Shariat SF**, Baltzer PA. Utility and limitations of 3-Tesla diffusion-weighted magnetic resonance imaging for differentiation of renal tumors. *Eur J Radiol*. 2014 Mar 24. PMID: 24709332
69. Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, **Shariat SF**, Maggi M, Zattoni F, Carini M, Novara G. Impact of Medical Treatments for Male Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia on Ejaculatory Function: A Systematic Review and Meta-Analysis. *J Sex Med*. 2014 Apr 7. PMID: 24708055
70. de Martino M, Leitner CV, Seemann C, Hofbauer SL, Lucca I, Haitel A, **Shariat SF**, Klatte T. Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma. *BJU Int*. 2014 Apr 4. PMID:24698164
71. Martínez-Salamanca JI, Linares E, González J, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Evans CP, Gontero P, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Nguyen HG, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Faba OR, Russo P, **Shariat SF**, Spahn M, Terrone C, Tilki D, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). *Curr Urol Rep*. 2014 May;15(5):404. PMID: 24682884
72. Soave A, Dahlem R, Hansen J, Weisbach L, Minner S, Engel O, Kluth LA, Chun FK, **Shariat SF**, Fisch M, Rink M. Gender-specific outcomes of bladder cancer patients: A stage-specific analysis in a contemporary, homogenous radical cystectomy cohort. *Eur J Surg Oncol*. 2014 Mar 13. PMID:24674298
73. Ravi P, Trinh VQ, Sun M, Sammon J, Sukumar S, Gervais MK, **Shariat SF**, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD. Is there any evidence of a "July effect" in patients undergoing major cancer surgery? *Can J Surg*. 2014 Apr;57(2):82-8. PMID: 24666444
74. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, **Shariat S**, Cantiello F, Damiano R, Guazzoni G, Montorsi F, Briganti A. How to Optimize Patient Selection for Robot-Assisted Radical Prostatectomy: Functional Outcome Analyses from a Tertiary Referral Center. *J Endourol*. 2014 Mar 24. PMID :24660774
75. **Shariat SF**. Incorporating biomarker research in a real-world setting: Challenges of a prophecy. *Urol Oncol*. 2014 Apr;32(3):219-221. doi: 10.1016/j.urolonc.2014.01.006. Review. PMID: 24679461
76. Szarvas T, Reis H, Kramer G, **Shariat SF**, Vom Dorp F, Tschirdewahn S, Schmid KW, Kovalszky I, Rübber H. Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. *Hum Pathol*. 2014 Apr;45(4):674-82. PMID: 24656090
77. Szarvas T, Tschirdewahn S, Niedworok C, Kramer G, Sevcenco S, Reis H, **Shariat SF**, Rübber H, Dorp FV. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. *Int J Cancer*. 2014 Feb 24. PMID: 24615121
78. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, **Shariat SF**, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review. *Eur Urol*. 2014 Feb 26. pii: S0302-2838(14)00167-5. PMID: 24613684
79. Sevcenco S, Krssak M, Javor D, Ponhold L, Kuehhas FE, Fajkovic H, Haitel A, **Shariat SF**, Baltzer PA. Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy. *World J Urol*. 2014 Mar 9. PMID: 24609220

81. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, **Shariat SF**, Scherr DS. Robotic-assisted radical cystectomy with extracorporeal urinary diversion for urothelial carcinoma of the bladder: analysis of complications and oncologic outcomes in 175 patients with a median follow-up of 3 years. *Urology*. 2013 Dec;82(6):1323-9. PMID: 24295248
82. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, **Shariat SF**, Abdollah F, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol*. 2014 Jan 28. PMID: 24495466
83. Becker A, Bianchi M, Hansen J, Tian Z, **Shariat SF**, Popa I, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Benefit in regionalization of care for patients treated with nephrectomy: a Nationwide Inpatient Sample. *World J Urol*. 2014 Feb 11. PMID: 24515596
84. Klatte T, Xylinas E, Rieken M, Rouprêt M, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, **Shariat SF**. Effect of ABO blood type on mortality in patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Urol Oncol*. 2014 Feb 1. PMID: 24495451
85. Gandaglia G, Popa I, Abdollah F, Schiffmann J, **Shariat SF**, Briganti A, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol*. 2014 Jan 24. PMID: 24486024
86. Messer JC, **Shariat SF**, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female Gender Is Associated With a Worse Survival After Radical Cystectomy for Urothelial Carcinoma of the Bladder: A Competing Risk Analysis. *Urology*. 2014 Jan 30. PMID: 24485993
87. Seisen T, Colin P, Hupertan V, Yates DR, Xylinas E, Nison L, Cussenot O, Neuzillet Y, Bensalah K, Novara G, Montorsi F, Zigeuner R, Remzi M, **Shariat SF**, Rouprêt M. Post-operative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localized and/or locally advanced upper tract urothelial carcinoma without metastasis. *BJU Int*. 2014 Jan 21. PMID: 24447471
88. Wang LC, Xylinas E, Kent MT, Kluth LA, Rink M, Jamzadeh A, Rieken M, Al Awamlh BA, Trinh QD, Sun M, Karakiewicz PI, Novara G, Chrystal J, Zerbib M, Scherr DS, Lotan Y, Vickers A, **Shariat SF**. Combining smoking information and molecular markers improves prognostication in patients with urothelial carcinoma of the bladder. *Urol Oncol*. 2014 Jan 13. PMID: 24433754
89. Matin SF, **Shariat SF**, Milowsky MI, Hansel DE, Kassouf W, Koppie T, Bajorin D, Grollman AP. Highlights from the first symposium on upper tract urothelial carcinoma. *Urol Oncol*. 2014 Jan 4. pii: S1078-1439(13)00340-2. PMID: 24397995
90. Lee DJ, Xylinas E, Rieken M, Khani F, Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Guo CC, Rioux-Leclercq N, Haitel A, Bolenz C, Bensalah K, Sagalowsky AI, Montorsi F, Lotan Y, **Shariat SF**, Robinson BD, Margulis V. Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol*. 2013 Dec 25. PMID: 2438844
91. Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, **Shariat SF**, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS

- 2011 research group. Prediction of 90-day Mortality After Radical Cystectomy for Bladder Cancer in a Prospective European Multicenter Cohort. *Eur Urol*. 2013 Dec 27. PMID: 24388438
92. Xylinas E, **Shariat SF**. BCG maintenance treatment: An optimal scheme? *Prog Urol*. 2014 Jan;24(1):1-2. doi: 10.1016/j.purol.2013.08.319. Epub 2013 Sep 21. PubMed PMID: 24365621.
93. Krabbe LM, Westerman ME, Bagrodia A, Gayed BA, Khalil D, Kapur P, **Shariat SF**, Raj GV, Sagalowsky AI, Cadeddu JA, Lotan Y, Margulis V. Surgical management of the distal ureter during radical nephroureterectomy is an independent predictor of oncological outcomes: Results of a current series and a review of the literature. *Urol Oncol*. 2014 Jan;32(1):54.e19-26. PubMed PMID: 24360665.
94. Trudeau V, Becker A, Roghmann F, **Shariat SF**, Kluth LA, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh QD, Karakiewicz PI, Sun M. Local tumor destruction in renal cell carcinoma- An inpatient population-based study. *Urol Oncol*. 2014 Jan;32(1):54.e1-7. PubMed PMID:24360664.
95. Briganti A, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, **Shariat SF**, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Patterns and Predictors of Early Biochemical Recurrence After Radical Prostatectomy and Adjuvant Radiation Therapy in Men With pT3N0 Prostate Cancer: Implications for Multimodal Therapies. *Int J Radiat Oncol Biol Phys*. 2013 Dec 1;87(5):960-7. doi: 10.1016/j.ijrobp.2013.09.015. Epub 2013 Oct 23. PMID: 24351411
96. Briganti A, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, **Shariat S**, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol*. 2013 Dec 12. PMID: 24345725
97. Klatte T, Xylinas E, Rieken M, Kluth LA, Rouprêt M, Pycha A, Fajkovic H, Seitz C, Karakiewicz PI, Lotan Y, Babjuk M, de Martino M, Scherr DS, **Shariat SF**. Impact of ABO blood type on outcomes of patients with primary non-muscle-invasive bladder cancer. *J Urol*. 2013 Dec 10. PMID: 24333243
98. Xylinas E, Kluth LA, Lotan Y, Daneshmand S, Rieken M, Karakiewicz PI, **Shariat SF**. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. *Urol Oncol*. 2013 Dec 11. PMID: 24332648
99. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, Sharifi N, Jamzadeh A, Kassouf W, Kaushik D, Boorjian SA, Roghmann F, Noldus J, Masson-Lecomte A, Vordos D, Ikeda M, Matsumoto K, Hagiwara M, Kikuchi E, Fradet Y, Izawa J, Rendon R, Fairey A, Lotan Y, Bachmann A, Zerbib M, Fisch M, Scherr DS, Vickers A, **Shariat SF**. Gender-specific Differences in Clinicopathologic Outcomes Following Radical Cystectomy: An International Multi-institutional Study of More Than 8000 Patients. *Eur Urol*. 2013 Dec 5. PMID: 24331151
100. Lee RK, Abol-Enein H, Artibani W, Bochner B, Dalbagni G, Daneshmand S, Fradet Y, Hautmann RE, Lee CT, Lerner SP, Pycha A, Sievert KD, Stenzl A, Thalmann G, **Shariat SF**. Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. *BJU Int*. 2014 Jan;113(1):11-23. PMID: 24330062
101. Kaag M, Trost L, Thompson RH, Favaretto R, Elliott V, **Shariat SF**, Maschino A, Vertosick E, Raman JD, Dalbagni G. Pre-operative predictors of renal function decline following radical nephroureterectomy for upper tract urothelial carcinoma. *BJU Int*. 2013 Dec 9. PMID: 24314050
102. Xylinas E, Green DA, Otto B, Jamzadeh A, Kluth L, Lee RK, Robinson BD, **Shariat SF**, Scherr DS. Robotic-assisted Radical Cystectomy With Extracorporeal Urinary Diversion for Urothelial

- Carcinoma of the Bladder: Analysis of Complications and Oncologic Outcomes in 175 Patients With a Median Follow-up of 3 Years. *Urology*. 2013 Dec;82(6):1323-9. PMID: 24295248
103. Sooriakumaran P, Srivastava A, **Shariat SF**, Stricker PD, Ahlering T, Eden CG, Wiklund PN, Sanchez-Salas R, Mottrie A, Lee D, Neal DE, Ghavamian R, Nyirady P, Nilsson A, Carlsson S, Xylinas E, Loidl W, Seitz C, Schramek P, Roehrborn C, Cathelineau X, Skarecky D, Shaw G, Warren A, Delprado WJ, Haynes AM, Steyerberg E, Roobol MJ, Tewari AKA Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. *Eur Urol*. 2013 Nov 24. PMID: 24290695
 104. Youssef RF, Lotan Y, Sagalowsky AI, **Shariat SF**, Wood CG, Raman JD, Langner C, Zigeuner R, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Radical nephroureterectomy for pathologic T4 upper tract urothelial cancer: can oncologic outcomes be improved with multimodality therapy? *Int Braz J Urol*. 2013 Sep-Oct;39(5):614-21. doi: 10.1590/S1677-5538.IBJU.2013.05.02. PMID: 24267122
 105. Klatte T, **Shariat SF**, Remzi M. Systematic review and meta-analysis of perioperative and oncological outcomes of laparoscopic cryoablation versus laparoscopic partial nephrectomy for the treatment of small renal tumors. *J Urol*. 2013 Nov 11. PMID: 24231845
 106. Xylinas E, Rouprêt M, **Shariat SF**. Segmental ureterectomy for upper tract urothelial carcinoma: Two procedures with different indications. *Urol Oncol*. 2013 Nov;31(8):1841-3. PMID: 24210083
 107. Trinh VQ, Karakiewicz PI, Sammon J, Sun M, Sukumar S, Gervais MK, **Shariat SF**, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Trinh QD. Venous Thromboembolism After Major Cancer Surgery: Temporal Trends and Patterns of Care. *JAMA Surg*. 2013 Nov 6. doi: 10.1001/jamasurg.2013.3172. PMID: 24197279
 108. Dell'oglio P, Abdollah F, Suardi N, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, **Shariat SF**, Montorsi F, Briganti A. External validation of the european association of urology recommendations for pelvic lymph node dissection in patients treated with robotic-assisted radical prostatectomy. *J Endourol*. 2013 Nov 4. PMID: 24188052
 109. Raman JD, Lin YK, Kaag M, Atkinson T, Crispen P, Wille M, Smith N, Hockenberry M, Guzzo T, Peyronnet B, Bensalah K, Simhan J, Kutikov A, Cha E, Herman M, Scherr D, **Shariat SF**, Boorjian SA. High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. *Urol Oncol*. 2013 Oct 17. PMID: 24140248
 110. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Babjuk M, Bachmann A, Scherr DS, **Shariat SF**. Effect of diabetes mellitus and metformin use on oncologic outcomes of patients treated with radical cystectomy for urothelial carcinoma. *Urol Oncol*. 2013 Oct 17. PMID: 24140245
 111. Xylinas E, Robinson BD, Kluth LA, Volkmer BG, Hautmann R, Küfer R, Zerbib M, Kwon E, Thompson RH, Boorjian SA, **Shariat SF**. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. *Eur J Surg Oncol*. 2013 Sep 18. doi:pii: S0748-7983(13)00762-2. 10.1016/j.ejso.2013.08.023. PMID:24140000
 112. Ploussard G, **Shariat SF**, Dragomir A, Kluth LA, Xylinas E, Masson-Lecomte A, Rieken M, Rink M, Matsumoto K, Kikuchi E, Klatte T, Boorjian SA, Lotan Y, Roghmann F, Fairey AS, Fradet Y, Black PC, Rendon R, Izawa J, Kassouf W. Conditional Survival After Radical Cystectomy for Bladder Cancer: Evidence for a Patient Changing Risk Profile over Time. *Eur Urol*. 2013 Oct 9. doi:pii: S0302-2838(13)01053-1. 10.1016/j.eururo.2013.09.050. PMID:24139235

113. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, **Shariat SF**, Kim SP, Perrotte P, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate*. 2013 Oct 16. doi: 10.1002/pros.22742. PMID: 24132735
114. Solomon DA, Kim JS, Bondaruk J, **Shariat SF**, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T. Frequent truncating mutations of STAG2 in bladder cancer. *Nat Genet*. 2013 Dec;45(12):1428-30. doi: 10.1038/ng.2800. Epub 2013 Oct 13. PMID:24121789
115. Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, Briganti A, Kautzky-Willer A, Bachmann A, **Shariat SF**. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2013 Sep 20. PMID:24113620
116. Babjuk M., Burger M., Zigeuner R., **Shariat S.**, VanRhijn B., Comperat E., Sylvester R., Kaasinen E., Boehe A., Palou J., Roupert M.: Recommendations on the treatment of non-muscle invasive bladder cancer. *Egyptian Journal of Urology* 19 (2): 58-62, 2013
117. Pummer K, Rieken M, Augustin H, Gutsch T, **Shariat SF**. Innovations in diagnostic imaging of localized prostate cancer. *World J Urol*. 2013 Sep 28. PMID: 24078105
118. Kapur P, Christie A, Raman JD, Then MT, Nuhn P, Buchner A, Bastian P, Seitz C, **Shariat SF**, Bensalah K, Rioux-Leclercq N, Xie XJ, Lotan Y, Margulis V, Brugarolas J. BAP1 immunohistochemistry in a multi-institutional cohort predicts outcomes in patients with clear cell renal cell carcinoma. *J Urol*. 2013 Sep 24. PMID: 24076305
119. Misraï V, Faron M, Guillotreau J, Bruguière E, Bordier B, **Shariat SF**, Rouprêt M. Assessment of the learning curves for photoselective vaporization of the prostate using GreenLight™ 180-Watt-XPS laser therapy: defining the intra-operative parameters within a prospective cohort. *World J Urol*. 2013 Sep 26. PMID: 24072009
120. Xylinas E, Kluth L, Passonni N, Trinh QD, Rieken M, Lee RK, Fajkovic H, Novara G, Margulis V, Raman JD, Lotan Y, Rouprêt M, Aziz A, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Walton T, Karakiewicz PI, Montorsi F, Zerbib M, Scherr DS, **Shariat SF**. Prediction of Intravesical Recurrence After Radical Nephroureterectomy: Development of a Clinical Decision-making Tool. *Eur Urol*. 2013 Sep 19. PMID: 24070577
121. Roghmann F, Becker A, Trinh QD, Djahagirian O, Tian Z, Meskawi M, **Shariat SF**, Graefen M, Karakiewicz P, Noldus J, Sun M. Updated assessment of neobladder utilization and morbidity according to urinary diversion after radical cystectomy: A contemporary US-population-based cohort.
122. *Can Urol Assoc J*. 2013 Sep;7(9-10):E552-60. PMID:24069095
123. Rieken M, Kluth LA, Xylinas E, Fajkovic H, Becker A, Karakiewicz PI, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Pummer K, Lee RK, Faison T, Scherr DS, Kautzky-Willer A, Bachmann A, Tewari A, **Shariat SF**. Association of diabetes mellitus and metformin use with biochemical recurrence in patients treated with radical prostatectomy for prostate cancer. *World J Urol*. 2013 Sep 24. PMID:24062093
124. Krabbe LM, Lotan Y, Bagrodia A, Gayed BA, Darwish OM, Youssef RF, Bolenz C, Sagalowsky AI, Raj GV, **Shariat SF**, Kapur P, Margulis V. Prospective comparison of molecular signatures in

- urothelial cancer of the bladder and the upper urinary tract: is there evidence for discordant biology? *J Urol*. 2013 Sep 20. PMID: 24060642
125. Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, Briganti A, Scherr DS, Graefen M, Tewari AK, **Shariat SF**. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? *Urol Oncol*. 2013 Sep 18. PMID: 24055425
 126. Xylinas E, Kluth LA, Rieken M, Karakiewicz PI, Lotan Y, **Shariat SF**. Urine markers for detection and surveillance of bladder cancer. *Urol Oncol*. 2013 Sep 17 PMID: 24054865
 127. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Fajkovic H, Babjuk M, Kautzky-Willer A, Bachmann A, Scherr DS, **Shariat SF**. Association of Diabetes Mellitus and Metformin Use with Oncological Outcomes of Patients with non-muscle invasive Bladder Cancer. *BJU Int*. 2013 Sep 5. PMID: 24053906
 128. Kluth LA, Xylinas E, Kent M, Hagiwara M, Kikuchi E, Matsumoto K, Ikeda M, Dalpiaz O, Zigeuner R, Aziz A, Fritsche HM, Deliere A, Raman JD, Bensalah K, Al-Matar B, Gakis G, Novara G, Klätte T, Remzi M, Comploj E, Pycha A, Rouprêt M, Tagawa ST, Chun FK, Scherr DS, Vickers A, **Shariat SF**. Predictors of survival in patients with disease recurrence following radical nephroureterectomy. *BJU Int*. 2013 Jul 19. PMID: 24053651
 129. Kluth LA, Xylinas E, Rieken M, Ghouayel ME, Sun M, Karakiewicz PI, Lotan Y, Chun FK, Boorjian SA, Lee RK, Briganti A, Rouprêt M, Fisch M, Scherr DS, **Shariat SF**. Impact of perioperative blood transfusion on the outcome of patients undergoing radical cystectomy for urothelial carcinoma of the bladder. *BJU Int*. 2013 Sep 5. PMID: 24053618
 130. Rom M, Waldert M, Schatzl G, Swietek N, **Shariat SF**, Klätte T. Bladder outlet obstruction in men with castration-resistant prostate cancer. *BJU Int*. 2013 PMID: 24053594
 131. **Shariat SF**, Passoni N, Bagrodia A, Rachakonda V, Xylinas E, Robinson B, Kapur P, Sagalowsky AI, Lotan Y. Prospective evaluation of a preoperative biomarker panel for prediction of upstaging at radical cystectomy. *BJU Int*. 2013 Jul 2. PMID: 24053584
 132. Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Rouprêt M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, Briganti A, Montorsi F, Tewari A, **Shariat SF**. Prognosis of patients with pelvic lymph node metastasis following radical prostatectomy: value of extranodal extension and size of the largest lymph node metastasis. *BJU Int*. 2013 Jul 2. PMID: 24053552
 133. de Martino M, Waldert M, Haitel A, Schatzl G, **Shariat SF**, Klätte T. Evaluation of ABO blood group as a prognostic marker in renal cell carcinoma. *BJU Int*. 2013 Sep 5. PMID: 24053513
 134. Xylinas E, Kluth LA, Rieken M, Lee RK, Elghouayel M, Ficarra V, Margulis V, Lotan Y, Rouprêt M, Martinez-Salamanca JI, Matsumoto K, Seitz C, Karakiewicz PI, Zerbib M, Scherr DS, **Shariat SF**. Impact of smoking status and cumulative exposure on intravesical recurrence of upper tract urothelial carcinoma after radical nephroureterectomy. *BJU Int*. 2013 Aug 12. PMID: 24053463
 135. Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, **Shariat SF**, Fisch M, Graefen M, Karakiewicz PI, Briganti A, Chun FK. Percentage of High-Grade Tumor Volume does not Meaningfully Improve Prediction of Early Biochemical Recurrence after Radical Prostatectomy Compared to Gleason Score. *BJU Int*. 2013 Aug 23. PMID: 24053339

136. Rink M, Sharifi N, Fritsche HM, Aziz A, Miller F, Kluth LA, Ngamsri T, Dahlem R, Chun FK, **Shariat SF**, Stenzl A, Fisch M, Gakis G. Impact of Preoperative Anemia on Oncological Outcomes of Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. *J Urol*. 2013 Sep 11. PMID:24036235
137. Gandaglia G, Bianchi M, Trinh QD, Becker A, Larouche A, Abdollah F, Rognmann F, Tian Z, **Shariat SF**, Briganti A, Montorsi F, Karakiewicz PI, Sun M. Survival after nephroureterectomy for upper tract urothelial carcinoma: A population-based competing-risks analysis. *Int J Urol*. 2013 Aug 29. PMID: 24033809
138. Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. *BJU Int*. 2013 Jun 13. PMID: 24007240
139. Kluth LA, **Shariat SF**, Kratzik C, Tagawa S, Sonpavde G, Rieken M, Scherr DS, Pummer K. The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy. *World J Urol*. 2013 Sep 3. PMID: 23999854
140. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, Briganti A, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, **Shariat SF**. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2013 PMID: 23999669
141. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, Lotan Y, Karakiewicz PI, Holmäng S, Babjuk M, Fajkovic H, Seitz C, Klatte T, Pycha A, Bachmann A, Scherr DS, **Shariat SF**. Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder. *Eur Urol*. 2013 Aug 27. PMID: 23998688
142. Xylinas E, Cha EK, Khani F, Kluth LA, Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, Rubin MA, Scherr DS, **Shariat SF**, Robinson BD. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. *J Urol*. 2013 Aug 28. PMID: 23994370
143. Xylinas E, Kent M, Kluth L, Pycha A, Comploj E, Svatek RS, Lotan Y, Trinh QD, Karakiewicz PI, Holmang S, Scherr DS, Zerbib M, Vickers AJ, **Shariat SF**. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder. *Br J Cancer*. 2013 Sep 17;109(6):1460-6. PMID:23982601
144. Rink M, Babjuk M, Catto JW, Jichlinski P, **Shariat SF**, Stenzl A, Stepp H, Zaak D, Witjes JA. Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature. *Eur Urol*. 2013 Jul 19. PMID: 23906669
145. Brookman-May SD, May M, **Shariat SF**, Novara G, Zigeuner R, Cindolo L, De Cobelli O, De Nunzio C, Pahernik S, Wirth MP, Longo N, Simonato A, Serni S, Siracusano S, Volpe A, Morgia G, Bertini R, Dalpiaz O, Stief C, Ficarra V; Members of the CORONA-Project, the SATURN-Project, and the Young Academic Urologists Renal Cancer Group. Time to recurrence is a significant predictor of cancer-specific survival after recurrence in patients with recurrent renal cell carcinoma - results from a comprehensive multi-centre database (CORONA/SATURN-Project). *BJU Int*. 2013 May 23. PMID: 23890378
146. Weisbach L, Dahlem R, Simone G, Hansen J, Soave A, Engel O, Chun FK, **Shariat SF**, Fisch M, Rink M. Lymph node dissection during radical cystectomy for bladder cancer treatment: considerations on relevance and extent. *Int Urol Nephrol*. 2013 Jul 25. PMID: 23884728

147. Audenet F, Audouin M, Drouin SJ, Comperat E, Mozer P, Chartier-Kastler E, Méjean A, Cussenot O, **Shariat SF**, Rouprêt M. Charlson score as a single pertinent criterion to select candidates for active surveillance among patients with small renal masses. *World J Urol.* 2013 Jul 20. PMID: 23873357
148. Krabbe LM, Bagrodia A, Lotan Y, Gayed BA, Darwish OM, Youssef RF, John G, Harrow B, Jacobs C, Gaitonde M, Sagalowsky AI, **Shariat SF**, Kapur P, Margulis V. Ki-67 is an independent predictor of oncological outcomes in patients with high-grade upper tract urothelial carcinoma: results of a prospective analysis and a review of the literature. *J Urol.* 2013 Jul 16. PMID: 23871758
149. Tilki D, Nguyen HG, Dall'era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, **Shariat SF**, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of Histologic Subtype on Cancer-specific Survival in Patients with Renal Cell Carcinoma and Tumor Thrombus. *Eur Urol.* 2013 Jul 10. PMID: 23871402
150. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, **Shariat SF**, Briganti A. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol.* 2013 Jul 2. PMID: 23850255
151. Sammon JD, Karakiewicz PI, Sun M, Ravi P, Ghani KR, Jeong W, Bianchi M, Hansen J, Perrotte P, Peabody JO, Rogers CG, **Shariat SF**, Menon M, Trinh QD. Robot-assisted vs. Laparoscopic Partial Nephrectomy: utilization rates and perioperative outcomes. *Int Braz J Urol.* 2013 May-Jun;39(3):377-86. PMID: 23849569
152. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, **Shariat SF**, Beldegrun AS, Klatte T. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized non-clear cell renal cell carcinoma. *J Urol.* 2013 Jul 2. PMID: 23831313
153. Babjuk M, Burger M, Zigeuner R, **Shariat SF**, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013. *Eur Urol.* 2013 Jun 12. PMID: 23827737
154. Brookman-May S, May M, **Shariat SF**, Zigeuner R, Chromecki T, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Tubaro A, Feciche B, Coman I, Truss M, Pahernik S, Wirth MP, Zastrow S, Dalpiaz O, Fenske F, Waidelich R, Stief C, Gunia S; Members of the CORONA Project. Prognostic Effect of Sarcomatoid Dedifferentiation in Patients With Surgically Treated Renal Cell Carcinoma: A Matched-Pair Analysis. *Clin Genitourin Cancer.* 2013 Jun 29. doi:pii: S1558-7673(13)00087-6. 10.1016/j.clgc.2013.04.026. PMID: 23820063
155. Crivelli JJ, Xylinas E, Kluth LA, Rieken M, Rink M, **Shariat SF**. Effect of Smoking on Outcomes of Urothelial Carcinoma: A Systematic Review of the Literature. *Eur Urol.* 2013 Jun 19. doi:pii: S0302-2838(13)00608-8. 10.1016/j.eururo.2013.06.010. PMID: 23810104
156. Crivelli JJ, Xylinas E, Kluth LA, da Silva RD, Chrystal J, Novara G, Karakiewicz PI, David SG, Scherr DS, Lotan Y, **Shariat SF**. Effect of statin use on outcomes of non-muscle-invasive bladder cancer. *BJU Int.* 2013 Jul;112(2):E4-E12. doi: 10.1111/bju.12150. PMID: 23795797

157. Trinh VQ, Trinh QD, Tian Z, Hu JC, **Shariat SF**, Perrotte P, Karakiewicz PI, Sun M. In-hospital mortality and failure-to-rescue rates after radical cystectomy. *BJU Int.* 2013 Jul;112(2):E20-7. doi: 10.1111/bju.12214. PMID: 23795794
158. Merseburger AS, Herrmann TR, **Shariat SF**, Kyriazis I, Nagele U, Traxer O, Liatsikos EN. EAU Guidelines on Robotic and Single-site Surgery in Urology. *Eur Urol.* 2013 Aug;64(2):277-91. doi: 10.1016/j.eururo.2013.05.034. Epub 2013 May 25. PMID: 23764016
159. Gakis G, Boorjian SA, Briganti A, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, **Shariat SF**, Stenzl A, Wirth M, Stief CG. The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. *Eur Urol.* 2013 May 22. doi:pii: S0302-2838(13)00500-9. 10.1016/j.eururo.2013.05.033. PMID: 23735200
160. Drouin SJ, Comperat E, Varinot J, Vaessen C, Bitker MO, Chartier-Kastler E, Mozer P, **Shariat SF**, Cussenot O, Rouprêt M. The surgical approach can be determined from the pathological specimen obtained after open or robot-assisted laparoscopic radical prostatectomy. *World J Urol.* 2013 May 31. PMID: 23723015
161. Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. *BJU Int.* 2013 Jun;111(8):E283-9. doi: 10.1111/bju.12115. PMID: 23714646
162. Becker A, Roghmann F, Trinh QD, Hansen J, Tian Z, **Shariat SF**, Noldus J, Perrotte P, Graefen M, Karakiewicz PI, Sun M. Sociodemographic disparities in the treatment of small renal masses. *BJU Int.* 2013 Jun;111(8):E274-82. doi: 10.1111/bju.12111. PMID: 23714645
163. Kluth LA, Rink M, Ahyai SA, Fisch M, **Shariat SF**, Dahm P. [Randomized controlled trials terminated prematurely : Beneficial therapy effects.] *Urologe A.* 2013 May 29. German. PMID: 23712423
164. Kluth LA, Rink M, Chun FK, Fisch M, **Shariat SF**, Dahm P. [The likelihood ratio : Estimation of the impact of a diagnostic test on treatment decision]. *Urologe A.* 2013 Jul;52(7):982-5. doi: 10.1007/s00120-013-3145-1. German. PMID: 23708004
165. Rink M, Kluth LA, **Shariat SF**, Fisch M, Dahlem R, Dahm P. [Kaplan-Meier analysis in urological practice]. *Urologe A.* 2013 Jun;52(6):838-41. doi: 10.1007/s00120-013-3150-4. German. PMID: 23703691
166. Trinh QD, Bjartell A, Freedland SJ, Hollenbeck BK, Hu JC, **Shariat SF**, Sun M, Vickers AJ. A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy. *Eur Urol.* 2013 Apr 19. doi:pii: S0302-2838(13)00375-8. 10.1016/j.eururo.2013.04.012. PMID 23664423
167. Bianchi M, Becker A, Trinh QD, Abdollah F, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI, Sun M. An analysis of patients with T2 renal cell carcinoma (RCC) according to tumour size: a population-based analysis. *BJU Int.* 2013 Apr 12. PMID: 23651446
168. Tilki D, Brausi M, Colombo R, Evans CP, Fradet Y, Fritsche HM, Lerner SP, Sagalowsky A, **Shariat SF**, Bochner BH. lymphadenectomy for bladder cancer at the time of radical cystectomy. *Eur Urol.* 2013 Apr 29. PMID: 23648149
169. Lotan Y, Bagrodia A, Passoni N, Rachakonda V, Kapur P, Arriaga Y, Bolenz C, Margulis V, Raj GV, Sagalowsky AI, **Shariat SF**. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. *Eur Urol.* 2013 Apr 3. PMID: 23571005

170. Sun M, **Shariat SF**, Trinh QD, Meskawi M, Bianchi M, Hansen J, Abdollah F, Perrotte P, Karakiewicz PI. An evidence-based guide to the selection of sequential therapies in metastatic renal cell carcinoma. *Ther Adv Urol*. 2013 Apr;5(2):121-8. PMID: 23554847
171. Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, **Shariat SF**, Chun F. The impact of intravesical Gemcitabine and 1/3 dose Bacillus Calmette Guerin instillation therapy on the quality of life in non-muscle-invasive bladder cancer patients: results of a prospective, randomised phase II trial. *J Urol*. 2013 Mar 29. PMID: 23545101
172. Xylinas E, Kluth LA, Crivelli JJ, Rieken M, Margulis V, Seitz C, **Shariat SF**. Impact of statin use on oncologic outcomes of patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *Eur Urol*. 2013 Jun;63(6):1134-5. PMID: 23540954
173. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester R, Burger M, Cowan N, Böhle A, Van Rhijn BW, Kaasinen E, Palou J, **Shariat SF**. European guidelines on upper tract urothelial carcinomas: 2013 update. *Eur Urol*. 2013 Jun;63(6):1059-71. PMID: 23540953
174. Kluth LA, Rink M, **Shariat SF**, Chun FK, Fisch M, Dahm P. Use and interpretation of the number needed to treat in urological practice. *Urologe A*. 2013 May;52(5):682-5. PMID: 23532201
175. Bagrodia A, Kuehhas FE, Gayed BA, Wood CG, Raman JD, Kapur P, Derweesh IH, Bensalah K, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Comparative analysis of oncologic outcomes of partial ureterectomy vs radical nephroureterectomy in upper tract urothelial carcinoma. *Urology*. 2013 May;81(5):972-8. PMID: 23523292
176. Sammon J, Trinh VQ, Ravi P, Sukumar S, Gervais MK, **Shariat SF**, Larouche A, Tian Z, Kim SP, Kowalczyk KJ, Hu JC, Menon M, Karakiewicz PI, Trinh QD, Sun M. Health care-associated infections after major cancer surgery: Temporal trends, patterns of care, and effect on mortality. *Cancer*. 2013 Mar 19. PMID: 23512473
177. Dariane C, Le Cossec C, Drouin SJ, Wolff B, Granger B, Mozer P, Bitker MO, **Shariat SF**, Cussenot O, Rouprêt M. Comparison of oncologic outcomes after radical prostatectomy in men diagnosed with prostate cancer with PSA levels below and above 4 ng/mL. *World J Urol*. 2013 Apr 26. PMID: 23619479
178. Rink M, Kluth LA, **Shariat SF**, Dahlem R, Fisch M, Dahm P. [Confidence intervals and p-values in urology: Interpretation and misinterpretation.] *Urologe A*. 2013 Mar 21. German. PMID: 2351185
179. Rink M, Kluth LA, **Shariat SF**, Chun FK, Fisch M, Dahm P. [Use of PubMed to improve evidence-based medicine in routine urological practice]. *Urologe A*. 2013 Mar;52(3):367-72. German. PMID: 23503794
180. Sun M, Trinh QD, Bianchi M, Hansen J, Abdollah F, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Extent of lymphadenectomy does not improve the survival of patients with renal cell carcinoma and nodal metastases: biases associated with the handling of missing data. *BJU Int*. 2013 Mar 12. PMID: 23490031
181. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: A trend analysis. *Cancer Epidemiol*. 2013 Feb 25. PMID: 2348548
182. Cindolo L, Chiodini P, Brookman-May S, De Cobelli O, May M, Squillacciotti S, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Wirth MP, Dalpiaz O, Chromecki TF, **Shariat SF**,

- Sanchez-Chapado M, Del Carmen Santiago Martin M, Rocco B, Salzano L, Lotrecchiano G, Berardinelli F, Schips L. Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. *BJU Int.* 2013 Mar 7 PMID: 23470199
183. Xylinas E, Rink M, Robinson BD, Lotan Y, Babjuk M, Brisuda A, Green DA, Kluth LA, Pycha A, Fradet Y, Faison T, Lee RK, Karakiewicz PI, Zerbib M, Scherr DS, **Shariat SF**. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Cancer.* 2013 Mar 2. PMID: 23466126
184. Rink M, Xylinas E, Trinh QD, Lotan Y, Margulis V, Raman JD, Fisch M, Lee RK, Chun FK, Abdennabi J, Seitz C, Pycha A, Zlotta AR, Karakiewicz PI, Babjuk M, Scherr DS, **Shariat SF**: Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. *BJU Int.* 2013 Mar 6. PMID: 23465088
185. Xylinas E, Rink M, Margulis V, Clozel T, Lee RK, Comploj E, Novara G, Raman JD, Lotan Y, Weizer A, Roupret M, Pycha A, Scherr DS, Seitz C, Ficarra V, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, **Shariat SF**: Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. *BJU Int.* 2013 Mar 6. PMID: 23464979
186. Trinh QD, Sun M, Kim SP, Sammon J, Kowalczyk KJ, Friedman AA, Sukumar S, Ravi P, Muhletaler F, Agarwal PK, **Shariat SF**, Hu JC, Menon M, Karakiewicz PI. The impact of hospital volume, residency, and fellowship training on perioperative outcomes after radical prostatectomy. *Urol Oncol.* 2013 Feb 28. PMID: 23453659
187. May M, Ficarra V, **Shariat SF**, Zigeuner R, Chromecki T, Cindolo L, Burger M, Gunia S, Feciche B, Wenzl V, Aziz A, Chun F, Becker A, Pahernik S, Simeone C, Longo N, Zucchi A, Antonelli A, Mirone V, Stief C, Novara G, Brookman-May S; Members of the CORONA- and the SATURN projects, and the Young Academic Urologists Renal Cancer Group. Impact of clinical and histopathological parameters on disease-specific survival in patients with collecting duct renal cell carcinoma - Development of a disease-specific risk-model. *J Urol.* 2013 Feb 19. PMID: 23434943
188. Bianchi M, Becker A, Abdollah F, Trinh QD, Hansen J, Tian Z, **Shariat SF**, Perrotte P, Karakiewicz PI, Sun M. Rates of open versus laparoscopic and partial versus radical nephrectomy for T1a renal cell carcinoma: A population-based evaluation. *Int J Urol.* 2013 Feb 19. PMID: 23418921
189. Sun M, Ravi P, Karakiewicz PI, Sukumar S, Sammon J, Bianchi M, **Shariat SF**, Jeong W, Ghani KR, Hansen J, Friedman A, Perrotte P, Peabody JO, Menon M, Trinh QD. Is there a relationship between leapfrog volume thresholds and perioperative outcomes after radical cystectomy? *Urol Oncol.* 2013 Feb 9. PMID: 23403162
190. da Silva RD, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Chade D, Guglielmetti GB, Pycha A, Lotan Y, Karakiewicz PI, Sun M, Fajkovic H, Zerbib M, Scherr DS, **Shariat SF**: Impact of Statin Use on Oncological Outcomes of Patients with Urothelial Carcinoma of the Bladder Treated With Radical Cystectomy. *J Urol.* 2013 Feb 7. PMID: 23395802
191. Kluth LA, Xylinas E, Crivelli JJ, Passoni N, Comploj E, Pycha A, Chrystal J, Sun M, Karakiewicz PI, Gontero P, Lotan Y, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder. *J Urol.* 2013 Jan 31. PMID: 23376707

192. Larré S, Catto JW, Cookson MS, Messing EM, **Shariat SF**, Soloway MS, Svatek RS, Lotan Y, Zlotta AR, Grossman HB. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. *Eur Urol*. 2013 PMID: 23313034
193. Hansen J, Rink M, Graefen M, **Shariat S**, Chun FK: Assays for Prostate Cancer: Changing the Screening Paradigm? *Mol Diagn Ther*. 2013 Jan 25. PMID:23355098
194. Margulis V, **Shariat SF**, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *Eur Urol*. 2012 PMID: 23273681
195. Xylinas E, Rink M, Margulis V, Faison T, Comploj E, Novara G, Raman JD, Lotan Y, Guillonneau B, Weizer A, Pycha A, Scherr DS, Seitz C, Sun M, Trinh QD, Karakiewicz PI, Montorsi F, Zerbib M, Gönen M, **Shariat SF**. Prediction of true nodal status in patients with pathological lymph node negative upper tract urothelial carcinoma at radical nephroureterectomy. *J Urol*. 2012 Dec 14. PMID: 23253960
196. Trinh QD, Sukumar S, Schmitges J, Bianchi M, Sun M, **Shariat SF**, Sammon JD, Jeldres C, Zorn KC, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Effect of nodal metastases on cancer-specific mortality after cytoreductive nephrectomy. *Ann Surg Oncol*. 2012 Dec 23. PMID: 23263779
197. Rink M, Zabor EC, Furberg H, Xylinas E, Ehdaie B, Novara G, Babjuk M, Pycha A, Lotan Y, Trinh QD, Chun FK, Lee RK, Karakiewicz PI, Fisch M, Robinson BD, Scherr DS, **Shariat SF**. Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. *Eur Urol*. 2012 Nov 27 PMID: 23206854 the
198. Najari BB, Rink M, Li PS, Karakiewicz PI, Scherr DS, Shabsigh R, Meryn S, Schlegel PN, **Shariat SF**. Sex disparities in cancer mortality: risks of being a man in the U.S. *J Urol*. 2012 Nov 30. PMID: 23206422
199. Kluth LA, Fajkovic H, Xylinas E, Crivelli JJ, Passoni N, Rouprêt M, Becker A, Comploj E, Pycha A, Holmang S, Gupta A, Lotan Y, Karakiewicz PI, Gontero P, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. *World J Urol*. 2012 Nov 30. PMID: 23196773
200. Tilki D, **Shariat SF**, Lotan Y, Rink M, Karakiewicz PI, Schoenberg MP, Lerner SP, Sonpavde G, Sagalowsky AI, Gupta A. Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy. *BJU Int*. 2012 Nov 26. PMID: 23181623
201. Xylinas E, Cha EK, Sun M, Rink M, Trinh QD, Novara G, Green DA, Pycha A, Fradet Y, Daneshmand S, Svatek RS, Fritsche HM, Kassouf W, Scherr DS, Faison T, Crivelli JJ, Tagawa ST, Zerbib M, Karakiewicz PI, **Shariat SF**. Risk stratification of pT1-3N0 patients after radical cystectomy for adjuvant chemotherapy counselling. *Br J Cancer*. 2012 Nov 20;107(11):1826-32. PMID: 23169335
202. Green DA, Osterberg EC, Xylinas E, Rink M, Karakiewicz PI, Scherr DS, **Shariat SF**. Predictive tools for prostate cancer staging, treatment response and outcomes. *Arch Esp Urol*. 2012 Nov;65(9):787-807. English, Spanish. PMID:23154603
203. Cha EK, Tirsar LA, Schwentner C, Hennenlotter J, Christos PJ, Stenzl A, Mian C, Martini T, Pycha A, Schmitz-Dräger BJ **Shariat SF**. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. *World J Urol*. 2012 Nov 5. PMID: 23124847

204. Thuret R, Sun M, Budaus L, Abdollah F, Liberman D, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. *Cancer Causes Control*. 2012 Oct 30. PMID: 23109172
205. Rouprêt M, Hupertan V, Seisen T, Colin P, Xylinas E, Yates DR, Fajkovic H, Lotan Y, Raman JD, Zigeuner R, Remzi M, Bolenz C, Novara G, Kassouf W, Ouzzane A, Rozet F, Cussenot O, Martinez-Salamanca JI, Fritsche HM, Walton TJ, Wood CG, Bensalah K, Karakiewicz PI, Montorsi F, Margulis V, **Shariat SF**. Prediction of cancer-specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized post-operative nomogram using decision curve analysis. *J Urol*. 2012 Oct 23. PMID: 23103802
206. Xylinas E, Rink M, Novara G, Green DA, Clozel T, Fritsche HM, Guillonneau B, Lotan Y, Kassouf W, Tilki D, Babjuk M, Karakiewicz PI, Montorsi F, Abdennabi J, Trinh QD, Svatek RS, Scherr DS, Zerbib M, **Shariat SF**. Predictors of Survival in Patients With Soft Tissue Surgical Margin Involvement at Radical Cystectomy. *Ann Surg Oncol*. 2012 Oct 26. PMID: 23099729
207. Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, **Shariat SF**, Briganti A, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. *Can Urol Assoc J*. 2012 Aug;6(4):245-50. PMID: 23093532
208. Carlsson SV, Tafe LJ, Chade DC, Sjoberg DD, Passoni N, **Shariat SF**, Eastham J, Scardino PT, Fine SW, Touijer KA. Pathological features of lymph node metastases in predicting biochemical recurrence after radical prostatectomy for prostate cancer. *J Urol*. 2012 Oct 18. PMID: 23085057
209. Sammon JD, Karakiewicz PI, Sun M, Sukumar S, Ravi P, Ghani KR, Bianchi M, Peabody JO, **Shariat SF**, Perrotte P, Hu JC, Menon M, Trinh QD. Robot-assisted vs. Open radical prostatectomy: The differential effect of regionalization, procedure volume and operative approach. *J Urol*. 2012 Oct 18. PMID: 23085052
210. Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, **Shariat SF**, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. *Eur Urol*. 2012 Oct 4. PMID: 23083902
211. Rink M, Xylinas E, Babjuk M, Hansen J, Pycha A, Comploj E, Lotan Y, Sun M, Karakiewicz PI, Abdennabi J, Fajkovic H, Loidl W, Chun FK, Fisch M, Scherr DS, **Shariat SF**. Impact of Smoking on Outcomes of Patients with a History of Recurrent Nonmuscle Invasive Bladder Cancer. *J Urol*. 2012 Oct 17. PMID: 23083868
212. Thuret R, Sun M, Abdollah F, Budaus L, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Karakiewicz PI. Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. *BJU Int*. 2012 Oct 12. PMID: 23057865
213. Rouprêt M, Xylinas E, Colin P, Kluth L, Karakiewicz P, **Shariat SF**. Oncologic Outcomes and Survival in pT0 Tumors After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: Results from of a Large Multicenter International Collaborative Study. *Eur Urol*. 2012 Sep 23. PMID: 23040206
214. Abdollah F, Abdo A, Sun M, Schmitges J, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. *Int J Urol*. 2012 Oct 8. PMID: 23039245

215. Sun M, Bianchi M, Hansen J, Abdollah F, Trinh QD, Lughezzani G, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. *Int J Urol*. 2012 Oct 8. PMID: 23039208
216. Catto JW, **Shariat SF**. The Changing Face of Renal Cell Carcinoma: The Impact of Systematic Genetic Sequencing on Our Understanding of This Tumor's Biology. *Eur Urol*. 2012 Sep 26. PMID: 23026395
217. Green DA, Rink M, Xylinas E, Matin SF, Stenzl A, Roupret M, Karakiewicz PI, Scherr DS, **Shariat SF**. Urothelial Carcinoma of the Bladder and the Upper Tract: Disparate Twins. *J Urol*. 2012 Sep 27. PMID: 23023150
218. Fajkovic H, Cha EK, Xylinas E, Rink M, Pycha A, Seitz C, Bolenz C, Dunning A, Novara G, Trinh QD, Karakiewicz PI, Margulis V, Raman JD, Walton TJ, Baba S, Carballido J, Otto W, Montorsi F, Lotan Y, Kassouf W, Fritsche HM, Bensalah K, Zigeuner R, Scherr DS, Sonpavde G, Roupret M, **Shariat SF**. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma. *World J Urol*. 2012 Sep 26. PMID: 23011256
219. Xylinas E, Kluth L, Mangal S, Roupret M, Karakiewicz PI, **Shariat SF**. Predictive tools for clinical decision-making and counseling of patients with upper tract urothelial carcinoma. *World J Urol*. 2012 Sep 18. PMID: 22986907
220. Trinh QD, Bianchi M, Hansen J, Tian Z, Abdollah F, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI, Sun M. In-hospital Mortality and Failure to Rescue After Cytoreductive Nephrectomy. *Eur Urol*. 2012 Sep 7. pii: S0302-2838(12)01022-6. PMID: 22981674
221. Rink M, Xylinas E, Babjuk M, Pycha A, Karakiewicz PI, Novara G, Dahlem R, **Shariat SF**. Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Sep 5. . PMID: 22980442
222. Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, **Shariat SF**, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J. Treatment Options Available for Bacillus Calmette-Guérin Failure in Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Sep 3. PMID: 22959049
223. Green DA, Rink M, Cha EK, Xylinas E, Chughtai B, Scherr DS, **Shariat SF**, Lee RK. Cost-effective treatment of low-risk carcinoma not invading bladder muscle. *BJU Int*. 2012 Sep 7. PMID: 22958598
224. Rink M, Park K, Volkmer BG, Xylinas E, Hansen J, Cha EK, Robinson BD, Hautmann R, Küfer R, Engel O, Chun FK, Dahlem R, Rubin MA, **Shariat SF**, Mosquera JM. Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy. *Urol Oncol*. 2012 Sep 1. pii: S1078-1439(12)00237-2. PMID: 22944196
225. Rink M, Lee DJ, Kent M, Xylinas E, Fritsche HM, Babjuk M, Brisuda A, Hansen J, Green DA, Aziz A, Cha EK, Novara G, Chun FK, Lotan Y, Bastian PJ, Tilki D, Gontero P, Pycha A, Baniel J, Mano R, Ficarra V, Trinh QD, Tagawa ST, Karakiewicz PI, Scherr DS, Sjoberg DD, **Shariat SF**; for the Bladder Cancer Research Consortium. Predictors of cancer-specific mortality after disease recurrence following radical cystectomy. *BJU Int*. 2012 Sep 3. PMID: 22938654
226. Bachir BG, **Shariat SF**, Zlotta A, Svatek R, Black PC, Shah JB, Kassouf W; on behalf of the Bladder Cancer Think Tank (Bladder Cancer Advocacy Network) and Canadian Bladder Cancer Network (Bladder Cancer Canada). Demographic analysis of randomized controlled trials in bladder cancer. *BJU Int*. 2012 Aug 29. doi: 10.1111/j.1464-410X.2012.11401.x. PMID: 22928764
227. Rink M, Furberg H, Zabor EC, Xylinas E, Babjuk M, Pycha A, Lotan Y, Karakiewicz PI, Novara G, Robinson BD, Montorsi F, Chun FK, Scherr DS, **Shariat SF**. Impact of Smoking and Smoking

- Cessation on Oncologic Outcomes in Primary Non-muscle-invasive Bladder Cancer. *Eur Urol*. 2012 Aug 21. PMID: 22925575
228. Xylinas E, Roupêt M, Kluth L, Scherr DS, **Shariat SF**; for the Upper Tract Urothelial Carcinoma Collaboration (UTUCC). Collaborative Research Networks as a Platform for Virtual Multidisciplinary, International Approach to Managing Difficult Clinical Cases: An Example from the Upper Tract Urothelial Carcinoma Collaboration. *Eur Urol*. 2012 Aug 20. PMID: 22921717
229. Reifsnnyder JE, Ramasamy R, Ng CK, Dipietro J, Shin B, **Shariat SF**, Del Pizzo JJ, Scherr DS. Laparoscopic and open partial nephrectomy: complication comparison using the Clavien system. *JSLs*. 2012 Jan-Mar;16(1):38-44. PMID: 22906328
230. Sammon J, Trinh QD, Sun M, Bianchi M, Schmitges J, **Shariat SF**, Ghani KR, Sukumar S, Jeldres C, Briganti A, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. The effect of gender on nephrectomy perioperative outcomes: a national survey. *Can J Urol*. 2012 Aug;19(4):6337-44. PMID: 22892256
231. Skeldon SC, Semotiuk K, Aronson M, Holter S, Gallinger S, Pollett A, Kuk C, van Rhijn B, Bostrom P, Cohen Z, Fleshner NE, Jewett MA, Hanna S, **Shariat SF**, Van Der Kwast TH, Evans A, Catto J, Bapat B, Zlotta AR. Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. *Eur Urol*. 2012 Aug 2. PMID: 22883484
232. Adibi M, Youssef R, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Montorsi F, Bolenz C, Margulis V. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: Comparison over the three decades. *Int J Urol*. 2012 Aug 12. PMID: 22882743
233. Fajkovic H, Cha EK, Jeldres C, Robinson BD, Rink M, Xylinas E, Chromecki TF, Breinl E, Svatek RS, Donner G, Tagawa ST, Tilki D, Bastian PJ, Karakiewicz PI, Volkmer BG, Novara G, Joul A, Faison T, Sonpavde G, Daneshmand S, Lotan Y, Scherr DS, **Shariat SF**. Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis. *Eur Urol*. 2012 Jul 20. PMID: 22877503
234. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeny LA, La Vecchia C, **Shariat SF**, Lotan Y. Epidemiology and Risk Factors of Urothelial Bladder Cancer. *Eur Urol*. 2012 Jul 25. PMID: 22877502
235. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, Marks LS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, Briganti A, **Shariat SF**, Chun FK. Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. *Eur Urol*. 2012 Jul 20. PMID: 22854248
236. Xylinas E, **Shariat SF**, Zerbib M. Uptake of Laparoscopic Radical Nephroureterectomy in France: A 2003-2011 National Practice Report. *Eur Urol*. 2012 Jul 21. PMID: 22840352
237. Rink M, **Shariat SF**, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PJ, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek RS. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy? *World J Urol*. 2012 Jul 26. PMID: 22832587
238. Hansen J, Rink M, Bianchi M, Kluth LA, Tian Z, Ahyai SA, **Shariat SF**, Briganti A, Steuber T, Fisch M, Graefen M, Karakiewicz PI, Chun FK. External validation of the updated briganti

- nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. *Prostate*. 2012 Jul 20. doi: 10.1002/pros.22559. PMID: 22821742
239. Sukumar S, Sun M, Karakiewicz PI, Friedman AA, Chun FK, Sammon J, Ghani KR, Ravi P, Bianchi M, Jeong W, **Shariat SF**, Hansen J, Peabody JO, Elder JS, Menon M, Trinh QD. National trends and disparities in the use of minimally invasive adult pyeloplasty. *J Urol*. 2012 Sep;188(3):913-8. Epub 2012 Jul 20. PMID: 22819404
240. Rink M, Hansen J, Cha EK, Green DA, Babjuk M, Svatek RS, Xylinas E, Tagawa ST, Faison T, Novara G, Karakiewicz PI, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Comploj E, Tilki D, Bastian PJ, Chun FK, Dahlem R, Scherr DS, **Shariat SF**: Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. *BJU Int*. 2012 Jul 19. PMID: 22809039
241. Rink M, Sjoberg D, Comploj E, Margulis V, Xylinas E, Lee RK, Hansen J, Cha EK, Raman JD, Remzi M, Bensalah K, Novara G, Matin SF, Chun FK, Kikuchi E, Kassouf W, Martinez-Salamanca JI, Lotan Y, Seitz C, Pycha A, Zigeuner R, Karakiewicz PI, Scherr DS, Vickers AJ, **Shariat SF**. Risk of Cancer-specific Mortality following Recurrence After Radical Nephroureterectomy. *Ann Surg Oncol*. 2012 Jul 18. PMID: 22805867
242. Green DA, Rink M, Hansen J, Cha EK, Robinson B, Tian Z, Chun FK, Tagawa S, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**: Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy. *BJU Int*. 2012 Jul 13. PMID: 22805163
243. Novara G, Ficarra V, Rosen RC, Artibani W, Costello A, Eastham JA, Graefen M, Guazzoni G, **Shariat SF**, Stolzenburg JU, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Wilson TG. Systematic Review and Meta-analysis of Perioperative Outcomes and Complications After Robot-assisted Radical Prostatectomy. *Eur Urol*. 2012 Jun 2. PMID: 22749853
244. Novara G, Ficarra V, Mocellin S, Ahlering TE, Carroll PR, Graefen M, Guazzoni G, Menon M, Patel VR, **Shariat SF**, Tewari AK, Van Poppel H, Zattoni F, Montorsi F, Mottrie A, Rosen RC, Wilson TG. Systematic Review and Meta-analysis of Studies Reporting Oncologic Outcome After Robot-assisted Radical Prostatectomy. *Eur Urol*. 2012 Jun 2. PMID: 22749851
245. Brookman-May S, May M, **Shariat SF**, Xylinas E, Stief C, Zigeuner R, Chromecki T, Burger M, Wieland WF, Cindolo L, Schips L, De Cobelli O, Rocco B, De Nunzio C, Feciche B, Truss M, Gilfrich C, Pahernik S, Hohenfellner M, Zastrow S, Wirth MP, Novara G, Carini M, Minervini A, Simeone C, Antonelli A, Mirone V, Longo N, Simonato A, Carmignani G, Ficarra V; members of the CORONA project and the SATURN project. Features Associated with Recurrence Beyond 5 Years After Nephrectomy and Nephron-Sparing Surgery for Renal Cell Carcinoma: Development and Internal Validation of a Risk Model (PRELANE score) to Predict Late Recurrence Based on a Large Multicenter Database (CORONA/SATURN Project). *Eur Urol*. 2012 Jun 22. PMID: 22748912
246. Rink M, Xylinas E, Margulis V, Cha EK, Ehdaie B, Raman JD, Chun FK, Matsumoto K, Lotan Y, Furberg H, Babjuk M, Pycha A, Wood CG, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**; for the Upper Tract Urothelial Carcinoma Collaboration. Impact of Smoking on Oncologic Outcomes of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. *Eur Urol*. 2012 Jun 22. PMID: 22743166
247. Chromecki TF, Cha EK, Fajkovic H, Rink M, Ehdaie B, Svatek RS, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Daneshmand S, Kassouf W, Durand M, Novara G, Fritsche HM, Burger M, Izawa JJ, Brisuda A, Babjuk M, Pummer K, **Shariat SF**: Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy. *BJU Int*. 2012 Jun 21. PMID: 22727036

248. **Shariat SF**, Rink M, Ehdaie B, Xylinas E, Babjuk M, Merseburger AS, Svatek RS, Cha EK, Tagawa ST, Fajkovic H, Novara G, Karakiewicz PI, Trinh QD, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Chun FK, Sonpavde G, Joulal A, Scherr DS, Gonen M. Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy. *Eur Urol*. 2012 Jun 16. PMID: 22727174
249. Rink M, Adam M, Hansen J, Chun FK, Ahyai SA, Remzi M, Schlomm T, Engel O, Heuer R, Eichelberg C, Fisch M, Dahlem R, **Shariat SF**: Upper tract urothelial carcinoma : An update on clinical and pathological prognostic factors. *Urologe A*. 2012 Jun 16. PMID: 22699513
250. Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, **Shariat SF**. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. *J Urol*. 2012 Jun 12. PMID: 22698626
251. Hansen J, Sun M, Bianchi M, Rink M, Tian Z, Hanna N, Meskawi M, Schmitges J, **Shariat SF**, Chun FK, Perrotte P, Graefen M, Karakiewicz PI. Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma treated with partial nephrectomy. *Urology*. 2012 Jun 12. PMID: 22698478
252. Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, Briganti A, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Is a treatment delay in radical prostatectomy safe in individuals with low-risk prostate cancer? *J Sex Med*. 2012 Jun 6. PMID: 22672479
253. Ehdaie B, Furberg H, Zabor EC, Ostroff JS, **Shariat SF**, Bochner BH, Coleman JA, Dalbagni G. Impact of smoking status at diagnosis on disease recurrence and death in upper tract urothelial carcinoma. *BJU Int*. 2012 May 29. PMID: 22642265
254. Sun M, Bianchi M, Trinh QD, Hansen J, Abdollah F, Hanna N, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥ 75 years with multiple comorbidities. *BJU Int*. 2012 May 22. PMID: 22612472
255. Degraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, **Shariat SF**, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, Matusik RJ. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. *PLoS One*. 2012;7(5):e36669. Epub 2012 May 10. PMID: 22590586
256. Xylinas E, Rink M, Cha EK, Clozel T, Lee RK, Fajkovic H, Comploj E, Novara G, Margulis V, Raman JD, Lotan Y, Kassouf W, Fritsche HM, Weizer A, Martinez-Salamanca JI, Matsumoto K, Zigeuner R, Pycha A, Scherr DS, Seitz C, Walton T, Trinh QD, Karakiewicz PI, Matin S, Montorsi F, Zerbib M, **Shariat SF**. Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol*. 2012 May 4. PMID: 22579047
257. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, **Shariat SF**, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. *J Urol*. 2012 May 12. PMID: 22578732
258. Meskawi M, Sun M, Trinh QD, Bianchi M, Hansen J, Tian Z, Rink M, Ismail S, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. A Review of Integrated Staging Systems for Renal Cell Carcinoma. *Eur Urol*. 2012 May 3. PMID: 22575911

259. Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. *Int J Urol*. 2012 May 10. PMID: 22574746
260. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Prospective Evaluation of Molecular Markers for the Staging and Prognosis of Upper Tract Urothelial Carcinoma. *Eur Urol*. 2012 Apr 17. PMID: 22552216
261. Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, **Shariat SF**. Histologic Variants of Upper Tract Urothelial Carcinoma Do Not Affect Response to Adjuvant Chemotherapy After Radical Nephroureterectomy. *Eur Urol*. 2012 Apr 17. No abstract available. PMID: 22537797
262. Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, **Shariat SF**. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. *BJU Int*. 2012 PMID: 22500557
263. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. *Int J Urol*. 2012 Mar 14. PubMed PMID: 22416788.
264. Sammon JD, Morgan M, Djahangirian O, Trinh QD, Sun M, Ghani KR, Jeong W, Jhaveri J, Ehlert M, Schmitges J, Bianchi M, **Shariat SF**, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Marital status: a gender-independent risk factor for poorer survival after radical cystectomy. *BJU Int*. 2012 Mar 27. PubMed PMID: 22449122.
265. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Hansen J, Eichelberg C, Perrotte P, **Shariat SF**, Menon M, Montorsi F, Graefen M, Karakiewicz PI. Annual prostatectomy volume is related to rectal laceration rate after radical prostatectomy. *Urology*. 2012 Apr;79(4):796-803. PubMed PMID: 22469573.
266. Sun M, Bianchi M, Hansen J, Trinh QD, Abdollah F, Tian Z, Sammon J, **Shariat SF**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Chronic kidney disease after nephrectomy in patients with small renal masses: a retrospective observational analysis. *Eur Urol*. 2012 Mar 31. PubMed PMID: 22483407.
267. Lotan Y, Goodman PJ, Youssef RF, Svatek RS, **Shariat SF**, Tangen CM, Thompson IM Jr, Klein EA. Evaluation of vitamin E and Selenium supplementation for the prevention of bladder cancer in SWOG coordinated SELECT. *J Urol*. 2012 Apr 11. PubMed PMID: 22498220.
268. Green DA, Durand M, Gumpeni N, Rink M, Cha EK, Karakiewicz PI, Scherr DS, **Shariat SF**. Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques. *BJU Int*. 2012 Apr 13. PubMed PMID: 22500557.
269. Xylinas E, Rink M, Margulis V, Karakiewicz PI, Bensalah K, **Shariat SF**. Histologic variants of upper tract urothelial carcinoma do not affect response to adjuvant chemotherapy after radical nephroureterectomy. *Eur Urol*. 2012 Apr 17. PubMed PMID: 22537797.
270. Bagrodia A, Youssef RF, Kapur P, Darwish OM, Cannon C, Belsante MJ, Gerecci D, Sagalowsky AI, **Shariat SF**, Lotan Y, Margulis V. Prospective evaluation of molecular markers for the staging and prognosis of upper tract urothelial carcinoma. *Eur Urol*. 2012 Apr 17. PubMed PMID: 22552216.
271. Xylinas E, Rink M, Margulis V, Karakiewicz P, Novara G, **Shariat SF**: Multifocal carcinoma in situ of the upper tract is associated with high risk of bladder cancer recurrence. *Eur Urol*. 2012 Feb 25. PMID: 22402109

272. Trinh QD, Sun M, Sammon J, Tian Z, Bianchi M, **Shariat SF**, Jeong W, Ghani KR, Jeldres C, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Leapfrog volume thresholds and perioperative complications after radical prostatectomy. *Cancer*. 2012 Mar 5. doi: 10.1002/cncr.27486. PMID: 22392599
273. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, **Shariat SF**, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. *Eur Urol*. 2012 Feb 23. PMID 22381168
274. Youssef R, Kapur P, **Shariat SF**, Arendt T, Kabbani W, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Prognostic value of apoptotic markers in squamous cell carcinoma of the urinary bladder. *BJU Int*. 2012 Feb 28. PMID: 22372762
275. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, **Shariat SF**, Vickers A. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. *BJU Int*. 2012 Mar;109 Suppl 2:1-7. PMID: 22257098
276. Rink M, Cha EK, Green D, Hansen J, Robinson BD, Lotan Y, Sagalowsky AI, Chun FK, Karakiewicz PI, Fisch M, Scherr DS, **Shariat SF**. Biomolecular predictors of urothelial cancer behavior and treatment outcomes. *Curr Urol Rep*. 2012 Feb 23. PMID: 22354565
277. Bianchi M, Trinh QD, Sun M, Sammon J, Schmitges J, **Shariat SF**, Sukumar S, Ghani KR, Jeldres C, Perrotte P, Rogers CG, Briganti A, Peabody JO, Montorsi F, Menon M, Karakiewicz PI: Discharge patterns after radical cystectomy: contemporary trends in the United States. *J Urol*. 2012 Feb 13. PMID: 22335867
278. Rink M, Ehdaie B, Cha EK, Green DA, Karakiewicz PI, Babjuk M, Margulis V, Raman JD, Svatek RS, Fajkovic H, Lee RK, Novara G, Hansen J, Daneshmand S, Lotan Y, Kassouf W, Fritsche HM, Pycha A, Fisch M, Scherr DS, **Shariat SF**: Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. *Eur Urol*. 2012 Feb 15. PMID: 22349570
279. Roscigno M, Cha EK, Rink M, Seitz C, Novara G, Chromecki TF, Fritsche HM, Matsumoto K, Walton TJ, Carballido J, Filippo Da Pozzo L, Bertini R, Ficarra V, Otto W, Karakiewicz PI, Pycha A, Fajkovic H, Naspro R, Scherr DS, Montorsi F, **Shariat SF**. International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. *BJU Int*. 2012 Feb 20. PMID: 22348322
280. Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, **Shariat SF**, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: Competing-risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study. *Int J Radiat Oncol Biol Phys*. 2012 Feb 11. PMID: 22330991
281. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Thuret R, Tian Z, **Shariat SF**, Montorsi F, Perrotte P, Karakiewicz PI. Treatment Management of Small Renal Masses in the 21st Century: A Paradigm Shift. *Ann Surg Oncol*. 2012 Feb 10. PMID: 2232295
282. Schmitges J, Trinh QD, Sun M, Hansen J, Bianchi M, Jeldres C, Perrotte P, Dahlem R, **Shariat SF**, Chun FK, Montorsi F, Menon M, Fisch M, Graefen M, Karakiewicz PI. Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. *BJU Int*. 2012 Feb 9. PMID: 22321256
283. Schmitges J, Trinh QD, Sun M, Abdollah F, Bianchi M, Budäus L, Salomon G, Schlomm T, Perrotte P, **Shariat SF**, Montorsi F, Menon M, Graefen M, Karakiewicz PI. Venous thromboembolism after radical prostatectomy: the effect of surgical caseload. *BJU Int*. 2012 Feb 7.

PMID: 22313499

284. Trinh QD, Sun M, Sammon J, Bianchi M, Sukumar S, Ghani KR, Jeong W, Dabaja A, **Shariat SF**, Perrotte P, Agarwal PK, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Disparities in access to care at high-volume institutions for uro-oncologic procedures. *Cancer*. 2012 Feb 1. PMID:22298310
285. Rink M, Chun FK, Chromecki TF, Fajkovic H, Dahlem R, Fisch M, **Shariat SF**. [Advanced bladder cancer in elderly patients : Prognostic outcomes and therapeutic strategies.] *Urologe A*. 2012 Jan 28. German. PMID: 22282102
286. Cha EK, **Shariat SF**, Kormaksson M, Novara G, Chromecki TF, Scherr DS, Lotan Y, Raman JD, Kassouf W, Zigeuner R, Remzi M, Bensalah K, Weizer A, Kikuchi E, Bolenz C, Roscigno M, Koppie TM, Ng CK, Fritsche HM, Matsumoto K, Walton TJ, Ehdaie B, Tritschler S, Fajkovic H, Martínez-Salamanca JI, Pycha A, Langner C, Ficarra V, Patard JJ, Montorsi F, Wood CG, Karakiewicz PI, Margulis V. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur Urol*. 2012 Jan 23. PMID: 22284969
287. **Shariat SF**, Zigeuner R, Rink M, Margulis V, Hansen J, Kikuchi E, Kassouf W, Raman JD, Remzi M, Koppie TM, Bensalah K, Guo CC, Mikami S, Sircar K, Ng CK, Haitel A, Kabbani W, Chun FK, Wood CG, Scherr DS, Karakiewicz PI, Langner C. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current tnm classification. *Eur Urol*. 2012 Jan 24. PMID: 22285763
288. Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, **Shariat SF**. Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature. *Eur Urol*. 2012 Jan 23. PMID: 22280856
289. Rink M, Chun FK, Dahlem R, Soave A, Minner S, Hansen J, Stoupiec M, Coith C, Kluth LA, Ahyai SA, Friedrich MG, **Shariat SF**, Fisch M, Pantel K, Riethdorf S. Prognostic Role and HER2 Expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. *Eur Urol*. 2012 Jan 20. PMID: 22277196
290. Fajkovic H, Cha EK, Jeldres C, Donner G, Chromecki TF, Margulis V, Novara G, Lotan Y, Raman JD, Kassouf W, Seitz C, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Breinl E, Pycha A, Ficarra V, Montorsi F, Karakiewicz PI, Scherr DS, **Shariat SF**. Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma. *J Urol*. 2012 Jan 14. PMID:22248522
291. Rink M, Fajkovic H, Cha EK, Gupta A, Karakiewicz PI, Chun FK, Lotan Y, **Shariat SF**: Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma. *Eur Urol*. 2012 Jan 5. PMID: 22226583
292. Hanna N, Sun M, Trinh QD, Hansen J, Bianchi M, Montorsi F, **Shariat SF**, Graefen M, Perrotte P, Karakiewicz PI. Propensity-Score-Matched Comparison of Perioperative Outcomes Between Open and Laparoscopic Nephroureterectomy: A National Series. *Eur Urol*. 2011 Dec 22. PMID: 22209172
293. Trinh QD, Sammon J, Sun M, Ravi P, Ghani KR, Bianchi M, Jeong W, **Shariat SF**, Hansen J, Schmitges J, Jeldres C, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Perioperative Outcomes of Robot-Assisted Radical Prostatectomy Compared With Open Radical Prostatectomy: Results From the Nationwide Inpatient Sample. *Eur Urol*. 2011 Dec 22. PMID: 22206800

294. Sun M, Abdollah F, Bianchi M, Trinh QD, **Shariat SF**, Jeldres C, Tian Z, Hansen J, Briganti A, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. *Eur J Cancer*. 2011 Dec 21. PMID: 22196034
295. Clements T, Messer JC, Terrell JD, Herman MP, Ng C, Scherr D, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, **Shariat SF**, Raman JD: High grade ureteroscopic biopsy is associated with advanced pathology of upper tract urothelial carcinoma tumors at definitive surgical resection. *J Endourol*. 2011 Dec 22. PMID: 22192113
296. Yafi FA, Novara G, **Shariat SF**, Gupta A, Matsumoto K, Walton TJ, Fritsche HM, El-Hakim A, Trischler S, Martínez-Salamanca JI, Seitz C, Ficarra V, Zattoni F, Karakiewicz PI, Kassouf W. Impact of tumour location versus multifocality in patients with upper tract urothelial carcinoma treated with nephroureterectomy and bladder cuff excision: a homogeneous series without perioperative chemotherapy. *BJU Int*. 2011 Dec 16. PMID: 22177329
297. Kroeger N, Rampersaud EN, Patard JJ, Klatt T, Birkhäuser FD, **Shariat SF**, Lang H, Rioux-Leclercq N, Remzi M, Zomorodian N, Kabbinavar FF, Beldegrun AS, Pantuck AJ Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. *J Urol*. 2012 Feb;187(2):418-23. Epub 2011 Dec 15. PMID: 22177164
298. Schmitges J, Trinh QD, Bianchi M, Sun M, Abdollah F, Ahyai SA, Jeldres C, Steuber T, Perrotte P, **Shariat SF**, Menon M, Montorsi F, Graefen M, Karakiewicz PI: The effect of annual surgical caseload on the rates of in-hospital pneumonia and other in-hospital outcomes after radical prostatectomy. *Int Urol Nephrol*. 2011 Dec 13. PMID: 22160759
299. Sun M, Trinh QD, Bianchi M, Hansen J, Hanna N, Abdollah F, **Shariat SF**, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI. A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. *Eur Urol*. 2011 Dec 3. PMID: 22172373
300. **Shariat SF**, Chromecki TF, Cha EK, Karakiewicz PI, Sun M, Fradet Y, Isbarn H, Scherr DS, Bastian PJ, Pummer K, Fajkovic H, Sagalowsky AI, Ashfaq R, Doblinger M, Cote RJ, Lotan Y. Risk Stratification of Organ Confined Bladder Cancer After Radical Cystectomy Using Cell Cycle Related Biomarkers. *J Urol*. 2011 Dec 14. PMID: 22177145
301. Sun M, Bianchi M, Trinh QD, Abdollah F, Schmitges J, Jeldres C, **Shariat SF**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Hospital Volume is a Determinant of Postoperative Complications, Blood Transfusion and Length of Stay After Radical or Partial Nephrectomy. *J Urol*. 2011 Dec 14. PMID: 22177151
302. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Tian Z, **Shariat SF**, Briganti A, Perrotte P, Montorsi F, Karakiewicz PI. Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. *Urology*. 2011 Dec;78(6):1363-7. PMID:22137704
303. Trinh QD, Bianchi M, Sun M, Sammon J, Schmitges J, **Shariat SF**, Sukumar S, Jeldres C, Zorn K, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Discharge patterns after radical prostatectomy in the United States of America. *Urol Oncol*. 2011 Nov 17. PMID: 22100070
304. Ehdaie B, Maschino A, **Shariat SF**, Rioja J, Hamilton RJ, Lowrance WT, Poon SA, Al-Ahmadie HA, Herr HW. Comparative Outcomes of Pure Squamous Cell Carcinoma and Urothelial Carcinoma With Squamous Differentiation in Patients Treated With Radical Cystectomy. *J Urol*. 2011 Nov 14. PMID: 22088332

305. Chromecki TF, Cha EK, Pummer K, Scherr DS, Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz PI, **Shariat SF**. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. *BJU Int*. 2011 Nov 11. PMID: 22077633
306. Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, **Shariat SF**, Svatek RS, Taylor JM; on Behalf of the Bladder Cancer Think Tank, and Bladder Cancer Advocacy Network: Comprehensive handbook for developing a bladder cancer cystectomy database. *Urol Oncol*. 2011 Nov 4. PMID: 22056403
307. Trinh QD, Schmitges J, Bianchi M, Sun M, **Shariat SF**, Sammon J, Jeldres C, Zorn K, Sukumar S, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI. Node-positive renal cell carcinoma in the absence of distant metastases: predictors of cancer-specific mortality in a population-based cohort. *BJU Int*. 2011 Nov 1. PMID: 22044638
308. Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, **Shariat SF**. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). *BJU Int*. 2011 Oct 28. PMID: 22035221
309. **Shariat SF**, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, Fajkovic H, Novara G, David SG, Daneshmand S, Fradet Y, Lotan Y, Sagalowsky AI, Clozel T, Bastian PJ, Kassouf W, Fritsche HM, Burger M, Izawa JI, Tilki D, Abdollah F, Chun FK, Sonpavde G, Karakiewicz PI, Scherr DS, Gonen M. Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment. *Eur Urol*. 2011 Oct 21. PMID: 22033174
310. Najari BB, Rink M, Graefen M, **Shariat SF**, Chun FK. Does low-risk prostate cancer detection change with repeat biopsies? *Eur Urol*. 2012 Jan;61(1):230-1. Epub 2011 Oct 18. PMID: 22024602
311. Brookman-May S, May M, Zigeuner R, **Shariat SF**, Scherr DS, Chromecki T, Moch H, Wild PJ, Mohamad-Al-Ali B, Cindolo L, Wieland WF, Schips L, De Cobelli O, Rocco B, Santoro L, De Nunzio C, Tubaro A, Coman I, Feciche B, Truss M, Dalpiaz O, Hohenfellner M, Gilfrich C, Wirth MP, Burger M, Pahernik S; Members of the CORONA Project (Collaborative Research on Renal Neoplasms Association). Collecting System Invasion and Fuhrman Grade But Not Tumor Size Facilitate Prognostic Stratification of Patients With pT2 Renal Cell Carcinoma. *J Urol*. 2011 Dec;186(6):2175-81. Epub 2011 Oct 19. PMID: 22014800
312. **Shariat S.**, Scherr D., Gupta A., Bianco F., Karakiewicz P., Zeltser I., Samadi D., Akhavan A.: Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis. *Arch. Esp. Urol*. 2011; 64 (8): 681-694. way. PMID:22052751
313. Trinh QD, Schmitges J, Sun M, Sammon J, **Shariat SF**, Zorn K, Sukumar S, Bianchi M, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Morbidity and mortality of radical prostatectomy differs by insurance status. *Cancer*. 2011 Aug 25. PMID: 22009603
314. Chromecki TF, Mauermann J, Cha EK, Svatek RS, Fajkovic H, Karakiewicz PI, Lotan Y, Tilki D, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Novara G, Fritsche HM, Ficarra V, Stief CG, Dinney CP, Skinner E, Pummer K, Fradet Y, **Shariat SF**: Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy. *World J Urol*. 2011 Oct 19. PMID: 22009117
315. Rink M, Chun FK, Robinson B, Sun M, Karakiewicz PI, Bensalah K, Fisch M, Scherr DS, Lee RK, Margulis V, **Shariat SF**: Tissue-based molecular markers for renal cell carcinoma. *Minerva Urol Nefrol*. 2011 Dec;63(4):293-308. PMID: 21996985
316. Sun M, Abdollah F, **Shariat SF**, Schmitges J, Trinh QD, Tian Z, Jeldres C, Abdo A, Bianchi M, Briganti A, Montorsi F, Perrotte P, Karakiewicz PI : Propensity-score matched comparison of

- complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: A national series. *Eur J Surg Oncol*. 2011 Oct 11. PMID: 21996370
317. Putluri N, Shojaie A, Vasu VT, Vared SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, Sana TR, Fischer SM, Sica G, Brat DJ, Shi H, Palapattu GS, Lotan Y, Weizer AZ, Terris MK, **Shariat SF**, Michailidis G, Sreekumar A: Metabolomic Profiling Reveals Potential Markers and Bioprocesses Altered in Bladder Cancer Progression. *Cancer Res*. 2011 Oct 11. PMID: 21990318
318. Alkhateeb SS, Neill M, Bar-Moshe S, Rhijn BV, Kakiashvili DM, Fleshner N, Jewett M, Petein M, Schulman C, Hanna S, Bostrom PJ, Roumeguere T, **Shariat SF**, Rorive S, Zlotta AR: Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. *Urol Ann*. 2011 Sep;3(3):119-26. PMID:21976923
319. Chromecki TF, Cha EK, Fajkovic H, Margulis V, Novara G, Scherr DS, Lotan Y, Raman JD, Kassouf W, Bensalah K, Weizer A, Kikuchi E, Roscigno M, Remzi M, Matsumoto K, Walton TJ, Pycha A, Ficarra V, Karakiewicz PI, Zigeuner R, Pummer K, **Shariat SF**: The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. *Eur Urol*. 2011 Sep 28. PMID: 21975249
320. Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large north american population-based cohort. *Eur Urol*. 2011 Nov;60(5):920-30. Epub 2011 Jun 29. PMID: 21741762
321. Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Kabbani W, Langner C, Guo CC, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int*. 2011 Oct;108(8):1286-1291. Epub 2011 Feb 18. PMID: 21332905
322. Sun M, Abdollah F, Schmitges J, Bianchi M, Tian Z, **Shariat SF**, Zorn K, Pharand D, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI: Cytoreductive nephrectomy in the elderly: a population-based cohort from the USA. *BJU Int*. 2011 Sep 27. PMID: 21951647
323. **Shariat SF**, Chromecki TF, Hoefler J, Barbieri CE, Scherr DS, Karakiewicz PI, Roehrborn CG, Montorsi F, Culig Z, Cavarretta IT: Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. *J Urol*. 2011 Sep 22. PMID: 21944124
324. Trinh QD, Schmitges J, Sun M, **Shariat SF**, Sukumar S, Bianchi M, Tian Z, Jeldres C, Sammon J, Perrotte P, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Radical prostatectomy at academic versus nonacademic institutions: a population based analysis. *J Urol*. 2011 Sep 22. PMID: 21944081
325. Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, **Shariat SF**, Fisch M, Graefen M, Pummer K, Chun FK: A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. *BJU Int*. 2011 Sep 21. PMID: 21939492
326. Cha EK, Tirsar LA, Schwentner C, Christos PJ, Mian C, Hennenlotter J, Martini T, Stenzl A, Pycha A, **Shariat SF**, Schmitz-Dräger BJ: Immunocytology is a strong predictor of bladder cancer

- presence in patients with painless hematuria: a multicentre study. *Eur Urol.* 2011 Sep 9. PMID: 21924544
327. Lee R, Chughtai B, Herman M, **Shariat SF**, Scherr DS: Cost-analysis comparison of robot-assisted laparoscopic radical cystectomy (RC) vs open RC. *BJU Int.* 2011 Sep;108(6):976-83. PMID: 21917100
328. Messer JC, Terrell JD, Herman MP, Ng CK, Scherr DS, Scoll B, Boorjian SA, Uzzo RG, Wille M, Eggener SE, Lucas SM, Lotan Y, **Shariat SF**, Raman JD: Multi-institutional validation of the ability of preoperative hydronephrosis to predict advanced pathologic tumor stage in upper-tract urothelial carcinoma. *Urol Oncol.* 2011 Sep 7. PMID: 21906967
329. Trinh QD, Schmitges J, Sun M, Sammon J, **Shariat SF**, Sukumar S, Zorn K, Bianchi M, Jeldres C, Perrotte P, Graefen M, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: Does partial nephrectomy at an academic institution result in better outcomes? *World J Urol.* 2011 Sep 9. PMID: 21904920
330. Trinh QD, Schmitges J, Sun M, Sukumar S, Sammon J, **Shariat SF**, Jeldres C, Bianchi M, Tian Z, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Improvement of racial disparities with respect to the utilization of minimally invasive radical prostatectomy in the United States. *Cancer.* 2011 Sep 6. doi: 10.1002/cncr.26527. PMID: 21898379
331. Trinh QD, Schmitges J, Sun M, **Shariat SF**, Sukumar S, Tian Z, Bianchi M, Sammon J, Perrotte P, Rogers CG, Graefen M, Peabody JO, Menon M, Karakiewicz PI: Open radical prostatectomy in the elderly: a case for concern? *BJU Int.* 2011 Sep 6. PMID:21895940
332. Abdo A, Trinh QD, Sun M, Schmitges J, Bianchi M, Sammon J, **Shariat SF**, Sukumar S, Zorn K, Jeldres C, Perrotte P, Rogers CG, Peabody JO, Menon M, Karakiewicz PI: The effect of insurance status on outcomes after partial nephrectomy. *Int Urol Nephrol.* 2011 Sep 6. PMID: 21894468
333. Bianchi M, Sun M, Jeldres C, **Shariat SF**, Trinh QD, Briganti A, Tian Z, Schmitges J, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI: Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. *Ann Oncol.* 2011 Sep 2. PMID: 21890909
334. Martinez-Salamanca JI, **Shariat SF**, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G: Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int.* 2011 Aug 24. PMID: 21883847
335. Abdollah F, Schmitges J, Sun M, **Shariat SF**, Briganti A, Abdo A, Tian Z, Perrotte P, Montorsi F, Karakiewicz PI: A population-based assessment of the National Comprehensive Cancer Network practice guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int.* 2011 Aug 22. PMID: 21880105
336. Sun M, Abdollah F, Schmitges J, Jeldres C, **Shariat SF**, Perrotte P, Karakiewicz PI: Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. *Open Access Journal of Urology* April 2011 Volume 2011:3 Pages 43 - 48
337. Sun M, Abdollah F, Bianchi M, Trinh QD, Jeldres C, Tian Z, **Shariat SF**, Widmer H, Zorn K, Menon M, Montorsi F, Perrotte P, Karakiewicz PI: A stage-for-stage and grade-for-grade analysis of cancer-specific mortality rates in renal cell carcinoma according to age: a competing-risks regression analysis. *Eur Urol.* 2011 Aug 5. PMID: 21868147
338. Barbieri CE, Cha EK, Chromecki TF, Dunning A, Lotan Y, Svatek RS, Scherr DS, Karakiewicz PI, Sun M, Mazumdar M, **Shariat SF**: Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial. *BJU Int.* 2011. PMID:

21851550

339. Abdollah F, Sun M, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, **Shariat SF**, Montorsi F, Karakiewicz PI: Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. *BJU Int.* 2011 Aug 24. PMID: 21883849
340. Remzi M, **Shariat S**, Huebner W, Fajkovic H, Seitz C.: Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years? *Ther Adv Urol.* 2011 Apr;3(2):69-80. PMID: 21869907
341. Abdollah F, Sun M, Jeldres C, Schmitges J, Thuret R, Djahangirian O, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis. *BJU Int.* 2011 Aug 2. PMID: 21810161
342. Roscigno M, Brausi M, Heidenreich A, Lotan Y, Margulis V, **Shariat SF**, Van Poppel H, Zigeuner R: Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. *Eur Urol.* 2011 Jul 14. PMID: 21798659
343. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Jeldres C, **Shariat SF**, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI: Hospital and surgical caseload are predictors of comprehensive surgical treatment for bladder cancer: a population based study. *J Urol.* 2011 Jul 23. PMID:21788051
344. Matsushita K, Cha EK, Matsumoto K, Baba S, Chromecki TF, Fajkovic H, Sun M, Karakiewicz PI, Scherr DS, **Shariat SF**: Immunohistochemical biomarkers for bladder cancer prognosis. *Int J Urol.* 2011 Jul 20. PMID: 21771101
345. Sun M, **Shariat SF**, Cheng C, Ficarra V, Murai M, Oudard S, Pantuck AJ, Zigeuner R, Karakiewicz PI: Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. *Eur Urol.* 2011 Jun 30. PMID: 21741163
346. **Shariat SF**, Patschan O, Chade DC, Karakiewicz PI, Ashfaq R, Lotan Y, Hotakainen K, Stenman UH, Bjartell A.: Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder. *World J Urol.* 2011 Jul 8. PMID: 21739120
347. Chromecki TF, Bensalah K, Remzi M, Verhoest G, Cha EK, Scherr DS, Novara G, Karakiewicz PI, **Shariat SF**: Prognostic factors for upper urinary tract urothelial carcinoma. *Nat Rev Urol.* 2011 PMID: 21727942
348. Jerónimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, **Shariat SF**: Epigenetics in prostate cancer: biologic and clinical relevance. *Eur Urol.* 2011 Jun 22. PMID: 21719191
349. Youssef RF, **Shariat SF**, Lotan Y, Cost N, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Chromecki TF, Montorsi F, Bolenz C, Margulis V: Urothelial carcinoma at the uretero-enteric junction: Multi-center evaluation of oncologic outcomes after radical nephroureterectomy. *Urol Oncol.* 2011 Jun 23. PMID: 21704538
350. Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Development and validation of a reference table for prediction of postoperative mortality rate in patients treated with radical cystectomy: a population-based study. *Ann Surg Oncol.* 2011 Jun 24. PMID: 21701925
351. **Shariat SF**, Savage C, Chromecki TF, Sun M, Scherr DS, Lee RK, Lughezzani G, Remzi M, Marberger MJ, Karakiewicz PI, Vickers AJ: Assessing the clinical benefit of nuclear matrix protein

- 22 in the surveillance of patients with non muscle-invasive bladder cancer and negative cytology: A decision-curve analysis. *Cancer*. 2011 Jul 1;117(13):2892-7. PMID: 21692050
352. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, **Shariat SF**, Zlotta AR: Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. *Eur Urol*. 2011 Jun 12. PMID: 21684071
353. Verhoest G, **Shariat SF**, Chromecki TF, Raman JD, Margulis V, Novara G, Seitz C, Remzi M, Rouprêt M, Scherr DS, Bensalah K: Predictive factors of recurrence and survival of upper tract urothelial carcinomas. *World J Urol*. 2011 Jun 17. PMID: 21681525
354. Chromecki TF, Cha EK, **Shariat SF**: Stage pT0 after radical cystectomy: are all patients equal? *Eur Urol*. 2011 Jun 7. PMID: 21665358
355. Nuhn P, Bastian PJ, Novara G, Svatek RS, Karakiewicz PI, Skinner E, Fradet Y, Izawa JI, Kassouf W, Montorsi F, Müller SC, Fritsche HM, Sonpavde G, Tilki D, Isbarn H, Ficarra V, Dinney CP, **Shariat SF**: Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery. *Urol Int*. 2011 Jun 9. PMID: 21659717
356. Fajkovic H, Halpern JA, Cha EK, Bahadori A, Chromecki TF, Karakiewicz PI, Breinl E, Merseburger AS, **Shariat SF**: Impact of gender on bladder cancer incidence, staging, and prognosis. *World J Urol*. 2011 Jun 9. PMID: 21656173
357. Abdollah F, Sun M, Thuret R, Abdo A, Morgan M, Jeldres C, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI.: The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study. *Cancer Causes Control*. 2011 Jun 5. PMID: 21643929
358. Cha EK, Ng CK, Jeun B, Dunning A, Reifsnnyder JE, Dipietro JR, Mazumdar M, Shih G, Auh YH, Del Pizzo JJ, **Shariat SF**, Scherr DS.: Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy. *World J Urol*. 2011 May 21. PMID: 21604019
359. Favaretto RL, **Shariat SF**, Savage C, Godoy G, Chade DC, Kaag M, Bochner BH, Coleman J, Dalbagni G.: Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma. *BJU Int*. 2011 Jun 1. PMID:21631698
360. **Shariat SF**, Semjonow A, Lilja H, Savage C, Vickers AJ, Bjartell A.: Tumor markers in prostate cancer I: blood-based markers. *Acta Oncol*. 2011 Jun;50 Suppl 1:61-75. PMID: 21604943
361. Burger M, **Shariat SF**, Fritsche HM, Martinez-Salamanca JI, Matsumoto K, Chromecki TF, Ficarra V, Kassouf W, Seitz C, Pycha A, Tritschler S, Walton TJ, Novara G: No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study. *World J Urol*. 2011 Jun 1. PMID: 21630120
362. Ehdaie B, Chromecki TF, Lee RK, Lotan Y, Margulis V, Karakiewicz PI, Novara G, Raman JD, Ng C, Lowrance WT, Scherr DS, **Shariat SF**: Obesity adversely impacts disease specific outcomes in patients with upper tract urothelial carcinoma. *J Urol*. 2011 May 13. PMID: 21571333
363. Sun M, Abdollah F, Budaüs L, Liberman D, Tian Z, Morgan M, Johal R, Schmitges J, **Shariat SF**, Montorsi F, Greafen M, Perrotte P, Karakiewicz PI: Trends of retroperitoneal lymphadenectomy use in patients with nonseminomatous germ cell tumor of the testis: a population-based study. *Ann Surg Oncol*. 2011 Apr 21. PMID: 21509630
364. Lee R, Ng CK, **Shariat SF**, Borkina A, Guimento R, Brumit KF, Scherr DS.: The economics of robotic cystectomy: cost comparison of open versus robotic cystectomy. *BJU Int*. 2011 Apr 18.

PMID: 21501370

365. Matsumoto K, Novara G, Gupta A, Margulis V, Walton TJ, Roscigno M, Ng C, Kikuchi E, Zigeuner R, Kassouf W, Fritsche HM, Ficarra V, Martignoni G, Tritschler S, Rodriguez JC, Seitz C, Weizer A, Remzi M, Raman JD, Bolenz C, Bensalah K, Koppie TM, Karakiewicz PI, Wood CG, Montorsi F, Iwamura M, **Shariat SF**: Racial differences in the outcome of patients with urothelial carcinoma of the upper urinary tract: an international study. *BJU Int*. 2011 Apr 20. PMID: 21507184
366. Abdollah F, Sun M, Briganti A, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, **Shariat SF**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI.: Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int*. 2011 Apr 20. PMID:21507189
367. Chromecki TF, Ehdaie B, Novara G, Pummer K, Zigeuner R, Seitz C, Pycha A, Lee RK, Cha EK, Karakiewicz PI, Ng C, Raman JD, Chun FK, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Bastian PJ, Martínez-Salamanca JI, Scherr DS, **Shariat SF**: Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy. *World J Urol*. 2011 Apr 17.
368. Abdollah F, Sun M, Thuret R, Schmitges J, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. *Ann Surg Oncol*. 2011 Apr 16.
369. Abdollah F, Sun M, **Shariat SF**, Schmitges J, Djahangirian O, Tian Z, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI: The importance of pelvic lymph node dissection in the elderly population: implications for interpreting the 2010 National Comprehensive Cancer Network practice guidelines for bladder cancer treatment. *J Urol*. 2011 Apr 13.
370. Abdollah F, Schmitges J, Sun M, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI: A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. *Prostate*. 2011 Apr 7. doi: 10.1002/pros.21376.
371. Kassouf W, Svatek RS, **Shariat SF**, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. *Urol Oncol*. 2011 Apr 7. [Epub ahead of print
372. Zlotta AR, Roumeguere T, Kuk C, Alkhateeb S, Rorive S, Lemy A, van der Kwast TH, Fleshner NE, Jewett MA, Finelli A, Schulman C, Lotan Y, **Shariat SF**, Nortier J: Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. *Eur Urol*. 2011 Mar 30. PMID: 21458152
373. Chade DC, **Shariat SF**, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'oglio M, Srougi M, Scardino PT, Eastham JA.: Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *Eur Urol*. 2011 Mar 17. PMID: 21420229
374. Gurbuz C, Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, Margulis V.: The impact of previous ureteroscopic tumor ablation on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. *J Endourol*. 2011 Mar 9. PMID: 21388245
375. Sun M, Abdollah F, Liberman D, Abdo A, Thuret R, Tian Z, **Shariat SF**, Montorsi F, Perrotte P,

- Karakiewicz PI: Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: A survival analysis. *Cancer*. 2011 Mar 8. doi: 10.1002/cncr.25969. PMID: 21387261
376. Thuret R, Sun M, Abdollah F, Schmitges J, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI: Conditional survival predictions after surgery for patients with penile carcinoma. *Cancer*. 2011 Feb 24. PMID: 21360525
377. Abdollah F, Sun M, Schmitges J, Thuret R, Djahangirian O, Jeldres C, Tian Z, **Shariat SF**, Perrotte P, Montorsi F, Karakiewicz PI. Surgical caseload is an important determinant of continent urinary diversion rate at radical cystectomy: a population-based study. *Ann Surg Oncol*. 2011 Feb 23. PMID: 21347778
378. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Scherr DS, Ficarra V, Dinney CP, Lotan Y, Fradet Y, **Shariat SF**: Prognostic risk stratification of pathological stage T3N0 bladder cancer after radical cystectomy. *J Urol*. 2011 Apr;185(4):1216-21. Epub 2011 Feb 22. PMID: 21334687
379. Messer J, **Shariat SF**, Brien JC, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Steinberg G, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Urinary cytology has a poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. *BJU Int*. 2011 Feb 14. PMID: 21320275.
380. Youssef R, **Shariat S**, Kapur P, Kabbani W, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y: Prognostic value of cyclooxygenase-2 expression in squamous cell carcinoma of the bladder. *J Urol*. 2011 Jan 20. PMID: 21255800.
381. Liberman D, Lughezzani G, Sun M, Alasker A, Thuret R, Abdollah F, Budaus L, Widmer H, Graefen M, Montorsi F, **Shariat SF**, Perrotte P, Karakiewicz PI: Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. *Urology*. 2011 Jan 20. PMID: 21256568.
382. Otto W, **Shariat SF**, Fritsche HM, Gupta A, Matsumoto K, Kassouf W, Martignoni G, Walton TJ, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Burger M, Karakiewicz PI, Ficarra V, Novara G: Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients. *World J Urol*. 2011 Jan 20. PMID: 21249372.
383. Svatek RS, **Shariat SF**, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP: Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. *BJU Int*. 2011 Jan 18. PMID: 21244604.
384. Mazzola CR, Ghoneim T, **Shariat SF**: [Emerging biomarkers for the diagnosis, staging and prognosis of prostate cancer]. *Prog Urol*. 2011 Jan;21(1):1-10. Epub 2010 Aug 14. French. PMID: 21193139
385. Youssef RF, **Shariat SF**, Lotan Y, Wood CG, Sagalowsky AI, Zigeuner R, Langner C, Montorsi F, Bolenz C, Margulis V.: Prognostic Effect of Urinary Bladder Carcinoma In Situ on Clinical Outcome of Subsequent Upper Tract Urothelial Carcinoma. *Urology*. 2010 Dec 15. PMID: 21167566
386. Sonpavde G, Khan MM, Lerner SP, Svatek RS, Novara G, Karakiewicz PI, Skinner E, Tilki D, Kassouf W, Fradet Y, Dinney CP, Fritsche HM, Izawa JI, Bastian PJ, Ficarra V, Schoenberg M, Sagalowsky AI, Lotan Y, **Shariat SF**.: Disease-free survival at 2 or 3 years correlates with 5-year

- overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. *J Urol*. 2010 Dec 16. PMID: 21167527
387. Thuret R, Sun M, Abdollah F, Budaus L, Lughezzani G, Liberman D, Morgan M, Johal R, Jeldres C, Latour M, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI.: Tumor grade improves the prognostic ability of American Joint Committee on cancer stage in patients with penile carcinoma. *J Urol*. 2010 Dec 16. PMID: 21167526
388. Ahallal Y, **Shariat SF**, Chade DC, Mazzola C, Reuter VE, Sandhu JS, Laudone VP, Touijer KA, Guillonneau BD.: Pilot study of salvage laparoscopic prostatectomy for the treatment of recurrent prostate cancer. *BJU Int*. 2010 Dec 16. PMID: 21166755
389. Budäus L, Abdollah F, Sun M, Johal R, Morgan M, Thuret R, Zorn KC, Lughezzani G, Isbarn H, Haese A, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI.: The impact of surgical experience on total hospital charges for minimally invasive prostatectomy: a population-based study. *BJU Int*. 2010 Dec 13. PMID: 21156018
390. Sfakianos J, **Shariat SF**, Favaretto RL, Rioja J, Herr HW: Impact of smoking on outcomes after intravesical Bacillus Calmette-Guérin therapy for urothelial carcinoma not invading muscle of the bladder. *BJU Int*. 2010 Nov 29. PMID: 2111461
391. Youssef RF, **Shariat SF**, Kapur P, Kabbani W, Ghoneim T, King E, Cockburn A, Mosbah A, Abol-Enein H, Ghoneim M, Lotan Y. Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. *Hum Pathol*. 2010 Nov 25. PMID: 21111452.
392. Sun M, Abdo A, Abdollah F, Schmitges J, Thuret R, Jeldres C, **Shariat SF**, Perrotte P, Karakiewicz PI. Management of upper urinary tract urothelial carcinoma. *Expert Rev Anticancer Ther*. 2010 Dec; PMID: 21110761.
393. Youssef R, Kapur P, Kabbani W, **Shariat SF**, Mosbah A, Abol-Enein H, Ghoniem M, Lotan Y. Bilharzial vs non-bilharzial related bladder cancer: pathological characteristics and value of cyclooxygenase-2 expression. *BJU Int*. 2010 Nov 24. PMID: 21105986.
394. Lowrance WT, Tarin TV, **Shariat SF**. Evidence-based comparison of robotic and open radical prostatectomy. *Scientific World Journal*. 2010 Nov 16; PMID: 21103791.
395. Sonpavde G, Khan MM, Svatek RS, Lee R, Novara G, Tilki D, Lerner SP, Amiel GE, Skinner E, Karakiewicz PI, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Ficarra V, Dinney CP, Lotan Y, Fradet Y, **Shariat SF**. Prognostic risk stratification of pathological stage T2N0 bladder cancer after radical cystectomy. *BJU Int*. 2010 Nov 19. PMID: 21087453.
396. Walton TJ, Novara G, Matsumoto K, Kassouf W, Fritsche HM, Artibani W, Bastian PJ, Martínez-Salamanca JI, Seitz C, Thomas SA, Ficarra V, Burger M, Tritschler S, Karakiewicz PI, **Shariat SF**. Oncological outcomes after laparoscopic and open radical nephroureterectomy: results from an international cohort. *BJU Int*. 2010 Nov 15. PMID: 21078048.
397. Mir C, **Shariat SF**, Van Der Kwast TH, Ashfaq R, Lotan Y, Evans A, Skeldon S, Hanna S, Vajpeyi R, Kuk C, Alkhateeb S, Morote J, Van Rhijn BW, Bostrom P, Yao J, Miyamoto H, Jewett M, Fleshner N, Messing E, Zlotta AR. Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. *BJU Int*. 2010 Nov 10. PMID: 21070579.
398. Yee DS, **Shariat SF**, Lowrance WT, Maschino AC, Savage CJ, Cronin AM, Scardino PT, Eastham JA. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens. *BJU Int*. 2010 Nov 2. PMID: 21050364.

399. Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, **Shariat SF**, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis. *Eur Urol*. 2010 Oct 27. PMID: 21035250.
400. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, **Shariat SF**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. *Eur Urol*. 2010 Oct 14. PMID: 20965646.
401. Budäus L, Sun M, Abdollah F, Zorn KC, Morgan M, Johal R, Liberman D, Thuret R, Isbarn H, Salomon G, Haese A, Montorsi F, **Shariat SF**, Perrotte P, Graefen M, Karakiewicz PI. Impact of Surgical Experience on In-Hospital Complication Rates in Patients Undergoing Minimally Invasive Prostatectomy: A Population-Based Study. *Ann Surg Oncol*. 2010 Oct 16. PMID: 20953720.
402. Budäus L, Abdollah F, Sun M, Morgan M, Johal R, Thuret R, Zorn KC, Isbarn H, **Shariat SF**, Montorsi F, Perrotte P, Graefen M, Karakiewicz PI. Annual surgical caseload and open radical prostatectomy outcomes: improving temporal trends. *J Urol*. 2010 Dec; Epub 2010 Oct 16. PMID: 20952010.
403. Barbieri CE, Lotan Y, Lee RK, Sonpavde G, Karakiewicz PI, Robinson B, Scherr DS, **Shariat SF**. Tissue-based molecular markers for bladder cancer. *Minerva Urol Nefrol*. 2010 Sep; PMID: 20940694.
404. Fritsche HM, Novara G, Burger M, Gupta A, Matsumoto K, Kassouf W, Sircar K, Zlattoni F, Walton T, Tritschler S, Baba S, Bastian PJ, Martínez-Salamanca JI, Seitz C, Otto W, Wieland WF, Karakiewicz PI, Ficarra V, Hartmann A, **Shariat SF**. Macroscopic sessile tumor architecture is a pathologic feature of biologically aggressive upper tract urothelial carcinoma. *Urol Oncol*. 2010 Oct 6. PMID: 20933445.
405. Crépel M, Jeldres C, Sun M, Lughezzani G, Isbarn H, Alasker A, Capitanio U, **Shariat SF**, Arjane P, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma. *Urology*. 2010 Oct; PMID: 20932408.
406. **Shariat SF**, Favaretto RL, Gupta A, Fritsche HM, Matsumoto K, Kassouf W, Walton TJ, Tritschler S, Baba S, Matsushita K, Bastian PJ, Martínez-Salamanca JI, Seitz C, Pycha A, Otto W, Karakiewicz PI, Ficarra V, Novara G. Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*. 2010 Oct 1. PMID: 20886219.
407. Chun FK, Epstein JI, Ficarra V, Freedland SJ, Montironi R, Montorsi F, **Shariat SF**, Schröder FH, Scattoni V. Optimizing Performance and Interpretation of Prostate Biopsy: A Critical Analysis of the Literature. *Eur Urol*. 2010 Sep 4. PMID: 20884114.
408. Liberman D, Alasker A, Sun M, Ismail S, Lughezzani G, Jeldres C, Budaus L, Thuret R, **Shariat SF**, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Radical cystectomy for patients with pT4 urothelial carcinoma in a large population-based study. *BJU Int*. 2010 Sep 22. PMID: 20860649.
409. Seitz C, Gupta A, **Shariat SF**, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Otto W, Tritschler S, Bastian PJ, Carballido J, Ficarra V, Karakiewicz PI, Artibani W, Mazzoleni G, Novara G. Association of tumor necrosis with pathological features and clinical outcome in 754 patients undergoing radical nephroureterectomy for upper tract urothelial carcinoma: an international validation study. *J Urol*. 2010 Nov; Epub 2010 Sep 17. PMID: 20846680.
410. Thuret R, Sun M, Lughezzani G, Budaus L, Liberman D, Abdollah F, Morgan M, Johal R, Jeldres C, Latour M, **Shariat SF**, Iborra F, Guiter J, Patard JJ, Perrotte P, Karakiewicz PI. A Contemporary

- Population-Based Assessment of the Rate of Lymph Node Dissection for Penile Carcinoma. *Ann Surg Oncol*. 2010 Sep 14. PMID: 20839061.
411. Lughezzani G, Sun M, **Shariat SF**, Budäus L, Thuret R, Jeldres C, Liberman D, Montorsi F, Perrotte P, Karakiewicz PI. A population-based competing-risks analysis of the survival of patients treated with radical cystectomy for bladder cancer. *Cancer*. 2010 Aug 27. PMID: 20803606.
 412. Lughezzani G, Briganti A, Karakiewicz PI, Kattan MW, Montorsi F, **Shariat SF**, Vickers AJ. Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. *Eur Urol*. 2010 Aug 6. PMID: 20727668.
 413. Favaretto RL, **Shariat SF**, Chade DC, Godoy G, Kaag M, Cronin AM, Bochner BH, Coleman J, Dalbagni G. Comparison between laparoscopic and open radical nephroureterectomy in a contemporary group of patients: are recurrence and disease-specific survival associated with surgical technique? *Eur Urol*. 2010 Aug 11. PMID: 20724065.
 414. Svatek RS, **Shariat SF**, Lasky RE, Skinner EC, Novara G, Lerner SP, Fradet Y, Bastian PJ, Kassouf W, Karakiewicz PI, Fritsche HM, Müller SC, Izawa JI, Ficarra V, Sagalowsky AI, Schoenberg MP, Siefker-Radtke AO, Millikan RE, Dinney CP. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. *Clin Cancer Res*. 2010 Sep 1;16(17):4461-7. Epub 2010 Jul 22. PMID: 20651056.
 415. Tilki D, Svatek RS, Novara G, Seitz M, Godoy G, Karakiewicz PI, Kassouf W, Fradet Y, Fritsche HM, Sonpavde G, Izawa JI, Ficarra V, Lerner SP, Schoenberg M, Stief CG, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, Reich O, **Shariat SF**. Stage pT0 at radical cystectomy confers improved survival: an international study of 4,430 patients. *J Urol*. 2010 Sep; Erratum in: *J Urol*. 2010 Nov; PMID: 20643448.
 416. Favaretto RL, **Shariat SF**, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G. The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. *Eur Urol*. 2010 Oct; Epub 2010 Jul 9. PMID: 20637540.
 417. **Shariat SF**, Chade DC, Karakiewicz PI, Scherr DS, Dalbagni G. Update on intravesical agents for non-muscle-invasive bladder cancer. *Immunotherapy*. 2010 May; Review. PMID: 20635902.
 418. Tilki D, Svatek RS, Karakiewicz PI, Novara G, Seitz M, Sonpavde G, Gupta A, Kassouf W, Fradet Y, Ficarra V, Skinner E, Lotan Y, Sagalowsky AI, Stief CG, Reich O, **Shariat SF**. pT3 Substaging is a prognostic indicator for lymph node negative urothelial carcinoma of the bladder. *J Urol*. 2010 Aug; Epub 2010 Jun 17. PMID: 20620401.
 419. Chade DC, **Shariat SF**, Adamy A, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcome of primary versus secondary bladder carcinoma in situ. *J Urol*. 2010 Aug; Epub 2010 Jun 17. PMID: 20620399.
 420. Margulis V, Youssef RF, Karakiewicz PI, Lotan Y, Wood CG, Zigeuner R, Kikuchi E, Weizer A, Raman JD, Remzi M, Roscigno M, Montorsi F, Bolenz C, Kassouf W, **Shariat SF**; Upper Tract Urothelial Carcinoma Collaborative Group. Preoperative multivariable prognostic model for prediction of nonorgan confined urothelial carcinoma of the upper urinary tract. *J Urol*. 2010 Aug; Epub 2010 Jun 17. PMID: 20620397.
 421. Lotan Y, **Shariat SF**, Schmitz-Dräger BJ, Sanchez-Carbayo M, Jankevicius F, Racioppi M, Minner SJ, Stöhr B, Bassi PF, Grossman HB. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer. *Urol Oncol*. 2010 Jul-Aug; PMID: 20610281.

422. **Shariat SF**, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ, Malats N. Statistical consideration for clinical biomarker research in bladder cancer. *Urol Oncol*. 2010 Jul-Aug; Review. PMID: 20610277.
423. Sun M, **Shariat SF**, Karakiewicz PI. Factors affecting outcome in renal cell carcinoma. *Curr Opin Urol*. 2010 Sep; Review. PMID: 20592610.
424. Jeldres C, Sun M, Lughezzani G, Isbarn H, **Shariat SF**, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Highly predictive survival nomogram after upper urinary tract urothelial carcinoma. *Cancer*. 2010 Aug 5; PMID: 20564085.
425. Chade DC, **Shariat SF**, Godoy G, Savage CJ, Cronin AM, Bochner BH, Donat SM, Herr HW, Dalbagni G. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. *J Urol*. 2010 Jul; PMID: 20546806.
426. Brien JC, **Shariat SF**, Herman MP, Ng CK, Scherr DS, Scoll B, Uzzo RG, Wille M, Eggener SE, Terrell JD, Lucas SM, Lotan Y, Boorjian SA, Raman JD. Preoperative hydronephrosis, ureteroscopy biopsy grade and urinary cytology can improve prediction of advanced upper tract urothelial carcinoma. *J Urol*. 2010 Jul; Epub 2010 May 15. PMID: 20478585.
427. Bigot P, Bernhard JC, Crepel M, Bensalah K, Azzouzi AR, de la Taille A, Salomon L, Tostain J, Ficarra V, Pantuck AJ, Belldegrun AS, Méjean A, Ferrière JM, Pfister C, Albouy B, Colombel M, Zini L, Villers A, Montorsi F, **Shariat S**, Rioux-Leclercq N, Patard JJ. [How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?]. *Prog Urol*. 2010 May; Epub 2010 Mar 29. French. PMID: 20471579.
428. Wheat JC, Weizer AZ, Wolf JS Jr, Lotan Y, Remzi M, Margulis V, Wood CG, Montorsi F, Roscigno M, Kikuchi E, Zigeuner R, Langner C, Bolenz C, Koppie TM, Raman JD, Fernández M, Karakiewicz P, Capitanio U, Bensalah K, Patard JJ, **Shariat SF**. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy. *Urol Oncol*. 2010 May 5. PMID: 20451416.
429. Novara G, Svatek RS, Karakiewicz PI, Skinner E, Ficarra V, Fradet Y, Lotan Y, Isbarn H, Capitanio U, Bastian PJ, Kassouf W, Fritsche HM, Izawa JI, Tilki D, Dinney CP, Lerner SP, Schoenberg M, Volkmer BG, Sagalowsky AI, **Shariat SF**. Soft tissue surgical margin status is a powerful predictor of outcomes after radical cystectomy: a multicenter study of more than 4,400 patients. *J Urol*. 2010 Jun; PMID: 20399473.
430. **Shariat SF**, Tilki D. Bladder cancer: Nomogram aids clinical decision making after radical cystectomy. *Nat Rev Urol*. 2010 Apr; PMID: 20383183.
431. Tilki D, Reich O, Svatek RS, Karakiewicz PI, Kassouf W, Novara G, Ficarra V, Chade DC, Fritsche HM, Gerwens N, Izawa JI, Lerner SP, Schoenberg M, Stief CG, Skinner E, Lotan Y, Sagalowsky AI, **Shariat SF**. Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299059.
432. **Shariat SF**, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H, Jeldres C, Sagalowsky AI, Ashfaq R, Lotan Y. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299037.
433. Yee DS, **Shariat SF**, Lowrance WT, Sterbis JR, Vora KC, Bochner BH, Donat SM, Herr HW, Dalbagni G, Sandhu JS. Impact of previous radiotherapy for prostate cancer on clinical outcomes of patients with bladder cancer. *J Urol*. 2010 May; Epub 2010 Mar 17. PMID: 20299035.

434. Lughezzani G, Sun M, Budäus L, Thuret R, **Shariat SF**, Perrotte P, Karakiewicz PI. Effect of the number of biopsy cores on prostate cancer detection and staging. *Future Oncol*. 2010 Mar; Review. PMID: 20222795.
435. Jeldres C, Lughezzani G, Sun M, Isbarn H, **Shariat SF**, Budaus L, Lattouf JB, Widmer H, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. *J Urol*. 2010 Apr; Epub 2010 Feb 19. PMID: 20171666.
436. **Shariat SF**, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. *BJU Int*. 2010 May; Epub 2010 Feb 2. PMID: 20132195.
437. Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, **Shariat SF**, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. *Int J Radiat Oncol Biol Phys*. 2010 Feb 1; PMID: 20117287.
438. Tilki D, Reich O, Karakiewicz PI, Novara G, Kassouf W, Ergün S, Fradet Y, Ficarra V, Sonpavde G, Stief CG, Skinner E, Svatek RS, Lotan Y, Sagalowsky AI, **Shariat SF**. Validation of the AJCC TNM substaging of pT2 bladder cancer: deep muscle invasion is associated with significantly worse outcome. *Eur Urol*. 2010 Jul; Epub 2010 Jan 20. PMID: 20097469.
439. Bolenz C, **Shariat SF**, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. *BJU Int*. 2010 Jan 19. PMID: 20089105.
440. Baillargeon-Gagné S, Jeldres C, Lughezzani G, Sun M, Isbarn H, Capitanio U, **Shariat SF**, Crépel M, Alasker A, Widmer H, Arjane P, Patard JJ, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A comparative population-based analysis of the rate of partial vs radical nephrectomy for clinically localized renal cell carcinoma. *BJU Int*. 2010 Feb; PMID: 20089096.
441. Sun M, Lughezzani G, Alasker A, Isbarn H, Jeldres C, **Shariat SF**, Budäus L, Lattouf JB, Valiquette L, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Comparative study of inguinal hernia repair after radical prostatectomy, prostate biopsy, transurethral resection of the prostate or pelvic lymph node dissection. *J Urol*. 2010 Mar; Epub 2010 Jan 18. PMID: 20083257.
442. Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martínez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, **Shariat SF**. Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. *Eur Urol*. 2010 Jun; Epub 2010 Jan 6. PMID: 20071073.
443. Raman JD, **Shariat SF**, Karakiewicz PI, Lotan Y, Sagalowsky AI, Roscigno M, Montorsi F, Bolenz C, Weizer AZ, Wheat JC, Ng CK, Scherr DS, Remzi M, Waldert M, Wood CG, Margulis V; for the Upper-Tract Urothelial Carcinoma Collaborative Group. Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy? *Urol Oncol*. 2010 Jan 5. PMID: 20056458.
444. Lughezzani G, Sun M, Perrotte P, Jeldres C, Alasker A, Isbarn H, Budäus L, **Shariat SF**, Guazzoni G, Montorsi F, Karakiewicz PI. The European Network for the Study of Adrenal Tumors staging

- system is prognostically superior to the international union against cancer-staging system: a North American validation. *Eur J Cancer*. 2010 Mar; Epub 2010 Jan 13. PMID: 20044246.
445. Chade DC, **Shariat SF**, Dalbagni G. Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review. *Int Braz J Urol*. 2009 Nov-Dec; discussion 651. PMID: 20028569.
446. Lughezzani G, Sun M, Jeldres C, Alasker A, Budäus L, **Shariat SF**, Latour M, Widmer H, Duclos A, Jolivet-Tremblay M, Montorsi F, Perrotte P, Karakiewicz PI. Adenocarcinoma versus urothelial carcinoma of the urinary bladder: comparison between pathologic stage at radical cystectomy and cancer-specific mortality. *Urology*. 2010 Feb; PMID: 20022091.
447. Lughezzani G, Sun M, Perrotte P, **Shariat SF**, Jeldres C, Budaus L, Alasker A, Duclos A, Widmer H, Latour M, Guazzoni G, Montorsi F, Karakiewicz PI. Should bladder cuff excision remain the standard of care at nephroureterectomy in patients with urothelial carcinoma of the renal pelvis? A population-based study. *Eur Urol*. 2010 Jun; Epub 2009 Dec 10. PMID: 20018438.
448. Zaak D, Burger M, Otto W, Bastian PJ, Denzinger S, Stief CG, Buchner H, Hartmann A, Wieland WF, **Shariat SF**, Fritsche HM. Predicting individual outcomes after radical cystectomy: an external validation of current nomograms. *BJU Int*. 2010 Aug; Epub 2009 Dec 11. PMID: 20002664.
449. **Shariat SF**, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. *Future Oncol*. 2009 Dec; Review. PMID: 20001796.
450. Jeldres C, Sun M, Isbarn H, Lughezzani G, Budäus L, Alasker A, **Shariat SF**, Lattouf JB, Widmer H, Pharand D, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A population-based assessment of perioperative mortality after nephroureterectomy for upper-tract urothelial carcinoma. *Urology*. 2010 Feb; Epub 2009 Dec 6. PMID: 19963237.
451. Crépel M, Jeldres C, Perrotte P, Capitanio U, Isbarn H, **Shariat SF**, Liberman D, Sun M, Lughezzani G, Arjane P, Widmer H, Graefen M, Montorsi F, Patard JJ, Karakiewicz PI. Nephron-sparing surgery is equally effective to radical nephrectomy for T1bN0M0 renal cell carcinoma: a population-based assessment. *Urology*. 2010 Feb; Epub 2009 Dec 4. PMID: 19962740.
452. Lughezzani G, Sun M, Perrotte P, **Shariat SF**, Jeldres C, Budäus L, Latour M, Widmer H, Duclos A, Bénard F, McCormack M, Montorsi F, Karakiewicz PI. Gender-related differences in patients with stage I to III upper tract urothelial carcinoma: results from the Surveillance, Epidemiology, and End Results database. *Urology*. 2010 Feb; Epub 2009 Dec 4. PMID: 19962727.
453. Zigeuner R, **Shariat SF**, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernández MI, Wood CG, Montorsi F, Ströbel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. *Eur Urol*. 2010 Apr; Epub 2009 Nov 25. PMID: 19959276.
454. Tilki D, Svatek RS, Karakiewicz PI, Isbarn H, Reich O, Kassouf W, Fradet Y, Novara G, Fritsche HM, Bastian PJ, Izawa JI, Stief CG, Ficarra V, Lerner SP, Schoenberg M, Dinney CP, Skinner E, Lotan Y, Sagalowsky AI, **Shariat SF**. Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. *J Urol*. 2010 Jan; Epub PubMed PMID: 19942232.
455. **Shariat SF**, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Lerner SP, Sagalowsky AI, Cote RJ, Lotan Y. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. *J Urol*. 2010 Jan; Epub. PMID: 19913255.

456. **Shariat SF**, Godoy G, Lotan Y, Droller M, Karakiewicz PI, Raman JD, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Wheat JC, Zigeuner R, Langner C, Wood CG, Margulis V. Advanced patient age is associated with inferior cancer-specific survival after radical nephroureterectomy. *BJU Int.* 2010 Jun; Epub 2009 Nov 13. PMID: 19912201.
457. **Shariat SF**, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. *BJU Int.* 2010 Feb;105(3):300-8. Epub 2009 Nov 13. Review. PMID: 19912200.
458. **Shariat SF**, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y, Isbarn H, Montorsi F, Jeldres C, Bastian PJ, Nielsen ME, Müller SC, Sagalowsky AI, Lotan Y. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. *Clin Cancer Res.* 2009 Nov 15; Epub 2009 Nov 10. PMID: 19903782.
459. Roscigno M, **Shariat SF**, Freschi M, Margulis V, Karakiewicz P, Suardi N, Remzi M, Zigeuner R, Bolenz C, Kikuchi E, Weizer A, Bensalah K, Sagalowsky A, Koppie TM, Raman J, Fernández M, Ströbel P, Kabbani W, Langner C, Wheat J, Guo CC, Kassouf W, Haitel A, Wood CG, Montorsi F. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. *Urology.* 2009 Nov; PMID: 19883824.
460. **Shariat SF**, Milowsky M, Droller MJ. Bladder cancer in the elderly. *Urol Oncol.* 2009 Nov-Dec; Review. PMID: 19879476.
461. Lughezzani G, Jeldres C, Isbarn H, **Shariat SF**, Sun M, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. A critical appraisal of the value of lymph node dissection at nephroureterectomy for upper tract urothelial carcinoma. *Urology.* 2010 Jan; Epub 2009 Oct 28. PMID: 19864000.
462. Karakiewicz PI, Suardi N, Capitanio U, Isbarn H, Jeldres C, Perrotte P, Sun M, Ficarra V, Zigeuner R, Tostain J, Mejean A, Cindolo L, Pantuck AJ, Belldegrün AS, Zini L, de la Taille A, Chautard D, Descotes JL, **Shariat SF**, Valeri A, Mulders PF, Lang H, Lechevallier E, Patard JJ. Conditional survival predictions after nephrectomy for renal cell carcinoma. *J Urol.* 2009 Dec; Epub 2009 Oct 17. PMID: 19836798.
463. Jeldres C, Cardinal H, Duclos A, **Shariat SF**, Suardi N, Capitanio U, Hébert MJ, Karakiewicz PI. Prediction of delayed graft function after renal transplantation. *Can Urol Assoc J.* 2009 Oct; PMID: 19829730.
464. Lughezzani G, Capitanio U, Jeldres C, Isbarn H, **Shariat SF**, Arjane P, Widmer H, Perrotte P, Montorsi F, Karakiewicz PI. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma: a population-based perspective. *Cancer.* 2009 Dec 15; PMID: 19824083.
465. Isbarn H, Patard JJ, Lughezzani G, Rioux-Leclercq N, Crépel M, Cindolo L, de la Taille A, Zini L, Villers A, **Shariat SF**, Bertini R, Karakiewicz PI. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma. *Urology.* 2010 Jun; Epub 2009 Sep 25. PMID: 19781745.
466. Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat A, Dinney CP, Lotan Y, **Shariat SF**. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. *Eur Urol.* 2010 Feb; Epub 2009 Sep 12. PMID: 19766384.

467. Isbarn H, Jeldres C, **Shariat SF**, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma. *J Urol*. 2009 Nov; Epub 2009 Sep 16. PMID: 19758662.
468. **Shariat SF**, Zimmern PE, Hilton K, Gruchalla RS. Prospective questionnaire-based evaluation of the prevalence of urinary incontinence in women with chronic cough. *Urol Int*. 2009; Epub 2009 Sep 10. PMID: 19752614.
469. Nuss GR, Morey AF, Jenkins AC, Pruitt JH, Dugi DD 3rd, Morse B, **Shariat SF**. Radiographic predictors of need for angiographic embolization after traumatic renal injury. *J Trauma*. 2009 Sep; discussion 582. PMID: 19741403.
470. Waldert M, Karakiewicz PI, Raman JD, Remzi M, Isbarn H, Lotan Y, Capitanio U, Bensalah K, Marberger MJ, **Shariat SF**. A delay in radical nephroureterectomy can lead to upstaging. *BJU Int*. 2010 Mar; Epub 2009 Sep 3. PMID: 19732052.
471. Lughezzani G, Jeldres C, Isbarn H, Sun M, **Shariat SF**, Widmer H, Arjane P, Graefen M, Perrotte P, Montorsi F, Karakiewicz PI. Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. *BJU Int*. 2010 Mar; Epub 2009 Sep 2. PMID: 19725824.
472. Lughezzani G, Jeldres C, Isbarn H, Perrotte P, **Shariat SF**, Sun M, Widmer H, Arjane P, Peloquin F, Pharand D, Patard JJ, Graefen M, Montorsi F, Karakiewicz PI. Tumor size is a determinant of the rate of stage T1 renal cell cancer synchronous metastasis. *J Urol*. 2009 Oct; Epub 2009 Aug 14. PMID: 19683281.
473. **Shariat SF**, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Rigaud J, Müller SC, Lerner SP, Montorsi F, Sagalowsky AI, Cote RJ, Lotan Y. p53 expression in patients with advanced urothelial cancer of the urinary bladder. *BJU Int*. 2010 Feb; Epub 2009 Jul 31. PMID: 19659466.
474. Crépel M, Isbarn H, Capitanio U, Liberman D, Jeldres C, Sun M, **Shariat SF**, Widmer H, Arjane P, Graefen M, Montorsi F, Patard JJ, Perrotte P, Karakiewicz PI. Does histologic subtype affect oncologic outcomes after nephron-sparing surgery? *Urology*. 2009 Oct; Epub 2009 Jul 22. PMID: 19628262.
475. Capitanio U, Isbarn H, **Shariat SF**, Jeldres C, Zini L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysis. *Urology*. 2009 Oct; Epub 2009 Jul 22. PMID: 19628260.
476. Raman JD, Ng CK, Scherr DS, Margulis V, Lotan Y, Bensalah K, Patard JJ, Kikuchi E, Montorsi F, Zigeuner R, Weizer A, Bolenz C, Koppie TM, Isbarn H, Jeldres C, Kabbani W, Remzi M, Waldert M, Wood CG, Roscigno M, Oya M, Langner C, Wolf JS, Ströbel P, Fernández M, Karakiewicz P, **Shariat SF**. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. *Eur Urol*. 2010 Jun; Epub 2009 Jul 15. PMID: 19619934.
477. Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, **Shariat SF**, Sun M, Lughezzani G, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. *Urology*. 2009 Oct; Epub 2009 Jul 18. PMID: 19616828.
478. **Shariat SF**, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y, Bastian PJ, Nielsen ME, Capitanio U, Jeldres C, Montorsi F, Müller SC, Karam JA, Heukamp LC, Netto G, Lerner SP,

- Sagalowsky AI, Cote RJ. p53 predictive value for pT1-2 N0 disease at radical cystectomy. *J Urol*. 2009 Sep; Epub 2009 Jul 17. PMID: 19616250.
479. Hellenthal NJ, **Shariat SF**, Margulis V, Karakiewicz PI, Roscigno M, Bolenz C, Remzi M, Weizer A, Zigeuner R, Bensalah K, Ng CK, Raman JD, Kikuchi E, Montorsi F, Oya M, Wood CG, Fernandez M, Evans CP, Koppie TM. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. *J Urol*. 2009 Sep; Epub 2009 Jul 17. PMID: 19616245.
480. Lughezzani G, Jeldres C, Isbarn H, Sun M, **Shariat SF**, Alasker A, Pharand D, Widmer H, Arjane P, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. *Eur J Cancer*. 2009 Dec; Epub 2009 Jul 15. PMID: 19615885.
481. Bolenz C, Lotan Y, Ashfaq R, **Shariat SF**. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. *Eur Urol*. 2009 Dec; Epub 2009 Jul 7. PMID: 19596509.
482. Isbarn H, Jeldres C, Capitanio U, Zini L, **Shariat SF**, Lughezzani G, Sun M, Ahyai SA, Duclos A, Jolivet-Tremblay M, Lattouf JB, Valiquette L, Perrotte P, Montorsi F, Graefen M, Karakiewicz PI. Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. *J Endourol*. 2009 Aug; PMID: 19591615.
483. Sun M, Lughezzani G, Jeldres C, Isbarn H, **Shariat SF**, Arjane P, Widmer H, Pharand D, Latour M, Perrotte P, Patard JJ, Karakiewicz PI. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma. *Eur Urol*. 2009 Nov; Epub 2009 Jun 21. PMID: 19573980.
484. Roscigno M, **Shariat SF**, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Sagalowsky A, Bensalah K, Raman JD, Bolenz C, Kassou W, Koppie TM, Wood CG, Wheat J, Langner C, Ng CK, Capitanio U, Bertini R, Fernández MI, Mikami S, Isida M, Ströbel P, Montorsi F. The extent of lymphadenectomy seems to be associated with better survival in patients with nonmetastatic upper-tract urothelial carcinoma: how many lymph nodes should be removed? *Eur Urol*. 2009 Sep; Epub 2009 Jun 18. PMID: 19559518.
485. Jeldres C, Isbarn H, Capitanio U, Zini L, Bhojani N, **Shariat SF**, Cloutier V, Lattouf JB, Duclos A, Jolivet-Tremblay M, Valiquette L, Saad F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Development and external validation of a highly accurate nomogram for the prediction of perioperative mortality after transurethral resection of the prostate for benign prostatic hyperplasia. *J Urol*. 2009 Aug; Epub 2009 Jun 17. PMID: 19535100.
486. Isbarn H, Karakiewicz PI, **Shariat SF**, Capitanio U, Palapattu GS, Sagalowsky AI, Lotan Y, Schoenberg MP, Amiel GE, Lerner SP, Sonpavde G. Residual pathological stage at radical cystectomy significantly impacts outcomes for initial T2N0 bladder cancer. *J Urol*. 2009 Aug; discussion 465. Epub 2009 Jun 13. PMID: 19524971.
487. Capitanio U, Jeldres C, Perrotte P, Isbarn H, Crépel M, Cloutier V, Baillargeon-Gagne S, **Shariat SF**, Duclos A, Arjane P, Widmer H, Saad F, Montorsi F, Karakiewicz PI. Population-based study of perioperative mortality after retroperitoneal lymphadenectomy for nonseminomatous testicular germ cell tumors. *Urology*. 2009 Aug; Epub 2009 Jun 7. PMID: 19501893.
488. Zini L, Capitanio U, Jeldres C, Lughezzani G, Sun M, **Shariat SF**, Isbarn H, Arjane P, Widmer H, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. External validation of a nomogram predicting mortality in patients with adrenocortical carcinoma. *BJU Int*. 2009 Dec; Epub 2009 Jun 2. PMID: 19493261.

489. Tilki D, Singer BB, **Shariat SF**, Behrend A, Fernando M, Irmak S, Buchner A, Hooper AT, Stief CG, Reich O, Ergün S. CEACAM1: a novel urinary marker for bladder cancer detection. *Eur Urol*. 2010 Apr; Epub 2009 May 28. PMID: 19487071.
490. Isbarn H, Jeldres C, Zini L, Perrotte P, Baillargeon-Gagne S, Capitanio U, **Shariat SF**, Arjane P, Saad F, McCormack M, Valiquette L, Peloquin F, Duclos A, Montorsi F, Graefen M, Karakiewicz PI. A population based assessment of perioperative mortality after cystectomy for bladder cancer. *J Urol*. 2009 Jul; Epub 2009 May 17. PMID: 19447427.
491. **Shariat SF**, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI, Isbarn H, Jeldres C, Rigaud J, Sagalowsky AI, Lotan Y. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. *J Urol*. 2009 Jul; discussion 84. Epub 2009 May 17. PMID: 19447418.
492. Capitanio U, Perrotte P, Zini L, Jeldres C, **Shariat SF**, Isbarn H, Arjane P, Peloquin F, Pharand D, Montorsi F, Karakiewicz PI. Nephrectomy improves survival in patients with invasion of adjacent viscera and absence of nodal metastases (stage T4N0 renal cell carcinoma). *BJU Int*. 2009 Sep; Epub 2009 Apr 15. PMID: 19389018.
493. Capitanio U, Perrotte P, Zini L, Suardi N, Antebi E, Cloutier V, Jeldres C, **Shariat SF**, Duclos A, Arjane P, Saad F, Montorsi F, Karakiewicz PI. Population-based analysis of normal total PSA and percentage of free/total PSA values: results from screening cohort. *Urology*. 2009 Jun; Epub 2009 Apr 18. PMID: 19376563.
494. Roscigno M, **Shariat SF**, Margulis V, Karakiewicz P, Remzi M, Kikuchi E, Langner C, Lotan Y, Weizer A, Bensalah K, Raman JD, Bolenz C, Guo CC, Wood CG, Zigeuner R, Wheat J, Kabbani W, Koppie TM, Ng CK, Suardi N, Bertini R, Fernández MI, Mikami S, Isida M, Michel MS, Montorsi F. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. *J Urol*. 2009 Jun; Epub 2009 Apr 16. PMID: 19371878.
495. Capitanio U, **Shariat SF**, Isbarn H, Weizer A, Remzi M, Roscigno M, Kikuchi E, Raman JD, Bolenz C, Bensalah K, Koppie TM, Kassouf W, Fernández MI, Ströbel P, Wheat J, Zigeuner R, Langner C, Waldert M, Oya M, Guo CC, Ng C, Montorsi F, Wood CG, Margulis V, Karakiewicz PI. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. *Eur Urol*. 2009 Jul; Epub 2009 Apr 3. PMID: 19361911.
496. Lotan Y, Capitanio U, **Shariat SF**, Hutterer GC, Karakiewicz PI. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection. *BJU Int*. 2009 May; Epub 2009 Mar 11. Erratum in: *BJU Int*. 2010 Apr; PMID: 19338566.
497. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, **Shariat SF**. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. *Prostate*. 2009 Jun 1; PMID: 19229851.
498. Zini L, Perrotte P, Capitanio U, Jeldres C, **Shariat SF**, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI. Radical versus partial nephrectomy: effect on overall and noncancer mortality. *Cancer*. 2009 Apr 1; PMID: 19195042.
499. Zini L, Cloutier V, Isbarn H, Perrotte P, Capitanio U, Jeldres C, **Shariat SF**, Saad F, Arjane P, Duclos A, Lattouf JB, Montorsi F, Karakiewicz PI. A simple and accurate model for prediction of cancer-specific mortality in patients treated with surgery for primary penile squamous cell carcinoma. *Clin Cancer Res*. 2009 Feb 1; PMID: 19188173.
500. Margulis V, **Shariat SF**, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG; Upper Tract Urothelial Carcinoma Collaboration The Upper Tract Urothelial

- Carcinoma Collaboration. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. *Cancer*. 2009 Mar 15; PMID: 19156917.
501. **Shariat SF**, Roehrborn CG. Using biopsy to detect prostate cancer. *Rev Urol*. 2008 Fall; PMID: 19145270.
502. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U, Montorsi F, Bastian PJ, Nielsen ME, Müller SC, Rigaud J, Heukamp LC, Netto G, Lerner SP, Sagalowsky AI, **Shariat SF**. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. *J Natl Cancer Inst*. 2009 Jan 21; Epub 2009 Jan 13. PMID: 19141773.
503. Ng CK, **Shariat SF**, Lucas SM, Bagrodia A, Lotan Y, Scherr DS, Raman JD. Does the presence of hydronephrosis on preoperative axial CT imaging predict worse outcomes for patients undergoing nephroureterectomy for upper-tract urothelial carcinoma? *Urol Oncol*. 2008 Dec 29. PMID: 19117771.
504. Capitanio U, Cloutier V, Zini L, Isbarn H, Jeldres C, **Shariat SF**, Perrotte P, Antebi E, Patard JJ, Montorsi F, Karakiewicz PI. A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population-based study. *BJU Int*. 2009 Jun; Epub 2008 Dec 8. PMID: 19076149.
505. Capitanio U, Suardi N, **Shariat SF**, Lotan Y, Palapattu GS, Bastian PJ, Gupta A, Vazina A, Schoenberg M, Lerner SP, Sagalowsky AI, Karakiewicz PI. Assessing the minimum number of lymph nodes needed at radical cystectomy in patients with bladder cancer. *BJU Int*. 2009 May; Epub 2008 Dec 8. PMID: 19076140.
506. Kikuchi E, Margulis V, Karakiewicz PI, Roscigno M, Mikami S, Lotan Y, Remzi M, Bolenz C, Langner C, Weizer A, Montorsi F, Bensalah K, Koppie TM, Fernández MI, Raman JD, Kassouf W, Wood CG, Suardi N, Oya M, **Shariat SF**. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. *J Clin Oncol*. 2009 Feb 1; Epub 2008 Dec 15. PMID: 19075275.
507. Cloutier V, Capitanio U, Zini L, Perrotte P, Jeldres C, **Shariat SF**, Arjane P, Patard JJ, Montorsi F, Karakiewicz PI. Thirty-day mortality after nephrectomy: clinical implications for informed consent. *Eur Urol*. 2009 Dec; Epub 2008 Nov 25. PMID: 19054604.
508. Capitanio U, Perrotte P, Hutterer GC, Suardi N, Jeldres C, **Shariat SF**, Duclos A, Arjane P, Montorsi F, Karakiewicz PI. Effect of body mass index on prostate-specific antigen and percentage free prostate-specific antigen: results from a prostate cancer screening cohort of 1490 men. *Int J Urol*. 2009 Jan; Epub 2008 Nov 27. PMID: 19054167.
509. **Shariat SF**, Scardino PT, Lilja H. Screening for prostate cancer: an update. *Can J Urol*. 2008 Dec; Review. PMID: 19046489.
510. Zini L, Capitanio U, Perrotte P, Jeldres C, **Shariat SF**, Arjane P, Widmer H, Montorsi F, Patard JJ, Karakiewicz PI. Population-based assessment of survival after cytoreductive nephrectomy versus no surgery in patients with metastatic renal cell carcinoma. *Urology*. 2009 Feb; Epub 2008 Nov 28. PMID: 19041122.
511. Salonia A, Briganti A, Gallina A, Karakiewicz P, **Shariat S**, Freschi M, Zanni G, Capitanio U, Bosi E, Rigatti P, Montorsi F. Sex hormone-binding globulin: a novel marker for nodal metastases prediction in prostate cancer patients undergoing extended pelvic lymph node dissection. *Urology*. 2009 Apr; Epub 2008 Nov 26. PMID: 19038425.
512. Karam JA, **Shariat SF**, Hsieh JT, Knowles MA. Genomics: a preview of genomic medicine. *BJU Int*. 2008 Nov;102(9 Pt B):1221-7. PMID: 19035885.

513. Gupta A, Karakiewicz PI, Roehrborn CG, Lotan Y, Zlotta AR, **Shariat SF**. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer. *Clin Cancer Res*. 2008 Nov 15; PMID: 19010854.
514. Bhojani N, Salomon L, Capitanio U, Suardi N, **Shariat SF**, Jeldres C, Zini L, Pharand D, Péloquin F, Arjane P, Abbou CC, De La Taille A, Montorsi F, Karakiewicz PI. External validation of the updated partin tables in a cohort of French and Italian men. *Int J Radiat Oncol Biol Phys*. 2009 Feb 1; Epub 2008 Nov 10. PMID: 19004573.
515. Bolenz C, **Shariat SF**, Fernández MI, Margulis V, Lotan Y, Karakiewicz P, Remzi M, Kikuchi E, Zigeuner R, Weizer A, Montorsi F, Bensalah K, Wood CG, Roscigno M, Langner C, Koppie TM, Raman JD, Mikami S, Michel MS, Ströbel P. Risk stratification of patients with nodal involvement in upper tract urothelial carcinoma: value of lymph-node density. *BJU Int*. 2009 Feb; Epub 2008 Oct 16. PMID: 18990164.
516. Remzi M, Haitel A, Margulis V, Karakiewicz P, Montorsi F, Kikuchi E, Zigeuner R, Weizer A, Bolenz C, Bensalah K, Suardi N, Raman JD, Lotan Y, Waldert M, Ng CK, Fernández M, Koppie TM, Ströbel P, Kabbani W, Murai M, Langner C, Roscigno M, Wheat J, Guo CC, Wood CG, **Shariat SF**. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. *BJU Int*. 2009 Feb; Epub 2008 Oct 16. Erratum in: *BJU Int*. 2009 Aug; Karakiewicz, Pierre [corrected to Karakiewicz, Pierre]. PMID: 18990163.
517. **Shariat SF**, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? *BJU Int*. 2009 Feb; Epub 2008 Sep 18. PMID: 18990135.
518. Zorn KC, Capitanio U, Jeldres C, Arjane P, Perrotte P, **Shariat SF**, Lee DI, Shalhav AL, Zagaja GP, Shikanov SA, Gofrit ON, Thong AE, Albala DM, Sun L, Karakiewicz PI. Multi-institutional external validation of seminal vesicle invasion nomograms: head-to-head comparison of Gallina nomogram versus 2007 Partin tables. *Int J Radiat Oncol Biol Phys*. 2009 Apr 1; Epub 2008 Oct 19. PMID: 18938046.
519. Svatek RS, Lotan Y, Karakiewicz PI, **Shariat SF**. Screening for bladder cancer using urine-based tumor markers. *Minerva Urol Nefrol*. 2008 Dec; Review. PMID: 18923361.
520. Herman MP, Svatek RS, Lotan Y, Karakiewicz PI, **Shariat SF**. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. *Minerva Urol Nefrol*. 2008 Dec; Review. PMID: 18923359.
521. Fernández MI, **Shariat SF**, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E, Oya M, Zigeuner R, Langner C, Weizer A, Lotan Y, Koppie TM, Raman JD, Karakiewicz P, Bensalah K, Schultz M, Bernier P. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. *Urology*. 2009 Jan; Epub 2008 Oct 8. Erratum in: *Urology*. 2010 May; Karakiewicz, Pierre [corrected to Karakiewicz, Pierre]. PMID: 18845322.
522. **Shariat SF**, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. *Cancer*. 2008 Dec 1; Review. PMID: 18823041.
523. Capitanio U, Zini L, Perrotte P, **Shariat SF**, Jeldres C, Arjane P, Pharand D, Widmer H, Péloquin F, Montorsi F, Patard JJ, Karakiewicz PI. Cyto-reductive partial nephrectomy does not undermine cancer control in metastatic renal cell carcinoma: a population-based study. *Urology*. 2008 Nov; Epub 2008 Sep 16. PMID: 18799207.
524. Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, **Shariat SF**, Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Montorsi F, Huland H, Karakiewicz PI. Partin Tables

- cannot accurately predict the pathological stage at radical prostatectomy. *Eur J Surg Oncol.* 2009 Feb; Epub 2008 Sep 10. PMID: 18786800.
525. Raman JD, Ng CK, **Shariat SF**, Margulis V, Montorsi F, Karakiewicz P; Upper-Tract Urothelial Carcinoma Collaboration. Outcomes for patients with pT0 disease after radical nephroureterectomy for upper-tract urothelial carcinoma. *BJU Int.* 2009 Jan; Epub 2008 Aug 18. PMID: 18717670.
526. Capitanio U, Briganti A, **Shariat SF**, Karakiewicz PI. The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol.* 2008 Oct; Epub 2008 Jul 21. PMID: 18703272.
527. Capitanio U, Ahyai S, Graefen M, Jeldres C, **Shariat SF**, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Pélouquin F, Pharand D, Arjane P, Huland H, Karakiewicz PI. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. *Urology.* 2008 Dec; Epub 2008 Aug 9. PMID: 18692880.
528. **Shariat SF**, Karam JA, Lotan Y, Karakiewicz PI. Critical evaluation of urinary markers for bladder cancer detection and monitoring. *Rev Urol.* 2008 Spring; PMID: 18660854.
529. Karakiewicz PI, Bhojani N, Capitanio U, Reuther AM, Suardi N, Jeldres C, Pharand D, Pélouquin F, Perrotte P, **Shariat SF**, Klein EA. External validation of the updated Partin tables in a cohort of North American men. *J Urol.* 2008 Sep; Epub 2008 Jul 17. PMID: 18635222.
530. **Shariat SF**, Karakiewicz PI, Suardi N, Kattan MW. Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. *Clin Cancer Res.* 2008 Jul 15; Review. PMID: 18628454.
531. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC, Montorsi F, **Shariat SF**. Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. *Eur Urol.* 2009 May; Epub 2008 Jun 23. PMID: 18585843.
532. **Shariat SF**, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V, Saad F, Slawin KM, Karakiewicz PI. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. *Clin Cancer Res.* 2008 Jun 15; PMID: 18559597.
533. **Shariat SF**, Trinh QD, Morey AF, Stage KH, Roehrborn CG, Valiquette L, Karakiewicz PI. Development of a highly accurate nomogram for prediction of the need for exploration in patients with renal trauma. *J Trauma.* 2008 Jun; PMID: 18545108.
534. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, **Shariat SF**. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. *Clin Cancer Res.* 2008 Jun 1. PMID: 18519764.
535. Capitanio U, Jeldres C, **Shariat SF**, Karakiewicz P. Clinicians are most familiar with nomograms and rate their clinical usefulness highest, look-up tables are second best. *Eur Urol.* 2008 Oct; Epub 2008 May 8. PMID: 18485579.
536. Karam JA, Margulis V, Montorsi F, Karakiewicz PI, Lotan Y, Kikuchi E, Weizer A, Zigeuner R, Bolenz C, **Shariat SF**. Carcinoma in situ of the upper urinary tract treated with radical nephroureterectomy-results from a multicenter study. *Eur Urol.* 2008 Oct; Epub 2008 May 8. PMID: 18485573.
537. Jeldres C, Suardi N, Capitanio U, Montorsi F, **Shariat SF**, Perrotte P, Pélouquin F, Pharand D, Graefen M, Karakiewicz PI. High surgical volume is associated with a lower rate of secondary therapy after radical prostatectomy for localized prostate cancer. *BJU Int.* 2008 Aug; Epub 2008 May 12. PMID: 18476966.

538. Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F, Graefen M, **Shariat SF**, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz PI. Mortality at 120 days after prostatic biopsy: a population-based study of 22,175 men. *Int J Cancer*. 2008 Aug 1. PMID: 18470914.
539. Walz J, **Shariat SF**, Suardi N, Perrotte P, Lotan Y, Palapattu GS, Gupta A, Bastian PJ, Rogers CG, Vazina A, Amiel GE, Sagalowsky AI, Schoenberg M, Lerner SP, Karakiewicz PI. Adjuvant chemotherapy for bladder cancer does not alter cancer-specific survival after cystectomy in a matched case-control study. *BJU Int*. 2008 Jun; PMID: 18454792.
540. **Shariat SF**, Jenkins A, Roehrborn CG, Karam JA, Stage KH, Karakiewicz PI. Features and outcomes of patients with grade IV renal injury. *BJU Int*. 2008 Sep; Epub 2008 Apr 24. PMID: 18435808.
541. Lotan Y, Bensalah K, Ruddell T, **Shariat SF**, Sagalowsky AI, Ashfaq R. Prospective evaluation of the clinical usefulness of reflex fluorescence in situ hybridization assay in patients with atypical cytology for the detection of urothelial carcinoma of the bladder. *J Urol*. 2008 Jun; Epub 2008 Apr 18. PMID: 18423745.
542. Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, **Shariat SF**, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU Int*. 2008 Jun; Epub 2008 Apr 16. PMID: 18422773.
543. Walz J, Suardi N, **Shariat SF**, Jeldres C, Perrotte P, Graefen M, Widmer H, Arjane P, Valiquette L, Hutterer G, Saad F, Karakiewicz PI. Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. *BJU Int*. 2008 Jul; Epub 2008 Apr 2. PMID: 18384631.
544. **Shariat SF**, Karakiewicz PI, Margulis V, Kattan MW. Inventory of prostate cancer predictive tools. *Curr Opin Urol*. 2008 May; Review. PMID: 18382238.
545. **Shariat SF**, Karam JA, Raman JD. Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomark Med*. 2008 Apr; PMID: 20477438.
546. Karakiewicz PI, Bhojani N, Neugut A, **Shariat SF**, Jeldres C, Graefen M, Perrotte P, Peloquin F, Kattan MW. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer. *J Sex Med*. 2008 Apr; PMID: 18371045.
547. Bhojani N, Perrotte P, Hutterer G, Suardi N, Jeldres C, **Shariat SF**, Capitanio U, Arjane P, Widmer H, Benard F, Peloquin F, Montorsi F, Karakiewicz P. Body mass index and its association with genitourinary disorders in men undergoing prostate cancer screening. *J Sex Med*. 2008 Sep; Epub 2008 Mar 19. PMID: 18355173.
548. **Shariat SF**, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI. External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. *J Clin Oncol*. 2008 Mar 20; PMID: 18349404.
549. **Shariat SF**, Margulis V, Karakiewicz PI. Rebuttal from authors re: James W.F. Catto. More nomograms or better evidence of efficacy: what do we need in urologic oncology? *Eur Urol*. 2008 Jul; Epub 2008 Mar 4. PMID: 18329787.
550. Margulis V, Lotan Y, Montorsi F, **Shariat SF**. Predicting survival after radical cystectomy for bladder cancer. *BJU Int*. 2008 Jul; Epub 2008 Mar 5. Review. PMID: 18325050.

551. Walz J, Montorsi F, Jeldres C, Suardi N, **Shariat SF**, Perrotte P, Arjane P, Graefen M, Pharand D, Karakiewicz PI. The effect of surgical volume, age and comorbidities on 30-day mortality after radical prostatectomy: a population-based analysis of 9208 consecutive cases. *BJU Int.* 2008 Apr. PMID: 18321316.
552. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, **Shariat SF**. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer. *Clin Cancer Res.* 2008 Mar 1; PMID: 18316564.
553. Gupta A, Lotan Y, Bastian PJ, Palapattu GS, Karakiewicz PI, Raj GV, Schoenberg MP, Lerner SP, Sagalowsky AI, **Shariat SF**; Bladder Cancer Research Consortium. Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomy. *Urology.* 2008 Feb; PMID: 18308108.
554. **Shariat SF**, Walz J, Roehrborn CG, Montorsi F, Jeldres C, Saad F, Karakiewicz PI. Early postoperative plasma transforming growth factor-beta1 is a strong predictor of biochemical progression after radical prostatectomy. *J Urol.* 2008 Apr; Epub 2008 Mar 4. PMID: 18295256.
555. Lotan Y, **Shariat SF**; NMP22 Study Group. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. *BJU Int.* 2008 Jun; Epub 2008 Feb 18. PMID: 18284410.
556. Karakiewicz PI, Capitanio U, **Shariat S**. Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. *Eur Urol.* 2009 Jul; Epub 2008 Feb 8. PMID: 18280634.
557. Bensalah K, Traxer O, **Shariat SF**, Zimmern P. [What are the differences between American and French urologists?]. *Prog Urol.* 2007 Nov; French. PMID: 18271424.
558. **Shariat SF**, Karakiewicz PI. Perspectives on prostate cancer biomarkers. *Eur Urol.* 2008 Jul; Epub 2008 Feb 4. PMID: 18262336.
559. Hutterer GC, Karakiewicz PI, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Serretta V, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Perrotte P, Lotan Y, Marberger MJ, **Shariat SF**. Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma. *BJU Int.* 2008 Mar. PMID: 18257856.
560. **Shariat SF**. Selecting patients for immediate cystectomy. *Rev Urol.* 2007 Fall. PMID: 18231621.
561. **Shariat SF**, Lamb DJ, Iyengar RG, Roehrborn CG, Slawin KM. Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. *Clin Cancer Res.* 2008 Jan 15. PMID: 18223237.
562. Bhojani N, Perrotte P, Jeldres C, Suardi N, Hutterer G, **Shariat SF**, Karakiewicz PI. The effect of comorbidities and socioeconomic status on sexual and urinary function in men undergoing prostate cancer screening. *J Sex Med.* 2008 Mar; Epub 2008 Jan 21. PMID: 18221289.
563. **Shariat SF**, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. *Eur Urol.* 2008 Jul; Epub 2008 Jan 15. Review. PMID: 18207314.
564. **Shariat SF**, Karam JA, Lerner SP. Molecular markers in bladder cancer. *Curr Opin Urol.* 2008 Jan; Review. PMID: 18090481.
565. **Shariat SF**, Karakiewicz PI. Screening for prostate cancer in 2007: the PSA era and its challenges are not over. *Eur Urol.* 2008 Mar; Epub 2007 Dec 7. PMID: 18079050.

566. Svatek RS, Karam J, Karakiewicz PI, Gallina A, Casella R, Roehrborn CG, **Shariat SF**. Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma. *J Urol*. 2008 Feb; PMID: 18076936.
567. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. *Urol Oncol*. 2007 Nov-Dec; PMID: 18047954.
568. **Shariat SF**, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ, Sagalowsky AI, Lotan Y. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. *Cancer*. 2008 Jan 15; PMID: 18008359.
569. Bensalah K, Lotan Y, Karam JA, **Shariat SF**. New circulating biomarkers for prostate cancer. *Prostate Cancer Prostatic Dis*. 2008; Epub 2007 Nov 13. Review. PMID: 17998918.
570. Jeldres C, Suardi N, Saad F, Montorsi F, **Shariat SF**, Perrotte P, Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI. High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer. *Eur Urol*. 2008 Jul; Epub 2007 Nov 6. PMID: 17997022.
571. Briganti A, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, **Shariat S**, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI. Prostate volume and adverse prostate cancer features: fact not artifact. *Eur J Cancer*. 2007 Dec; Epub 2007 Nov 8. PMID: 17996442.
572. Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, **Shariat SF**, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men. *Eur Urol*. 2008 Jul; Epub 2007 Oct 30. PMID: 17996358.
573. Walz J, Gallina A, Perrotte P, Jeldres C, Trinh QD, Hutterer GC, Traumann M, Ramirez A, **Shariat SF**, McCormack M, Perreault JP, Bénard F, Valiquette L, Saad F, Karakiewicz PI. Clinicians are poor raters of life-expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. *BJU Int*. 2007 Dec; PMID: 17979925.
574. Margulis V, Lotan Y, **Shariat SF**. Survivin: a promising biomarker for detection and prognosis of bladder cancer. *World J Urol*. 2008 Feb; Epub 2007 Oct 26. Review. PMID: 17962949.
575. **Shariat SF**, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. *BJU Int*. 2008 Mar; Epub 2007 Oct 17. Review. PMID: 17941930.
576. Bensalah K, Montorsi F, **Shariat SF**. Challenges of cancer biomarker profiling. *Eur Urol*. 2007 Dec; 2007 Oct 1. Review. PMID: 17919807.
577. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, **Shariat SF**. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. *Urology*. 2007 Sep; PMID: 17905101.
578. **Shariat SF**, Bensalah K, Karam JA, Roehrborn CG, Gallina A, Lotan Y, Slawin KM, Karakiewicz PI. Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer. *Clin Cancer Res*. 2007 Sep 15; PMID: 17875766.
579. **Shariat SF**, Svatek RS, Kabbani W, Walz J, Lotan Y, Karakiewicz PI, Roehrborn CG. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. *BJU Int*. 2008 Jan; Epub 2007 Sep 13. PMID: 17868422.

580. Bastian PJ, Hutterer GC, **Shariat SF**, Rogers CG, Palapattu GS, Lotan Y, Vazina A, Amiel GE, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP, Karakiewicz PI; Bladder Cancer Research Consortium. Macroscopic, but not microscopic, perivesical fat invasion at radical cystectomy is an adverse predictor of recurrence and survival. *BJU Int.* 2008 Feb; Epub 2007 Sep 10. PMID: 17850359.
581. Nielsen ME, Palapattu GS, Karakiewicz PI, Lotan Y, Bastian PJ, Lerner SP, Sagalowsky AI, Schoenberg MP, **Shariat SF**. A delay in radical cystectomy of >3 months is not associated with a worse clinical outcome. *BJU Int.* 2007 Nov; Epub 2007 Sep 3. PMID: 17784888.
582. Huang HY, **Shariat SF**, Sun TT, Lepor H, Shapiro E, Hsieh JT, Ashfaq R, Lotan Y, Wu XR. Persistent uroplakin expression in advanced urothelial carcinomas: implications in urothelial tumor progression and clinical outcome. *Hum Pathol.* 2007 Nov; Epub 2007 Aug 17. PMID: 17707461.
583. Walz J, Gallina A, Saad F, Montorsi F, Perrotte P, **Shariat SF**, Jeldres C, Graefen M, Bénard F, McCormack M, Valiquette L, Karakiewicz PI. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. *J Clin Oncol.* 2007 Aug 20. PMID: 17704404.
584. **Shariat SF**, Park S, Trinh QD, Roehrborn CG, Slawin KM, Karakiewicz PI. Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms. *J Urol.* 2007 Oct; Epub 2007 Aug 14. PMID: 17698116.
585. Karam JA, **Shariat SF**, Huang HY, Pong RC, Ashfaq R, Shapiro E, Lotan Y, Sagalowsky AI, Wu XR, Hsieh JT. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder. *Clin Cancer Res.* 2007 Aug 1. PMID: 17671122.
586. **Shariat SF**, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. *Future Oncol.* 2007 Aug. PMID: 17661720.
587. Malaeb BS, Rashid HH, Lotan Y, Khoddami SM, **Shariat SF**, Sagalowsky AI, McConnell JD, Roehrborn CG, Koeneman KS. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts. *Urol Oncol.* 2007 Jul-Aug. PMID: 17628294.
588. Briganti A, **Shariat SF**, Chun FK, Hutterer GC, Roehrborn CG, Gallina A, Rigatti P, Valiquette L, Montorsi F, Karakiewicz PI. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. *BJU Int.* 2007 Sep; Epub 2007 Jun 15. PMID: 17573893.
589. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, Briganti A, Walz J, Antebi E, **Shariat SF**, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. *Int J Cancer.* 2007 Aug 15; PMID: 17455251.
590. Walz J, Gallina A, Hutterer G, Perrotte P, **Shariat SF**, Graefen M, McCormack M, Bénard F, Valiquette L, Saad F, Karakiewicz PI. Accuracy of life tables in predicting overall survival in candidates for radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys.* 2007 Sep 1; Epub 2007 Apr 18. PMID: 17446004.
591. **Shariat SF**, Roehrborn CG, Karakiewicz PI, Dhimi G, Stage KH. Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. *J Trauma.* 2007 Apr; PMID: 17426551.

592. **Shariat SF**, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. *Mod Pathol*. 2007 Apr; Epub 2007 Mar 2. PMID: 17384651.
593. Chun FK, Briganti A, Gallina A, Hutterer GC, **Shariat SF**, Antebie E, Walz J, Roehrborn CG, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. *Eur Urol*. 2007 Oct; Epub 2007 Mar 20. PMID: 17383807.
594. Briganti A, Chun FK, Hutterer GC, Gallina A, **Shariat SF**, Salonia A, Scattoni V, Valiquette L, Montorsi F, Rigatti P, Graefen M, Huland H, Karakiewicz PI. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. *Eur Urol*. 2007 Sep; Epub 2007 Mar 6. PMID: 17350750.
595. **Shariat SF**, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. *Cancer*. 2007 Mar 15; PMID: 17311310.
596. Karam JA, Lotan Y, Roehrborn CG, Ashfaq R, Karakiewicz PI, **Shariat SF**. Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. *Prostate*. 2007 May 1. PMID: 17299799.
597. Margulis V, **Shariat SF**, Ashfaq R, Thompson M, Sagalowsky AI, Hsieh JT, Lotan Y. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder. *J Urol*. 2007 Mar. PMID: 17296438.
598. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG, **Shariat SF**. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. *Lancet Oncol*. 2007 Feb. PMID: 17267327.
599. Gallina A, Chun FK, Briganti A, **Shariat SF**, Montorsi F, Salonia A, Erbersdobler A, Rigatti P, Valiquette L, Huland H, Graefen M, Karakiewicz PI. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy. *Eur Urol*. 2007 Jul; Epub 2007 Jan 22. PMID: 17267098.
600. **Shariat SF**, Roehrborn CG, McConnell JD, Park S, Alam N, Wheeler TM, Slawin KM. Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. *J Clin Oncol*. 2007 Feb 1. PMID: 17264329.
601. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. *J Urol*. 2007 Feb. PMID: 17222615.
602. Margulis V, **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. *Clin Cancer Res*. 2006 Dec 15. PMID: 17189409.
603. Gallina A, Jeldres C, Chun FK, **Shariat SF**, Briganti A, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. *Eur Urol*. 2007 Nov; Epub 2006 Dec 11. PMID: 17174466.
604. **Shariat SF**, Karakiewicz PI, Palapattu GS, Amiel GE, Lotan Y, Rogers CG, Vazina A, Bastian PJ, Gupta A, Sagalowsky AI, Schoenberg M, Lerner SP. Nomograms provide improved accuracy for predicting survival after radical cystectomy. *Clin Cancer Res*. 2006 Nov 15. PMID: 17121885.

605. Nielsen ME, **Shariat SF**, Karakiewicz PI, Lotan Y, Rogers CG, Amiel GE, Bastian PJ, Vazina A, Gupta A, Lerner SP, Sagalowsky AI, Schoenberg MP, Palapattu GS; Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. *Eur Urol.* 2007 Mar; Epub 2006 Nov 13. PMID: 17113703.
606. **Shariat SF**, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. *J Urol.* 2006 Dec. PMID: 17085118.
607. **Shariat SF**, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. *Eur Urol.* 2007 Jan; Epub 2006 Sep 11. PMID: 17011114.
608. Slawin KM, **Shariat S**, Canto E. BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia. *Rev Urol.* 2005. PMID: 16985891.
609. **Shariat SF**, Naderi AS, Miles B, Slawin KM. Anomalies of the wolffian duct derivatives encountered at radical prostatectomy. *Rev Urol.* 2005 Spring. PMID: 16985813.
610. **Shariat SF**, Sadeghi F, Slawin KM. Vaccine-based immunotherapy for prostate cancer. *Rev Urol.* 2000 Fall. PMID: 16985756.
611. **Shariat SF**, Slawin KM. Gene therapy for prostate cancer. *Rev Urol.* 2000 Spring. PMID: 16985740.
612. **Shariat SF**, Haddad JL, Escudier S, Lerner SP. Metastatic transitional cell carcinoma of the urinary bladder to the shoulder girdle. *Rev Urol.* 2002 Spring. PMID: 16985663.
613. Slawin KM, Canto EI, **Shariat SF**, Gore JL, Kim E, Kattan MW, Wheeler TM, Nath RK. Sural Nerve Interposition Grafting during Radical Prostatectomy. *Rev Urol.* 2002 Winter. PMID: 16985648.
614. **Shariat SF**, Slawin KM. Peripheral blood rt-PCR assays for detection and prognosis of prostate cancer. *Rev Urol.* 2003 Winter. PMID: 16985619.
615. **Shariat SF**, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. *Rev Urol.* 2004 Spring. PMID: 16985579.
616. **Shariat SF**, Palapattu GS, Amiel GE, Karakiewicz PI, Rogers CG, Vazina A, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. *Urology.* 2006 Sep; Epub 2006 Sep 18. PMID: 16979748.
617. Karakiewicz PI, **Shariat SF**, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg M, Lerner SP. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. *J Urol.* 2006 Oct. PMID: 16952631.
618. **Shariat SF**, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. *Hum Pathol.* 2006 Dec; Epub 2006 Aug 10. PMID: 16949911.
619. **Shariat SF**, Marberger MJ, Lotan Y, Sanchez-Carbayo M, Zippe C, Lüdecke G, Boman H, Sawczuk I, Friedrich MG, Casella R, Mian C, Eissa S, Akaza H, Serretta V, Huland H, Hedelin H,

- Raina R, Miyanaga N, Sagalowsky AI, Roehrborn CG, Karakiewicz PI. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. *J Urol.* 2006 Sep. PMID: 16890655.
620. Chun FK, Briganti A, **Shariat SF**, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currlin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. *BJU Int.* 2006 Aug. PMID: 16879673.
621. Karakiewicz PI, **Shariat SF**, Palapattu GS, Perrotte P, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg M, Lerner SP. Precystectomy nomogram for prediction of advanced bladder cancer stage. *Eur Urol.* 2006 Dec; Epub 2006 Jun 23. PMID: 16831511.
622. Walsh LP, Zimmern PE, Pope N, **Shariat SF**; Urinary Incontinence Treatment Network. Comparison of the Q-tip test and voiding cystourethrogram to assess urethral hypermobility among women enrolled in a randomized clinical trial of surgery for stress urinary incontinence. *J Urol.* 2006 Aug. PMID: 16813912.
623. **Shariat SF**, Palapattu GS, Karakiewicz PI, Rogers CG, Vazina A, Bastian PJ, Schoenberg MP, Lerner SP, Sagalowsky AI, Lotan Y. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. *Eur Urol.* 2007 Jan; Epub 2006 Jun 8. PMID: 16793197.
624. Rogers CG, Palapattu GS, **Shariat SF**, Karakiewicz PI, Bastian PJ, Lotan Y, Gupta A, Vazina A, Gilad A, Sagalowsky AI, Lerner SP, Schoenberg MP. Clinical outcomes following radical cystectomy for primary nontransitional cell carcinoma of the bladder compared to transitional cell carcinoma of the bladder. *J Urol.* 2006 Jun. PMID: 16697800.
625. Palapattu GS, **Shariat SF**, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Lotan Y, Vazina A, Gupta A, Sagalowsky AI, Lerner SP, Schoenberg MP; Bladder Cancer Research Consortium. Cancer specific outcomes in patients with pT0 disease following radical cystectomy. *J Urol.* 2006 May. PMID: 16600721.
626. Karakiewicz PI, Benayoun S, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Marberger MJ, **Shariat SF**. Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder. *BJU Int.* 2006 May; Epub 2006 Mar 17. PMID: 16542342.
627. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI, **Shariat SF**. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer. *Cancer.* 2006 Apr 15. PMID: 16541433.
628. **Shariat SF**, Abdel-Aziz KF, Roehrborn CG, Lotan Y. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml. *Eur Urol.* 2006 Feb; Epub 2005 Dec 20. PMID: 16387412.
629. **Shariat SF**, Duchene D, Kabbani W, Mucher Z, Lotan Y. Gastrointestinal hemorrhage as first manifestation of metastatic testicular tumor. *Urology.* 2005 Dec. PMID: 16360470.
630. **Shariat SF**, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. *J Urol.* 2005 Nov. PMID: 16217391.
631. Lotan Y, Gupta A, **Shariat SF**, Palapattu GS, Vazina A, Karakiewicz PI, Bastian PJ, Rogers CG, Amiel G, Perotte P, Schoenberg MP, Lerner SP, Sagalowsky AI. Lymphovascular invasion is

- independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. *J Clin Oncol.* 2005 Sep 20; Epub 2005 Aug 22. PMID: 16116151.
632. Matsumoto K, **Shariat SF**, Ayala GE, Rauen KA, Lerner SP. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. *Urology.* 2005 Aug. PMID: 16040097.
633. **Shariat SF**, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. *Prostate.* 2005 Nov 1. PMID: 16015591.
634. **Shariat SF**, Matsumoto K, Casella R, Jian W, Lerner SP. Urinary levels of soluble e-cadherin in the detection of transitional cell carcinoma of the urinary bladder. *Eur Urol.* 2005 Jul; Epub 2005 Mar 8. PMID: 15967254.
635. **Shariat SF**, Herman MP, Casella R, Lotan Y, Karam JA, Stenman UH. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. *Eur Urol.* 2005 Sep. PMID: 15963628.
636. **Shariat SF**, Zippe C, Lüdecke G, Boman H, Sanchez-Carbayo M, Casella R, Mian C, Friedrich MG, Eissa S, Akaza H, Sawczuk I, Serretta V, Huland H, Hedelin H, Rupesh R, Miyanaga N, Sagalowsky AI, Wians F Jr, Roehrborn CG, Lotan Y, Perrotte P, Benayoun S, Marberger MJ, Karakiewicz PI. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder. *J Urol.* 2005 May. PMID: 15821471.
637. Ramirez A, Perrotte P, Valiquette L, Benard F, McCormack M, Saad F, Fournier C, **Shariat S**, Karakiewicz PI. Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. *Can J Urol.* 2005 Feb. PMID: 15777491.
638. Karakiewicz P, **Shariat SF**, Naderi A, Kadmon D, Slawin KM. Reliability of remembered International Index of Erectile Function domain scores in men with localized prostate cancer. *Urology.* 2005 Jan. PMID: 15667878.
639. Defreitas GA, Zimmern PE, Lemack GE, **Shariat SF**. Refining diagnosis of anatomic female bladder outlet obstruction: comparison of pressure-flow study parameters in clinically obstructed women with those of normal controls. *Urology.* 2004 Oct. PMID: 15491697.
640. Canto EI, Singh H, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection. *J Urol.* 2004 Sep. PMID: 15310993.
641. Khoddami SM, **Shariat SF**, Lotan Y, Saboorian H, McConnell JD, Sagalowsky AI, Roehrborn CG, Koeneman KS. Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. *BJU Int.* 2004 Jul. PMID: 15217428.
642. **Shariat SF**, Menesses-Diaz A, Kim IY, Muramoto M, Wheeler TM, Slawin KM. Tissue expression of transforming growth factor-beta1 and its receptors: correlation with pathologic features and biochemical progression in patients undergoing radical prostatectomy. *Urology.* 2004 Jun. PMID: 15183988.
643. Singh H, Karakiewicz P, **Shariat SF**, Canto EI, Nath RK, Kattan MW, Slawin KM. Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical prostatectomy. *Urology.* 2004 Jun. PMID: 15183964.

644. Canto EI, **Shariat SF**, Slawin KM. Molecular diagnosis of prostate cancer. *Curr Urol Rep.* 2004 Jun; Review. PMID: 15161569.
645. Canto EI, Singh H, **Shariat SF**, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. *Urology.* 2004 May. PMID: 15134977.
646. Link RE, **Shariat SF**, Nguyen CV, Farr A, Weinberg AD, Morton RA, Richardson B, Bernard D, Slawin KM. Variation in prostate specific antigen results from 2 different assay platforms: clinical impact on 2304 patients undergoing prostate cancer screening. *J Urol.* 2004 Jun. PMID: 15126793.
647. Lotan Y, **Shariat SF**, Khoddami SM, Saboorian H, Koeneman KS, Cadeddu JA, Sagalowsky AI, McConnell JD, Roehrborn CG. The percent of biopsy cores positive for cancer is a predictor of advanced pathological stage and poor clinical outcomes in patients treated with radical prostatectomy. *J Urol.* 2004 Jun. PMID: 15126787.
648. **Shariat SF**, Anwuri VA, Lamb DJ, Shah NV, Wheeler TM, Slawin KM. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. *J Clin Oncol.* 2004 May 1. PMID: 15117988.
649. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Predictors of prostate cancer after initial negative systematic 12 core biopsy. *J Urol.* 2004 May. PMID: 15076292.
650. Ohori M, Kattan MW, Koh H, Maru N, Slawin KM, **Shariat S**, Muramoto M, Reuter VE, Wheeler TM, Scardino PT. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. *J Urol.* 2004 May. PMID: 15076291.
651. Vazina A, Dugi D, **Shariat SF**, Evans J, Link R, Lerner SP. Stage specific lymph node metastasis mapping in radical cystectomy specimens. *J Urol.* 2004 May. PMID: 15076287.
652. **Shariat SF**, Kattan MW, Traxel E, Andrews B, Zhu K, Wheeler TM, Slawin KM. Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression. *Clin Cancer Res.* 2004 Mar 15. PMID: 15041717.
653. **Shariat SF**, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T, Gasser TC, Sagalowsky AI. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. *Eur Urol.* 2004 Mar. PMID: 15036675.
654. Stephenson AJ, **Shariat SF**, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, Klein EA, Kupelian PA, Roehrborn CG, Pistenmaa DA, Pacholke HD, Liauw SL, Katz MS, Leibel SA, Scardino PT, Slawin KM. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *JAMA.* 2004 Mar 17. PMID: 15026399.
655. **Shariat SF**, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF, Lerner SP. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. *J Clin Oncol.* 2004 Mar 15; Epub 2004 Feb 23. PMID: 14981102.
656. **Shariat SF**, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. *Cancer.* 2004 Feb 15. PMID: 14770431.
657. **Shariat SF**, Khoddami SM, Saboorian H, Koeneman KS, Sagalowsky AI, Cadeddu JA, McConnell JD, Holmes MN, Roehrborn CG. Lymphovascular invasion is a pathological feature of biologically

- aggressive disease in patients treated with radical prostatectomy. *J Urol*. 2004 Mar. PMID: 14767284.
658. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Improved detection of clinically significant, curable prostate cancer with systematic 12-core biopsy. *J Urol*. 2004 Mar. PMID: 14767277.
659. **Shariat SF**, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC, Lerner SP. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. *J Urol*. 2004 Feb. PMID: 14713774.
660. Singh H, Canto EI, **Shariat SF**, Kadmon D, Miles BJ, Wheeler TM, Slawin KM. Six additional systematic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. *J Urol*. 2004 Jan. PMID: 14665877.
661. Matsumoto K, **Shariat SF**, Casella R, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. *J Urol*. 2003 Dec. PMID: 14634390.
662. **Shariat SF**, Casella R, Monoski MA, Sulser T, Gasser TC, Lerner SP. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer. *J Urol*. 2003 Dec. PMID: 14634389.
663. Kattan MW, Eastham JA, Wheeler TM, Maru N, Scardino PT, Erbersdobler A, Graefen M, Huland H, Koh H, **Shariat SF**, Slawin KM, Otori M. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol*. 2003 Nov. PMID: 14532778.
664. **Shariat SF**, Kattan MW, Song W, Bernard D, Gottenger E, Wheeler TM, Slawin KM. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy. *Cancer Res*. 2003 Sep 15. PMID: 14522912.
665. **Shariat SF**, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner SP. Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. *J Urol*. 2003 Sep. PMID: 12913755.
666. Kattan MW, **Shariat SF**, Andrews B, Zhu K, Canto E, Matsumoto K, Muramoto M, Scardino PT, Otori M, Wheeler TM, Slawin KM. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer. *J Clin Oncol*. 2003 Oct 1; Epub 2003 Aug 11. PMID: 12913106.
667. **Shariat SF**, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. *Cancer Res*. 2003 Aug 1. PMID: 12907647.
668. **Shariat SF**, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. *Urology*. 2003 Jun. PMID: 12809883.
669. **Shariat SF**, Monoski MA, Andrews B, Wheeler TM, Lerner SP, Slawin KM. Association of plasma urokinase-type plasminogen activator and its receptor with clinical outcome in patients undergoing radical cystectomy for transitional cell carcinoma of the bladder. *Urology*. 2003 May. PMID: 12736046.

670. Canto EI, **Shariat SF**, Slawin KM. Biochemical staging of prostate cancer. *Urol Clin North Am*. 2003 May; Review. PMID: 12735503.
671. **Shariat SF**, Kattan MW, Erdamar S, Nguyen C, Scardino PT, Spencer DM, Wheeler TM, Slawin KM. Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein. *J Clin Oncol*. 2003 Apr 1. PMID:12663708.
672. **Shariat SF**, Kim J, Nguyen C, Wheeler TM, Lerner SP, Slawin KM. Correlation of preoperative levels of IGF-I and IGFBP-3 with pathologic parameters and clinical outcome in patients with bladder cancer. *Urology*. 2003 Feb. PMID: 12597948.
673. **Shariat SF**, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP. Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. *J Urol*. 2003 Mar. PMID: 12576817.
674. Casella R, **Shariat SF**, Monoski MA, Lerner SP. Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. *Cancer*. 2002 Dec 15. PMID: 12467062.
675. **Shariat SF**, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. *Cancer Res*. 2002 Oct 15. PMID: 12384565.
676. Andrews B, **Shariat SF**, Kim JH, Wheeler TM, Slawin KM, Lerner SP. Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. *J Urol*. 2002 Mar. PMID: 11832773.
677. **Shariat SF**, Lamb DJ, Kattan MW, Nguyen C, Kim J, Beck J, Wheeler TM, Slawin KM. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. *J Clin Oncol*. 2002 Feb 1. PMID: 11821468.
678. **Shariat SF**, Kim JH, Andrews B, Kattan MW, Wheeler TM, Kim IY, Lerner SP, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma. *Cancer*. 2001 Dec 15. PMID: 11753975.
679. Kim JH, **Shariat SF**, Kim IY, Menesses-Diaz A, Tokunaga H, Wheeler TM, Lerner SP. Predictive value of expression of transforming growth factor-beta(1) and its receptors in transitional cell carcinoma of the urinary bladder. *Cancer*. 2001 Sep 15. PMID: 11745225.
680. **Shariat SF**, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. *Urology*. 2001 Dec. PMID: 11744478.
681. Tokunaga H, **Shariat SF**, Green AE, Brown RM, Zhou JH, Benedict WF, Lerner SP. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. *Int J Radiat Oncol Biol Phys*. 2001 Sep 1. PMID: 11516846.
682. **Shariat SF**, Shalev M, Menesses-Diaz A, Kim IY, Kattan MW, Wheeler TM, Slawin KM. Preoperative plasma levels of transforming growth factor beta(1)(TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. *J Clin Oncol*. 2001 Jun 1. PMID: 11387358.

683. Gore JL, **Shariat SF**, Miles BJ, Kadmon D, Jiang N, Wheeler TM, Slawin KM. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. *J Urol*. 2001 May. PMID:11342916.
684. Byrne RR, **Shariat SF**, Brown R, Kattan MW, Morton RA JR, Wheeler TM, Lerner SP. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. *J Urol*. 2001 May. PMID: 11342899.
685. Leventis AK, **Shariat SF**, Slawin KM. Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. *Radiology*. 2001 May. PMID: 11323468.
686. **Shariat SF**, Desai S, Song W, Khan T, Zhao J, Nguyen C, Foster BA, Greenberg N, Spencer DM, Slawin KM. Adenovirus-mediated transfer of inducible caspases: a novel "death switch" gene therapeutic approach to prostate cancer. *Cancer Res*. 2001 Mar 15. PMID: 11289132.
687. Leventis AK, **Shariat SF**, Utsunomiya T, Slawin KM. Characteristics of normal prostate vascular anatomy as displayed by power Doppler. *Prostate*. 2001 Mar 1. PMID: 11241550.
688. Leventis AK, **Shariat SF**, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. *J Clin Oncol*. 2001 Feb 15; Erratum in: *J Clin Oncol* 2001 Apr 1. PMID: 11181666.
689. **Shariat SF**, Pahlavan S, Baseman AG, Brown RM, Green AE, Wheeler TM, Lerner SP. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. *Urology*. 2001 Jan. PMID: 11164145.
690. Slawin KM, **Shariat SF**, Nguyen C, Leventis AK, Song W, Kattan MW, Young CY, Tindall DJ, Wheeler TM. Detection of metastatic prostate cancer using a splice variant-specific reverse transcriptase-polymerase chain reaction assay for human glandular kallikrein. *Cancer Res*. 2000 Dec 15. PMID: 11156423.
691. **Shariat SF**, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM, Lerner SP. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. *Urology*. 2000 Nov 1. PMID: 11068290.
692. **Shariat SF**, Bergamaschi F, Adler HL, Nguyen C, Kattan MW, Wheeler TM, Slawin KM. Correlation of preoperative plasma IGF-I levels with pathologic parameters and progression in patients undergoing radical prostatectomy. *Urology*. 2000 Sep 1. PMID: 10962307.
693. Djavan B, **Shariat S**, Ghawidel K, Güven-Marberger K, Remzi M, Kovarik J, Hoerl WH, Marberger M. Impact of chronic dialysis on serum PSA, free PSA, and free/total PSA ratio: is prostate cancer detection compromised in patients receiving long-term dialysis? *Urology*. 1999 Jun. PMID: 10367847.
694. Djavan B, Fakhari M, **Shariat S**, Ghawidel K, Marberger M. A novel intraurethral prostatic bridge catheter for prevention of temporary prostatic obstruction following high energy transurethral microwave thermotherapy in patients with benign prostatic hyperplasia. *J Urol*. 1999 Jan. PMID: 10037387.
695. Djavan B, Roehrborn CG, **Shariat S**, Ghawidel K, Marberger M. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. *J Urol*. 1999 Jan. PMID: 10037386.
696. Djavan B, **Shariat S**, Fakhari M, Ghawidel K, Seitz C, Partin AW, Roehrborn CG, Marberger M. Neoadjuvant and adjuvant alpha-blockade improves early results of high-energy transurethral microwave thermotherapy for lower urinary tract symptoms of benign prostatic hyperplasia: a randomized, prospective clinical trial. *Urology*. 1999 Feb. PMID: 9933035.

697. Djavan B, Lin V, Kaplan EP, Richier JC, **Shariat S**, Marberger M, McConnell JD. Decreased elastin gene expression in noncompliant human bladder tissue: a competitive reverse transcriptase-polymerase chain reaction analysis. *J Urol*. 1998 Nov. PMID: 9783926.
698. Djavan B, **Shariat S**, Schäfer B, Marberger M. Tolerability of high energy transurethral microwave thermotherapy with topical urethral anesthesia: results of a prospective, randomized, single-blinded clinical trial. *J Urol*. 1998 Sep. PMID: 9720545.
699. Djavan B, Zlotta AR, Byttebier G, **Shariat S**, Omar M, Schulman CC, Marberger M. Prostate specific antigen density of the transition zone for early detection of prostate cancer. *J Urol*. 1998 Aug. PMID: 9679889.
700. Djavan B, Susani M, **Shariat S**, Zlotta AR, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation (RITA) of the prostate. *Tech Urol*. 1998 Jun. PMID: 9623628.
701. Djavan B, Zlotta AR, Susani M, Heinz G, **Shariat S**, Silverman DE, Schulman CC, Marberger M. Transperineal radiofrequency interstitial tumor ablation of the prostate: correlation of magnetic resonance imaging with histopathologic examination. *Urology*. 1997 Dec. PMID: 9426739.

NON-PEER-REVIEWED PUBLICATIONS

1. Grubmüller B., **Shariat S.**: Nicht muskelinvasives Blasenkarzinom: wie eine „zu späte“ radikale Zystektomie zu verhindern ist. *Spectrum Urologie* 2‘ 8-11, 2014
2. Maj-Hes A., **Shariat, S.**: Gesundheit der Österreicher auf der Kippe. Urologen vereint gegen den Tabakkonsum. *Spectrum Urologie* 3: 10-3, 2014
3. **Shariat S.**: Was bedeutet Behinderung? Unsere Sprache beeinflusst unser Denken. *Klinik* 5: 16-7, 2014
4. Lucca I, Klätte T, **Shariat SF**. Radical prostatectomy or watchful waiting in early prostate cancer. *Eur Urol*. 2014 Aug;66(2):386-7. PMID: 25305785
5. Catto JW, Cooperberg MR, Cornu JN, Gratzke C, Novara G, **Shariat S**, Vickers A. European Urology: Serving Our Readership Through Systematic Peer Review, Use of Reporting Standards, and Encouragement of Postpublication Review. *Eur Urol*. 2014 Aug 27. PMID: 25175422
6. **Shariat S.**: Bladder cancer: the curious case of a not so rare disease. *Curr Opin Urol*. 2014 Sep;24(5):483-6. PMID: 24992244
7. **Rink M., Shariat S.**: Re: global effects of smoking, of quitting, and of taxing tobacco. *Eur Urol*. 2014 Jul;66(1):176-8. doi: 10.1016/j.eururo.2014.03.039.
8. **Shariat S., Swietek N.**: Urologische Traumata. *Clinicum Urologie* 6-11, 1, 2014.
9. **Shariat SF, Klätte T.** Optimal results come from optimal surgery and optimal (neoadjuvant) systemic therapy. *BJU Int*. 2014 Apr;113(4):516-7. doi: 10.1111/bju.12611. PMID:24629083
10. Klätte T., **Shariat S.**: Impfungen & Immuntherapien: Prostatakarzinom-Impfung: Gegenwart und Zukunft. *medonline.at*
11. **Shariat S., Maddaluno D.**: Alte und neue therapiestrategien beim Nichturothelkarzinom. *Urologik* 5/13: 14-20, 2013
12. **Shariat S., Maddaluno D.**: Die zytoreduktive nephrektomie bei mRCC: die Frage ist nicht ob, sondern wann. *Haematologie & Onkologie* 5/13 p. 91-7.
13. Klätte T., **Shariat S.**: Novel Urinary Markers for Detection of Bladder Cancer-Are we Failing? *J Urol*. 2013 Oct 16. PMID:24139809

14. Xylinas E., Klatte T., Matin S., **Shariat S.:** Prognostic factors, markers and tools in upper tract urothelial carcinoma. *Urol List* 2013; 11(3):30-39
15. Schubert T., **Shariat S.,** Rieken M.: Alte und neue Marker in Diagnostik und Nachkontrolle. *Spectrum Urologie* 3:10-12, 2013
16. Mandel P., **Shariat S.,** Tilki D.: Lymphadenektomie bei klinisch nicht metastasierten Harnblasenkarzinom. *Spectrum Urologie* 3:28-30, 2013
17. Klatte T., **Shariat S.:** Aktuelle und relevante Studien Juli/August/September 2013 – ausgewählt vom Journal Club der urologischen Klinik am AKH Wien. *Spectrum Urologie* 3:42, 2013
18. **Shariat S.:** Meet the Expert – Prostata und Potenz. *Spectrum Urologie Sonderausgabe:* 1, 2013
19. Rieken M., **Shariat S.F.:** Biomarkers for screening and early detection of prostate cancer. *Hamdan Medical Journal*, 2013 Vol 6 Issue 2, p 121-9
20. Xylinas E, **Shariat SF.** Re: Prospective Randomized Phase II Trial of a Single Early Intravesical Instillation of Pirarubicin (THP) in the Prevention of Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma: The THP Monotherapy Study Group Trial. *Eur Urol.* 2013 Oct;64(4):683-4. PMID:23998501
21. Remzi M, **Shariat SF.** Bladder cancer: Is contrast-enhanced CT necessary for following up NMIBC? *Nat Rev Urol.* 2013 Sep;10(9):500-1. PMID: 23917120
22. Rieken M, **Shariat SF:** Renal Cancer Therapy: Going Forward by Going Backward? *Eur Urol.* 2013 Feb 16. PMID: 23433808
23. Xylinas E, Kluth L, **Shariat SF:** Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 Randomised Trial. *Eur Urol.* 2013 Jun;63(6):1132-3. PMID: 23608083
24. Kluth LA, Xylinas E, **Shariat SF:** Re: A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol.* 2013 Feb;63(2):399-400. PMID: 23272731
25. **Shariat SF.:** Vorwort - Focus Prostatakarzinom. *Spectrum Urologie* 2:11-16, 2012
26. Rink M., **Shariat SF.,** Graefen M.: Aktive Ueberwachung: wer, wann und wie? *Spectrum Urologie* 2:18-21, 2012
27. Kluth L., **Shariat SF.:** Akenzeichen XY ungelöst: Chemopraevention. *Spectrum Urologie* 2:22-23, 2012
28. **Shariat SF:** 13 Tipps für eine erfolgreiche urologische Forschung. *Urologik* 5:22-23, 2012
29. Catto JW, **Shariat SF.**The changing face of renal cell carcinoma: the impact of systematic genetic sequencing on our understanding of this tumor's biology. *Eur Urol.* 2012 Sep 26. PMID: 23026395
30. **Shariat SF,** Xylinas E. Biomarkers in personalised treatment of renal-cell carcinoma. *Lancet Oncol.* 2012 Jun 29. . PMID: 22759479
31. Tagawa ST, **Shariat SF:** Is adjunctive systemic chemotherapy after cystectomy for T2N+ disease of therapeutic benefit? *No. J Urol.* 2012 Aug;188(2):359-60. No abstract available. PMID: 22966496
32. Ehdaie B, **Shariat SF:** Magnetic Resonance Imaging-Targeted Prostate Biopsy: Back to the Future. *Eur Urol.* 2012 Jul 4. No abstract available. PMID: 22790287

33. **Shariat SF:** Reply Letter to the Editor. *Eur Urol.* 2012 Jun 28. PMID: 22763080
34. Rink M, Fajkovic H, **Shariat SF.** Das Modell der „klinischen Stadien“: Was es ist und warum wir es benötigen. *SPECTRUM urologie* (1): 8-11. 2012
35. Galsky MD, Tagawa ST, **Shariat SF:** Is adjunctive systemic chemotherapy after cystectomy for t2n+ disease of therapeutic benefit? *J Urol.* 2012 Jun 13. PMID: 22704119
36. Rink M, Cha EK, **Shariat SF.** Recent research will improve outcomes of patients with upper tract urothelial carcinoma. *Eur Urol.* 2011 Nov 3. PMID:22071142
37. Fajkovic H, Chromecki T., Breinl E., Pummer K., Eisenmenger M., **Shariat SF:** Geschlechts-spezifische Charakteristika des Harnblasenkarzinoms: Inzidenz, Staging und Prognose. *Urologik* 4: 4-9, 2011
38. Fajkovic H, **Shariat SF:** Renal cell carcinoma in the era of targeted therapy: the role of cytoreductive nephrectomy. *Urologik* 3: 22-25, 2011
39. Cha EK, **Shariat SF:** Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract: adapting new technologies for the diagnosis and management of upper tract urothelial carcinoma. *BJU Int.* 2011 Oct 10. PMID: 21985330
40. Rink M, **Shariat SF:** Can We Apply Nomograms Derived in the United States to European Patients? Yes, We Can! *Eur Urol.* 2011 Aug 27. PMID: 21885183
41. Ramasamy R, **Shariat S:** Book review of Evidence-based Urology. *BJUI.* 2011; 1007:1844
42. Merseburger AS, **Shariat S:** Urothelial carcinoma. *World J Urol.* 2011 Aug;29(4):405-7. Epub 2011 Jul 21. No abstract available. PMID: 21779833
43. Dubin J, Chromecki T., Beltran H., Goldenberg S., Cha E., Karakiewicz P., Zeltser I., Scherr D., Tagawa S., **Shariat S.:** Management of Castration-Resistant Prostate Cancer in 2011. *Annals Of Urology*, 2011
44. SunM., Abdollah F., Schmitges J., Jeldres C., **Shariat S.**, Perrotte P., Karakiewicz P.: Clinical experience and critical evaluation of the role of everolimus in advanced renal cell carcinoma. *Open Access Journal of Urology* 2011;3 43–48
45. Pierre I Karakiewicz, Cha EK, **Shariat S:** The use of 5 α -reductase inhibitors for the prevention and treatment of prostate cancer. *Eur Urol.* 2011 Jan 25. . PMID: 21277077.
46. Ahallal Y, **Shariat S**, Touijer KA: Les biomarqueurs émergents du cancer de la prostate: diagnostic, staging et pronostic. *Clinical Urology* 2010; 6:266-74.
47. **Shariat S**, Chromecki T: Highlights Bladder Cancer AUA 2010. *Debates on Bladder Cancer Yearbook* 2010, page 29-39. **Shariat S**, Tilki D: Bladder cancer: Nomogram aids clinical decision making after radical cystectomy. *Nat Rev Urol.* 2010 Apr;7(4):182-4.
49. **Shariat S**, Hammerich K: Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. *J Urol* 2008;179:1830-7; discussion 1837. *Eur Urol.* 2009 Jan;55(1):245-6.
50. **Shariat S**, Karam JA, Karakiewicz PI. Words of wisdom. Re: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. *N Engl J Med* 2007;356:2271-81. *Eur Urol.* 2009 Jan;55(1):250-2. PMID: 20050019.
51. Godoy G, Chade DC, **Shariat SF.** Words of wisdom. Re: Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy.

- Polascik TJ, Mayes JM, Sun L, Madden JF, Moul JW, Mouraviev V. *Eur Urol.* 2009 Sep; PMID: 19824127.
52. Karakiewicz PI, Suardi N, **Shariat SF**. The search for better prognostic factors for men treated for localized prostate cancer continues. *Eur Urol.* 2008 Apr; Epub 2007 Dec 17. PMID: 18093722.
 53. **Shariat SF**, Hammerich KH. Words of wisdom. Re: Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML. *J Urol* 2008; discussion 1837. *Eur Urol.* 2009 Jan; PMID: 20050015.
 54. Sonpavde G, **Shariat SF**: Preoperative chemotherapy for bladder cancer: A standard waits to be optimally deployed. *Cancer.* 2011 PMID: 21732335
 55. Lughezzani G, **Shariat S**, Sun M, Karakiewicz P.: Reply to Joan Palou, Oscar Rodríguez and Noel Clarke's Letter to the Editor re: Umberto Capitanio, Shahrokh F. Shariat, Hendrik Isbarn, et al. Comparison of Oncologic Outcomes for Open and Laparoscopic Nephroureterectomy: A Multi-Institutional Analysis of 1249 Cases. *Eur Urol* 2009;56:1-9.
 56. Isbarn H, Capitanio U, **Shariat S**, Karakiewicz P: Laparoscopic or open nephroureterectomy? Which is the more efficient way to go? *Eur Urol.* 2009 May 3.
 57. Capitanio U., **Shariat S.**, Karakiewicz P.: Reply. *Urology.* 2008 Dec;72(6):1212-3.
 58. Svatek R., **Shariat S.:** Words of wisdom. Re: Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. *Eur Urol.* 2008 Sep;54(3):690-1. PMID: 18792446.
 59. **Shariat S.**, Bolenz C., Karakiewicz P.: Words of wisdom. Re: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Escudier B, Pluzanska A, Koralewski P, et al., for the AVOREN Trial investigators. *Eur Urol.* 2008 Oct;54(4):948-9. PMID: 18953756.
 60. **Shariat S**, Karam J., Raman J.: Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers Med* 2(2): 165-80, 2008.
 61. Capitanio U., Briganti A., **Shariat S.**, Karakiewicz P.: The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol.* 2008 Jul 21.
 62. Gupta A., **Shariat S.**, for the Bladder Cancer Research Consortium: Reply by authors. *Urology.* 2008 Oct 7;
 63. Svatek R., **Shariat S.:** Editorial Comment on: Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. *Eur Urol.* 2008 Jul 14.
 64. **Shariat S.:** Editorial Comment on: Large-scale real-time reverse transcription-PCR approach of angiogenic pathways in human transitional cell carcinoma of the bladder: identification of VEGFA as a major independent prognostic marker. *Eur Urol.* 2008 May 23.
 65. **Shariat S.:** Editorial Comment on: Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. *Eur Urol.* 2008 May 21.
 66. **Shariat S.**, Skinner E., Montorsi F.: A tribute to John P. Stein (1962-2008): surgeon, scientist, teacher, and humanist. *Eur Urol.* 2008 Aug;54(2):479. 2008

67. **Shariat S.**, Karam J., Raman J.: Urine cytology and urine-based markers for bladder urothelial carcinoma detection and monitoring: developments and future prospects. *Biomarkers in Medicine* 2 (2), 165-180, 2008.
68. Karakiewicz P., Capitanio U., **Shariat S.**: Editorial Comment on: Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries. *Eur Urol.* 2008 Feb 8.
69. **Shariat S.**, Svatek R.: Editorial Comment on: Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy. *Eur Urol.* 2008 May 15. (Epub ahead of print)
70. **Shariat S.**, Margulis V., Karakiewicz P.: More nomograms or better evidence of efficacy: what do we need in urologic oncology? *Eur Urol.* 2008; 54:11-12.
71. **Shariat S.**, Karakiewicz P.: Perspectives on prostate cancer biomarkers. *Eur Urol.* 2008 Jul; 54(1):8-10.
72. **Shariat S.**, Karam J., Lotan Y.: Critical evaluation of urinary markers for bladder detection and monitoring. *Abstracts in Hematology & Oncology* 10(2), 2007.
73. **Shariat S.**, Karakiewicz P.: Screening for prostate cancer in 2007: the PSA era and its challenges are not over. *Eur Urol.* 2008 Mar;53(3):457-60.
74. Nielsen M., **Shariat S.**, Lotan Y.; on behalf of the Bladder Cancer Research Consortium (BCRC) Investigators: Reply to Vincent Fradet and Badrinath R. Konety. *BJU Int.* 2008 Jan; 101(2):258-259.
75. **Shariat S.**: Blasenkarzinom: Was der Praktiker wissen sollte! *Avicenna* 2(1): 24-9, 2007.
76. **Shariat S.**, Karam J., Roehrborn C.: Novel biomarkers for prostate cancer. *Abstracts in Hematology & Oncology* 10(3):21-30, 2007.
77. **Shariat S.**: Facing the challenges of T1 bladder cancer. *Issues in Urology*, 19(2): 54-55, 2007.
78. **Shariat S.**: Editorial: Will volume-based referral strategies reduce costs or just save lives? *European Urology*, 50(1): 62-63, 2006.
79. **Shariat S.**, Casella R., Lerner S.: Answer to letter from C. Sier and F. Blasi RE: Urinary level of urokinase-type plasminogen activator and its receptor in the detection of bladder cancer. *Cancer*, 98(9): 1995-6, 2003.
80. **Shariat S.**, Slawin K.: Peripheral blood RT-PCR assays for detection and prognosis of prostate cancer. *Reviews in Urology*, 5(1): 54-58, 2003.
81. Slawin K., **Shariat S.**, Canto E., Kattan M., Wheeler T.: Beyond PSA: new serum markers for improved diagnosis and management of prostate cancer. *Recent Advances and Research Updates* ISSN-0972-4699, 3(2): 175-186, 2002.
82. **Shariat S.**, Lerner S.: Editorial -The use of molecular markers for diagnosis, staging and prognosis in bladder cancer, *Oncology*, November; 15(11): 1479-80, 2001.
83. **Shariat S.**, Sadeghi F., Slawin K.: Vaccine-based immunotherapy for prostate cancer. *Reviews in Urology*, 2(4): 222-7, 2000.
84. **Shariat S.**, Slawin K.: Gene therapy for prostate cancer. *Reviews in Urology*, 2(2): 81-7, 2000.

ABSTRACTS over 800; available on request

BOOK CHAPTERS

1. Lee D., **Shariat S.**, Holzbeierlein J.: bladder cancer. *Geriatric Urology*. Ed T. Griebing. Springer 2014.
2. **Shariat S.**: Editor of book entitled *Upper Tract Urothelial Carcinoma*, Springer 2014
3. Xylinas E., Novara G., Remzi M., Karakiewicz P., and **Shariat S.**: Prognostics Factors, Molecular Markers, and Predictive Tools in Upper Tract Urothelial Carcinoma. *Upper Tract Urothelial Carcinoma*, Springer 2014
4. **Shariat S.** and Bochner B.: Urinary diversion. UpToDate. 2009-present
5. Lee R. and **Shariat S.**: Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes. In *Essentials and Updates in Urologic Oncology (2 Volume Set)* 2012. Editor: P.E. Spiess In *Essentials and Updates in Urologic Oncology (2 Volume Set)* 2012. Editor: P.E. Spiess. ISBN: 978-1-62081-494
https://www.novapublishers.com/catalog/product_info.php?products_id=33161
6. Lee R. and **Shariat S.**: Urinary diversions. In *Textbook of Urologic Oncology*. Spiess P. (eds), 2011.
7. Chromecki T., Margulis V., **Shariat S.**: Upper tract urothelial carcinoma. Editor: P.E. Spiess In *Essentials and Updates in Urologic Oncology (2 Volume Set)* 2012. Editor: P.E. Spiess. ISBN: 978-1-62081-494 https://www.novapublishers.com/catalog/product_info.php?products_id=33161
8. Bensalah K., **Shariat S.**, Patard J.: Prognostic factors for localized and metastatic renal cell carcinoma. In *Recent Advanced In Renal Cell Carcinoma*. Molins J. (eds), 2008.
9. **Shariat S.** and Roehrborn C.: Prostate cancer detection. In: *Textbook of Prostate Cancer*. Su L. (eds), 2009. ISBN13:9781416045755; ISBN10:1416045759; Elsevier Science Health Science div
10. **Shariat S.** and Kattan M.: Nomograms for prostate cancers. In: *Textbook of Prostate Cancer*. Thompson I. (eds), 2008.
11. **Shariat S.** and Kattan M.: Risk assessment in prostate cancers. In: *Textbook of Prostate Cancer*. Tewari A. (eds). Springer Verlag, Germany, 2008.
12. **Shariat S.**, Canto E., Slawin K.: Molecular genetics of BPH. In: *Textbook of Benign Prostatic Hyperplasia*. Chapter 9, Vol.2. Kirby R., McConnell J., Fitzpatrick J., Roehrborn C., Boyle P. (eds). Oxford, UK, Isis Medical Media Ltd, 2005.
13. M.Sun, **S.Shariat**, C. Cheng, V. Ficarra, M. Murai, S. Oudard, A.J. Pantuck, R. Zigeuner, P.I. Karakiewicz: Prognostic factors of renal cell carcinoma: A contemporary review. *Kidney Cancer*, (Eds: Z. Kirkali and P. Mulders) 2011 Edition, page 75-98.

SUMMARY OF RECENT RESEARCH**Minimal invasive instrumental therapy for benign prostatic hyperplasia**

Medical University of Vienna, Department of Urology, Vienna, Austria

P.I.: Dr. Michael Marberger

July 1997 – October 1998

- Development and exploration of minimally invasive treatments for benign prostatic hyperplasia (BPH)
- Conducted safety, efficacy, and long-term outcomes for transurethral microwave thermotherapy (TUMT)
- Involved in independent project design, technology troubleshooting, and evaluation of safety metrics

Minimal invasive instrumental focal treatment modalities for prostate cancer

Baylor College of Medicine, Scott Department of Urology, Houston, Texas, USA

P.I.: Drs. Kevin Slawin and Shahrokh Shariat

October 1998 – June 2002

- Creation of radiofrequency ablation (RFA) instruments for treatment of radio-recurrent prostate cancer
- Conducted feasibility and safety (Phase I and II) trials for novel medical device
- Responsible for clinical protocol design, patient recruitment, and imaging
- First published experience demonstrating PSA kinetics as a surrogate marker for tumor response in patients with advanced prostate cancer treated with focal ablation
- Development of the concept and implementation of focal ablation technique for the management of prostate cancer

Gene and vaccine therapies for urologic diseases with focus on bladder and prostate cancers

Baylor College of Medicine, Scott Department of Urology, Houston, Texas, USA

P.I.: Drs. Kevin Slawin, David Spencer, and Shahrokh Shariat (prostate)

P.I.: Dr. Seth Lerner and Shahrokh Shariat (bladder)

October 1998 – June 2002

- Development of gene and vaccine immunotherapies for prostate and bladder tumors.
- Construction of promotor-driven adenovirus vectors: PSA and hK-2 for prostate cancer and uroplakin for bladder cancer
- Use of herpes simplex virus thymidine kinase-activation of ganciclovir gene therapy for bladder cancer
- Development of adenovirus-driven caspase-3 and -9 gene-therapy for prostate cancer.
- Engineered chemically-inducers of dimerization for activation of caspase cascade to induce cell apoptosis
- Testing of gene therapeutic treatment modalities in preclinical models including human and murine cell lines and nude mouse orthotopic and xenograft models for prostate and bladder cancer
- Responsible for creation of Phase I protocol and subsequent acquisition of FDA Investigational New Drug Application (IND)

Detection and testing of prognostic/predictive value of clinically occult micrometastases in advanced prostate cancer

Baylor College of Medicine, Scott Department of Urology, Houston, Texas, USA

P.I.: Drs. Kevin Slawin and Shahrokh Shariat

June 2000 – July 2003

- Identification of target and development of reverse-transcriptase PCR assays to detect micrometastatic disease in high-risk prostate cancer patients
- Performed external validation of assay as well as quantitative confirmation of diagnostic results. Executed long-term followup of locally advanced prostate cancer patients to confirm diagnostic performance
- Identified occult micrometastatic tumor burden in histologically negative lymph nodes and cross-validated results with PSA, PSMA, and hK-2 immunohistochemistry

Research in prostate and bladder cancer- molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research

Baylor College of Medicine, Scott Department of Urology, Houston, Texas, USA

P.I.: Drs. Kevin Slawin, Seth Lerner, and Shahrokh Shariat

University of Texas Southwestern Medical Center, Department of Urology, Dallas, Texas, USA,

P.I.: Drs. Claus Roehrborn, Yair Lotan, and Shahrokh Shariat

June 1999 – present

Weill Cornell Medical Center, Department of Urology, New York, USA

P.I.: Drs. Shahrokh Shariat and Douglas Scherr

- Created annotated tissue and serum bank repositories for biomarker testing and validation
- Created hypothesis-driven discovery and validation of tissue- and blood-based biomarkers associated with prostate cancer presence, stage, prognosis, and metastasis-free survival
- Responsible for development and testing of novel assays for detection of genomic and protein-based biomarkers.
- Used a variety of techniques including RT-PCR, laser capture microdissection, high density tissue microarrays, SNP arrays, tiling arrays, and cDNA expression arrays in combination with clinical and morphologic parameters to identify significant associations between biomarkers and outcomes of interest
- Developed a systematic, phased, stepwise research pathway for testing and validating biomarkers.
- Discovery and validation of urinary biomarkers for early detection and surveillance of bladder cancer
- Created and implemented three prospective clinical trials for testing of NMP-22 in hematuric patients and patients at high risk for bladder cancer. Directed non-inferiority trial comparing NMP-22 to urinary cytology for surveillance of low grade bladder cancer
- Created an international tissue bank repository for biomarker testing
- Created multi-institutional, multi-specialty collaborative groups to scale the research to power necessary for clinical value testing (The Bladder Cancer Research Consortium, The Bladder Cancer Early Detection Network, and The Upper Tract Urothelial Carcinoma Collaboration)
- Co-pioneered novel statistical methods for assessing the clinical value of biomarkers in daily clinical decision-making
- Co-developed cost-effectiveness methodologies to assess the value of biomarkers
- Created multi-institutional collaborative efforts to implement my biomarker research model.
- Awarded two patents by the US Patent and Trademark Office and the European Patent Organization for development of biomarker nomograms to predict prostatic disease outcomes; Awarded one patent by the same organizations for development of biomarker nomogram to predict urothelial disease outcomes

Integrative epigenomics in bladder cancer

Weill Cornell Medical Center, Department of Urology, New York, USA

P.I.: Drs. Shahrokh Shariat

Collaborators: Thomaz Clozel, Oliver Elemento

September 2010 – present

- Performing integrative analysis of epigenetic and genetic settings in bladder cancer cell lines and animal models
- Modelling of critical biological pathways involved in mediating the malignant phenotype of tumors in individual patients
- Identification of transcription factors that contribute mechanistically to aberrant transcriptional programming in given tumors
- Hypothesis driven, rational design of therapeutic targets and drugs

Understanding, predicting, and overcoming resistance to cisplatin in bladder cancer

Weill Cornell Medical Center, Department of Urology, New York, USA

P.I.: Drs. Shahrokh Shariat

Collaborators: Thomaz Clozel, Oliver Elemento, Franziska Michor

September 2010 – present

- Predicting resistance to cisplatin using 35 different human cell lines

- Understanding mechanisms of resistance to cisplatin through GI50 and changes in RNA sequencing
- Studying methods to overcome resistance to cisplatin by synergistic combinations and/ or priming by new small compounds without increasing of toxicity
- Studying methods to understand cross-resistance to classical chemotherapeutics and new compounds with cisplatin using connectivity map
- Identifying signatures associated with resistance to cisplatin using RNA sequencing and metabolomics

Intravesical application of nanoparticle-mediated microwave thermotherapy (nTUMT) for treatment of bladder cancer

Weill Cornell Medical Center, Department of Urology, New York, USA

P.I.: Drs. Shahrokh Shariat and Richard Lee

September 2010 – present

- Engineering survivin-targeted, microwave responsive nanoparticles
- Testing survivin as a target for effective localization and destruction
- Developing an intravesical formulation for survivin-targeted nanoparticles
- Confirming that nTUMT nanoparticle specifically bind to bladder cancer cells in both cell culture and mouse xenograft models
- Adapting microwave devices to apply focused ablative heat energy at the cellular level and destroying tumor but minimizing damage to adjacent living tissue.
- Demonstrating focal generation and delivery of heat energy by nTUMT after excitation with microwave energy
- Testing feasibility, safety, and efficacy of this technique allows for effective localized tissue ablation